















Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy 




































Inhibitors of NF-κB: A20 and IκBβ 
Arnab De 
 
 While prompt activation of NF-κB is essential for optimal immune response, it is equally 
important to terminate the response to avoid tissue damage and perhaps even death resulting 
from organ failure. This thesis describes two inhibitors of NF-κB, A20 and IκBβ.  A20 is an 
essential inhibitor of NF-κB mediated inflammation as mice lacking A20 die from multi-organ 
inflammation and cachexia. Multiple biochemical approaches have suggested that A20 functions 
as a deubiquitinase by disassembling K63-linked regulatory ubiquitin chains from upstream 
adapter molecules like RIP1.  To determine the contribution of the deubiquitinase role of A20 in 
downregulating NF-κB, we generated and characterized a knock-in mouse lacking the 
deubiquitinase activity of A20. However, we find that these mice display normal NF-κB 
activation and show no signs of inflammation. Our results suggest that the deubiquitinase activity 
of A20 is dispensable for downregulating NF-κB. The second part of this thesis unravels a new 
biological pathway mediated by IκBβ. Unlike IκBα, which functions solely as an inhibitor of 
NF-κB, IκBβ can both inhibit and activate NF-κB depending on the physiological context. We 
hypothesized that this may be because IκBβ (unlike IκBα ) exists in two forms, a constitutively 
phosphorylated form and an unphosphorylated form. Prior work from our group has 
demonstrated that hypophosphorylated IκBβ complexes with p65:cRel and mediates the 
expression of certain inflammatory genes like TNFα . We report here that Glycogen Synthase 
Kinase 3β (GSK-3β ) interacts with and phosphorylates IκBβ at Serine-346. This 
phosphorylation masks the NLS of p65 in the phospho-IκBβ:p65:cRel complex, thereby 
  
sequestering the complex in the cytoplasm and mediating the anti-inflammatory role of IκBβ.  
We discovered a peptide that can inhibit this phosphorylation by abrogating the interaction 
between GSK-3β and IκBβ. Mice succumb to a sublethal dose of LPS when injected with this 
peptide because of increased production of TNFα (but not IL-6); thereby demonstrating the 
inflammatory role of unphosphorylated IκBβ in upregulating specific genes like TNFα. We 
propose a signaling model by which phosphorylation by GSK-3β  can regulate the functions of 
IκBβ in response to LPS. 
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1.1 Introduction to immune system 
Over time, we have evolved various sophisticated ‘immune-defense mechanisms’ to 
protect ourselves from other organisms, both large and small. While co-evolution of multicellular 
organisms and microbes have provided several essential mutual benefits for both [1], infectious 
diseases constitute a major threat to human health and a possible cause of death. Besides, it is 
also a major burden for the global economy. The sources of these infections are pathogenic 
organisms that include bacteria, viruses or other parasites. Hence, it is very important for the host 
to be able to respond to such harmful threats, and indeed our ability to clear these microbial 
infections is vital for survival. However, this is not easy given the enormous diversity of 
pathogens, and their ability to mutate, evolve and adapt rapidly to evade possible detection by 
the immune system.  Hence, multicellular organisms have evolved several sophisticated immune 
recognition mechanisms to “fight” pathogens. Immune cells are present throughout the body. 
They are either found near the skin or gut where they can monitor the entry of foreign substances 
or discretely encapsulated in the spleen or thymus [2].  In vertebrates, the immune mechanism 
may be broadly classified as ‘innate’ and ‘adaptive’ [3]. 
1) Innate immunity 
As suggested by the name, the innate immune system is evolutionarily ancient, and 
consists of anatomical barriers, immune cells and protective proteins that are always present right 
from birth. The phylogenetically conserved innate immune system is the first line of defence, 
initially presenting a physical obstacle to microbes, and subsequently fighting the microbes at the 
site of infection. The main components of the innate immune system include physical barriers 
(skin and epithelial layers), phagocytic cells that ‘eat’ microbes (neutrophils and macrophages), 
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dendritic cells (critically important for activation of the ‘adaptive’ arm of the immune system), 
natural killer (NK) cells, and circulating plasma proteins.  
In order to recognize various molecules of microbial origin, the cells of the innate 
immune system (macrophage, dendritic cells) have germline encoded receptors. The innate 
defense system is activated when these germline encoded receptors recognize the molecular 
patterns that are conserved in a wide range of pathogens (PAMPs).   
The first component of our immune system is the skin, which maintains a constant barrier 
against external infection. There are also other barrier tissues preventing harmful pathogens from 
getting inside the body.  If the pathogens succeed in breaching the “first line of defense”, and get 
into the body, the other cells of the innate immune system (macrophages, neutrophils) respond to 
the pathogens immediately, engulfing the foreign organisms by a process known as phagocytosis 
and killing them. 
Thus, this innate, germline-encoded, one-size-fits-all immune system is always available 
and ready to fight any infection. In most cases, the actions of the innate immune system is 
sufficient to clear the infection. However, should the non-specific innate response be insufficient 
to kill the pathogens, it is able to control the infection for a few days while simultaneously 
triggering the more specific adaptive immune response. 
2) Adaptive immunity 
This is the more evolutionary recent immune arm first seen in jawed vertebrates.  In 
general, the effector class of the adaptive immune response could be humoral (mediated by 
antibodies produced by B lymphocytes) or cell-mediated (mediated by T lymphocytes). A highly 
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diverse group of T cell and B cell receptors generated by the process of VDJ recombination and 
somatic hypermutation form the basis of adaptive immune recognition.  Receptors with 
appropriate specificities are clonally selected and expanded. “Clonal selection” forms the basis 
of “immunological memory”, a process that lets the host ‘adapt’ and remember the pathogen, 
enabling a more robust immunological response in case of a subsequent attack by the same 
pathogen.  This is a major advantage for advanced organisms over their microbial counterparts. 
However, there are two limitations of an adaptive response. Firstly, ‘clonal selection’ or the 
expansion and differentiation of specific lymphocyte clones to effector cells takes up to 4-7 days.  
Hence, no adaptive response can be mounted till this time, a considerable span for multiplication 
of fast replicating microorganisms.  Secondly, since these receptors are formed randomly, they 
cannot by itself distinguish pathogenic antigens. Hence, the adaptive immune system does not 
function independently and innate immune signals activate and control the extent of the adaptive 
response.  
Figure 1.1 shows the mechanisms of action of the innate and adaptive immune system. 
Innate immunity involves immediate, nonspecific response to pathogens. Thus, pattern-
recognition receptors (PRRs) on macrophages and neutrophils recognize pathogen-associated 
molecular patterns (PAMPs) in pathogens leading to phagocytosis and opsonization. This leads 
to the secretion of cytokines like tumour necrosis factor α (TNFα), and interleukin-1β (IL-1β) 
that mediate the inflammatory response. These initial defensive acts by the innate immune 
system trigger the adaptive immune system. The lymphocytes (T cells and B cells) of the 
adaptive immune system have receptors that bind to specific antigens. The full development of 
the adaptive response requires selection, expansion and differentiation of the specific responder 
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cells. This takes time (4-7 days), but leads to memory lymphocytes which remember the specific 
antigen they responded to [4].  
Although Elie Metchnikoff first described the innate immune system a century ago, the 
research in this field has been largely eclipsed by the intriguing discoveries of the many facets of 
the adaptive immune system. During this time, it was thought that the innate immune system 
only helps to keep the infection at bay while the adaptive immune system prepares to mount the 
specific and robust response. However discoveries in the last twenty years have clearly shown 
that the innate immune arm not only plays an essential role in detecting the infection and 
providing the immediate response, but also in simultaneously coordinating the initiation and 
determining the effector class of the adaptive response [5]. 
 
 
Figure 1.1: Innate and adaptive immune system (APC, antigen-presenting cell; BCR, B-
cell receptor) (adopted from[4])  
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The fundamental strategy by which the innate immune system recognizes pathogens is by 
detecting those unique constitutive and conserved microbial molecules that are absent in the host. 
These molecules are typically part of essential microbial metabolic pathways and are required to 
sustain microbial life. Thus, it is impossible for microbes to live without expressing these gene 
products. By evolving to recognize these critical microbial products, the host gains a significant 
advantage. Some of these substances include lipopolysaccharide (LPS), peptidoglycan, and 
lipoteichoic acids (LTAs); all molecules found only in bacteria and not produced by eukaryotic 
cells. Hence, the hosts see these molecules as ‘signatures of the pathogen’ and the recognition of 
such foreign microbial signatures is the first signal of an infection. While different strains and 
species of a common class of microbes (bacteria) may have minor variations in chemical 
structure (O-antigen subgroup of LPS is different in different bacterial species); the common 
invariant ‘molecular pattern’ is what is recognized by the host innate immune system (main 
lipid-A pattern of LPS). Since the targets of innate recognition is invariant and conserved, they 
are known as pathogen-associated molecular patterns (PAMPs). The receptors of the innate cells 
that are responsible for recognition of PAMPs are known as pattern-recognition receptors (PRR), 
a broad class of receptors that have evolved over time and this initial recognition is primarily 
responsible for the specificity in immune response against the non-self [6],  [7].  
 In order to recognize these different PAMPS, a number of PRRs have evolved in 
order to broadly sense the diversity of the microbial world (Figure 1.2). The PRRs directly 
engage the evolutionarily conserved PAMPS to constitute what is the first step of the innate 
immune response against invading microbes. The different PRRs may be expressed on the 
surface of cells, in intracellular compartments, or secreted into blood or tissue fluids. PRRs may 




Figure 1.2: Pattern recognition receptors and their cognate ligands: PRRs may be membrane 
bound or endosomal in order to recognize various PAMPs in different locations. [8] 
 
Transmembrane bound PRRs include the TLR (Toll-like receptors) family which are 
probably the most well known as well as the best characterized of the PAMPs. The C-type 
lection receptors (CLR) are another example of transmembrane receptors. The mannose 
receptors is a typical CLR expressed in macrophages which binds certain sugar molecules of 
some invading bacteria and viruses (this is especially important in the response against human 
immunodeficiency virus or HIV) [9].  
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Cytosolic PRRs recognize intracellular PAMPS. This is especially important when the invading 
microorganism has gotten inside the cell, either by itself or as a result of phagocytosis. They include 
CATERPILLAR/NOD-like receptors (NLRs) and RIG-l-like receptors (RLRs). The NLR family has 
around 20 members and bind to the peptidoglycans present in bacterial cell wall [10, 11], [12]. The RLRs 
play a crucial role in the immune response against viruses. Three different RLRs have been discovered, 
namely, RIG-I, MDA5 and LGP2. They sense viral replication in the host cytoplasm by interaction with 
dsRNA of viruses (host RNA is single stranded; a clear example of how the host immune system has 
evolved to distinguish between subtle differences in structures of ‘self’ and ‘non-self’) [13]. 
 As we see, our body has an elaborate mechanism to respond to the constant challenge of 
various pathogenic microorganisms which trigger the immune system. The essential first line of 
defense involves the sentinel macrophages, sensing the various PAMPS with their PRRs. 
Remarkably, while binding of different PAMPs to their specific PRRs may trigger different 
intracellular signaling cascades, they all converge and lead to the activation of the nuclear factor 
κB (NF-κB) pathway (initially inactive in resting conditions) and the consequent expression of 
many proinflammatory cytokines [14] (Figure 1.3). These proinflammatory cytokines are largely 
responsible for initiating the innate immune response by recruitment of additional professional 
phagocytes and subsequent pathogen clearance. They also shape the subsequent adaptive 
response [15]. One consequence of multiple pathways coalescing on a single transcription factor 
would be that dysregulation of NF-κB could be very harmful. Indeed, there are many reports 
associating dysregulation of NF-κB with different pathologies [16-18]. To avoid autoimmunity, 
it is essential that the activation of NF-κB be tightly regulated in order to limit the duration and 
magnitude of the response. This theses deals with two important inhibitors of NF-κB: IκBβ [19] 




Figure 1.3: Binding of PRRs to PAMPs converges on the NF-κB pathway via the activation of 
IKK complex (thus, signaling through the (a) TLRs (Myd88) (b) TLRs (TRIF) (c) RIGI (d) NOD 
pathogen-associated molecular patterns lead to NF-κB activation.(modified from [21]) 
 
1.2: NF-κB: an overview 
As seen in the last section, the mammalian immune response can be broadly subdivided 
into innate and adaptive responses. The first response is provided by the innate system and 
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begins with host-recognition of the pathogen. The subsequent responses take place at various 
levels of complexity at the cellular, tissue and organismal levels. The ultimate aim is to clear the 
pathogen. From a basic molecular point of view, it is insightful to distill the immune response 
into individual signal transduction events which alters gene expression at the cellular level, 
finally leading to a concerted immune response at the organismal level [21].  NF-κB, inactive in 
the basal state and activated upon sensing PAMPs, is one key transcription factor that plays a key 
role in mediating transcriptional changes. The gene products of the initial response include 
cytokines acting as ‘messengers’ of the ‘initial recognition of pathogens’, thereby propagating 
the immune response.  Additionally, these cytokines can also activate NF-κB, thereby focusing 
and elaborating the immune response. Thus, we find that NF-κB mediates critical aspects of the 
innate and adaptive responses in a surprisingly large number of cases. The importance of this 
inducible transcription factor can be gauged from the volume of research done in the past 25 
years since it was identified [22] as a nuclear factor interacting with immunoglobulin enhancer 
sequences [23], [24]. A search in PubMed using “NF-κB” alone results in more than 40,000 hits. 
While the underlying interest in studying NF-κB comes from its importance in health and 
disease, these studies also serve as a model for studying a wide range of biological responses that 
depend on inducible transcription factors. Inducible gene expression plays an important role in 
both prokaryotes and eukaryotes. It is an important regulator of normal physiology as well as the 
key in allowing multicellular organisms to adapt to chemical, environmental and pathogenic 
stresses. Fundamental biological processes including organ morphogenesis and differentiation of 




NF-κB has been found to be amenable to a wide range of experimentation at the 
biochemical, cellular and organismal levels. Most of the studies of NF-κB have been done from 
an immunological background, as the transcription factor plays an essential and evolutionarily 
conserved role in responding to immune insults. However, while much of our understanding of 
the pathway comes from studies in immunology, it is important to appreciate that NF-κB plays 
an important broader role in regulating gene expression that affects cell survival and apoptosis, 
differentiation and proliferation [19] [25]. 
A brief overview of the NF-κB pathway may be helpful here. NF-κB is bound to 
inhibitory proteins (IκB) and is inactive in the unstimulated state. The pathway is activated by 
inducing stimuli acting through receptors and adapter proteins to trigger IKK (activating kinase) 
activation. This leads to the phosphorylation, ubiquitination, and subsequent degradation of IκB.  
NF-κB is now free and undergoes a series of post-translational modifications to be fully activated 
(Figure 1.4). It translocates to the nucleus, binds to specific DNA sequences and turns on the 
transcription of its target genes.  Thus, the basic components of the pathway are the receptors and 
adaptor molecules, IKK complex, IκB proteins, and NF-κB subunits. The pathway is controlled 




Figure 1.4:  Basic NF-κB Signaling Pathway [25] 
 
 
In mammals, the NF-κB family of transcription factors is comprised of five constituent 
monomers: p50, p52, p65 (also RelA), c-Rel, and RelB (Figure 1.5). All of them have a N-
terminal DNA-binding domain which is also the domain necessary for homodimer/heterodimer 
formation. This N-terminal domain is also known as the Rel homology domain (RHD). The 
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crystal structures of multiple NF-κB dimers reveal that the RHD is comprised of two 
immunoglobulin-like folds. Of them, one is engaged in dimerization while the other is 
responsible for recognition of specific sites on the DNA. Minor differences in dimer interfaces 
determine partner preferences and selectivity in DNA binding [26]. Multiple posttranslational 
modifications (phosphorylation and acetylation) of different residues in these molecules further 
modulate DNA binding [27]. Subsequent transcriptional activities may additionally depend on 
the interaction of dimers with other activator proteins [28]. Activated NF-κB dimers can bind 
multiple, related DNA sequences called κB promoter sites to turn on the expression of different 
genes. The C-terminal transcription activation domains (TADs) are necessary for activator 
recruitment and consequent transcription of target genes. Only RelB, c-Rel, and p65 contain the 
TAD. Since p50 and p52 lack the TAD, they can act as transcriptional activators only upon 
association with RelB, c-Rel, and p65. However, p50 and p52 can form homodimers that bind to 
the DNA, and repress transcription. In order to positively regulate transcription, the p52 and p50 
subunits have to form heterodimers with the other factors that have TAD [25]. RelB also has a 
unique leucine zipper (LZ) motif in its N terminus which plays an important role in regulating 
transcription.  
In most cells, NF-κB complexes are sequestered in the cytoplasm and are inactive. This is 
because they are in a complex with inhibitory IκB proteins (proteins including IκBα, IκBβ, IκBɛ, 
IκBζ, p100, p105, Bcl3, IκBns) (Figure 1.5). The IκBα, IκBβ, and IκBɛ, are the prototypical 
IκBs. These proteins have multiple ankyrin repeats that are responsible for their inhibitory 
action. The ankyrin repeats mediate the binding of the inhibitor molecule to the NF-κB dimers, 
interfering with their nuclear localization signals (NLS). The C-terminus of p105 and p100 has 
multiple ankyrin repeats [29], allowing them to function like IκB [30]. Although the IκBs are 
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structurally quite similar, they may have different binding preferences [31], [32]. For example, 
while IκBα predominantly regulates the classical RelA-p50 heterodimers [33], IκBβ regulates the 
p65-cRel [34], [35] and the IκBɛ associates with p65-p65 homodimers as well as cRel:RelA 
heterodimers [31], [36, 37]. 
One of the basic questions at the time of discovery was to understand the process of 
liberation of the active nuclear factor-κB (NF-κB) from the IκB inhibitor. Initial discoveries 
suggested that in vitro phosphorylation with purified kinases released NF-κB from the inhibitory 
complexes. The same phenomenon was demonstrated in cell lines where it was shown that the 
stimulus-dependent activation of NF-κB indeed involved IκB phosphorylation [38, 39]. Thus, 
phosphorylation of IκBα at serines 32 and 36 [40, 41] was a prerequisite for the nuclear 
translocation of active NF-κB [42-46]. However, it was also evident that the phosphorylation of 
IκB was not enough to trigger NF-κB activation. The degradation of the phosphorylated IκB was 
also critical, as blocking the proteolysis of IκB could prevent NF-κB activation [47-51]. It turned 
out that signal-mediated phosphorylation of IκBα triggers subsequent ubiquitination and 
proteasomal degradation [52-55]. Multiple groups subsequently confirmed that β-TrCP was the 
E3 ubiquitin ligase for IκBα [56-59]. Incidentally, the first signal transduction system where 





Figure 1.5: Mammalian NF-κB, IκB and IKK protein families [25] Phosphorylation, 
ubiquitination, or acetylation are indicated with P, U, or Ac respectively. Inhibitory events or 
degradative phosphorylation and ubiquitination sites on p100, p105, and IκB proteins are 
indicated by red Ps and Us, respectively. (RHD, Rel homology domain; TAD, transactivation 
domain; LZ, leucine zipper domain; GRR, glycine-rich region; HLH, helix-loop-helix domain; 
Z, zinc finger domain; CC1/2, coiled-coil domains; NBD, NEMO-binding domain; MOD/UBD, 
minimal oligomerization domain and ubiquitin-binding domain; and DD, death domain). 
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While all the three major IκBs undergo proteasomal degradation upon stimulation, they 
do so with different kinetics [60]. To exemplify, IκBα is degraded very fast in around ~15-30 
minutes upon stimulation with TNF-α and lipopolysaccharide (LPS). It is then resynthesized in 
an NF-κB-dependent manner and demonstrates a classical negative feedback loop. The newly 
synthesized IκBα enters the nucleus and binds to deacetylated RelA:p50 heterodimers. The 
inactive inhibitor-heterodimer complex then shuttles back to the cytoplasm [61, 62]. Similar 
stimulation-induced degradation and resynthesis occurs for IκBβ and IκBɛ as well, but at a much 
slower rate [60]. Ultimately, these differences in kinetics in IκB degradation and resynthesis play 
an important role in the regulation of NF-κB activation. This topic is dealt with in the second part 
of the work presented in this thesis. 
The kinase responsible for phosphorylation of IκB in cells was later identified and named 
the IκB-kinase complex (IKK), which was shown to have both catalytic (IKKα and IKKβ) and 
regulatory (IKKγ/NEMO) subunits [63-67]. Based on the diversity of stimuli activating NF-κB 
and the number of IκBs, one could have expected that multiple kinases were responsible for 
phosphorylation of the different IκBs. As it turned out, only one kinase complex is responsible 
for the phosphorylation. Besides the traditional role in IκB phosphorylation, the IKK complex 
has also been shown to enhance the transcriptional activity of NF-κB by phosphorylating the 






1.3 NF-κB: The canonical pathway and non-canonical pathway 
There are two distinct pathways for NF-κB activation, the canonical pathway and the 
non-canonical pathway. They are activated by different ligands and kinases. The canonical 
pathway mediates the typical inflammatory responses, while the non-canonical pathway plays a 
role in the slow differentiation and maturation of immune cells and secondary lymphoid 
organogenesis. The canonical pathway is dependent on NEMO, while the non-canonical pathway 
does not depend on it [69] (Figure 1.6).  
While the two pathways are quite distinct, there are evidences of crosstalk between them 
[69]. The pathways are briefly described here: 
1) Canonical pathway: The canonical NF-κB signaling pathway is activated by pro-
inflammatory ligands that include PAMPS, cellular danger-associated molecular patterns 
(DAMPs) and cytokines. The effector NF-κB heterodimers activated downstream are mainly the 
p65:p50 and c-Rel:p50 heterodimers. Upon ligand binding to cognate receptors, various adapter 
proteins trigger the activation of IKK complexes containing the regulatory NEMO subunit. 
Deletion of NEMO causes massive liver degeneration resulting in embryonic lethality [70], 
demonstrating the importance of this pathway and NEMO for life. While this pathway is 
characterized by the essential requirement of the regulatory NEMO subunit, the catalytic subunit 
of IKK that is activated and responsible for phosphorylating the inhibitory IκB is IKKβ. IKKβ is 
activated by phosphorylation of its serine residues at positions 177 and 181 [71]. Additional 
evidence for the signaling axis of NEMO-IKKβ-p65 comes from the uncanny similarity of the 
phenotypes of the IKKβ knockout [72] and the RelA knockout  [73], both of which resemble the 
NEMO knockout and show apoptosis and degeneration in the liver.  
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A brief description of the pathway is provided here. The p65:p50 dimer is sequestered in 
the cytoplasm by the binding of IκBα.  The  IκBα:RelA:p50 trimer is mostly localized to the 
cytoplasm as the IκBα has a strong nuclear export signal.  However, this complex also shuttles 
between the nucleus and cytoplasm [74, 75]. This is because the binding of IκBα to p65:p50 
masks the NLS of p65 but fails to mask the NLS of p50 [33].  
Upon stimulation, the activated IKK phosphorylates IκBα on Ser32 and Ser36 [76]. The 
phosphorylated IκBα is now polyubiquitinated by degradative Lys48-linked polyubiquitin chains 
at Lys19 by the Skp1, Cdc53/Cullin1, and F-box protein β transducin repeat-containing protein 
(βTRCP) SCFIκ B E3 ubiquitin ligase complex [33]. This leads to the degradation of ubiquitinated 
IκBα via the 26S proteasome. The strong p65 NLS is now exposed and the p65:p50 dimers 
translocate to the nucleus. In addition to IκBα, IκBβ and IκBɛ are also substrates for IKK 
phosphorylation and subsequent degradation via similar pathways. [77]. That being said, the 
affinity of IKK to the various IκBs is markedly different.  Hence, the various IκB protected 
dimers are degraded with different kinetics. The net consequence is that the basally inactive NF-
κB transcription factors are inducibly activated by a diverse set of stimuli, all leading to the 
nuclear translocation and subsequent expression of NF-ΚB dependent genes [78, 79].  
2) Non-canonical pathway: This alternative NF-κB pathway is activated upon stimulation 
by a small subset of TNF family members that are involved in differentiation, maturation and 
development of immune cells. These include lymphotoxin β, LTαβ, BAFF (B cell–activating 
factor), CD40 ligand, RANKL (receptor activator of NF-κB ligand), and TWEAK (TNF-related 
weak inducer of apoptosis) [80-83]. Since developmental processes require sustained signaling, 
it is not surprising that the kinetics of activation and deactivation of this pathway is slower as 
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compared to the canonical pathway. Hence the pathway has a long-lasting activity, as opposed to 
the rapid transient activation of p65-p50 heterodimers by inflammatory stimuli.  
Biochemical characterization has shown that in unstimulated cells, RelB interacts with 
and is associated with p100. The RelB:p100 complex is stabilized by multi-domain interactions. 
Thus, p100 deficient cells show reduced levels of RelB and similarly, RelB knockout cells have 
less p100 protein [84, 85]. This alternative NF-κB pathway ultimately leads to the inducible 
proteasomal processing (as opposed to degradation) of p100 to p52 and activation of RelB:p52 
heterodimers. Another major distinction with the canonical pathway lies in that this pathway 
does not require NEMO. Instead, the non-canonical NF-κB pathway is activated strictly through 
a NEMO-independent IKKα mediated pathway [79, 82, 86, 87]. Ligand binding activates the 
NIK protein, which directly phosphorylates p100 at Ser866 and Ser870, and also phosphorylates 
IKKα [87, 88]. The activated IKKα then phosphorylates p100 in its ankyrin domain at Ser99, 
Ser108, Ser115, Ser123 and Ser872 [77, 89]. The SCG/βTRCP E3 ligase complex then 
recognizes the phosphorylated p100 and polyubiquitinates it with K48-linked ubiquitin chains 
[89, 90]. This leads to the consequent proteasomal processing of p100 by the 26S proteosome 
[91] [87, 88] to p52. The p52 then associates with the RelB that was previously associated with 
p100 to form the activated RelB:p52 dimers. 
Elegant genetic proof of NIK, IKKα and RelB as components of the non-canonical 
pathway comes from the remarkable similarity of the phenotypes of mice deficient for these 
genes [86], [92], [93]. They all show defective development of Peyer’s patches and other lymph 
nodes. Additionally, the phenotype of aly/aly mice (carries a point mutation in kinase domain of 
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Nik gene leading to inactivation of NIK) is similar to IkkαAA mice (mice have catalytic serines 




Figure 1.6: Canonical and Non-canonical NF-κB signaling [95] 
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1.4 A brief overview of the IKK complex 
The NF-κB pathway is activated by a whole range of extracellular ligands (both 
membrane bound and soluble). They include members of the TLR, TNFR, IL-1R superfamilies. 
Additionally, NF-κB has been recently shown to respond to changes in the intracellular 
environment as well. These changes may be a consequence of DNA damage, elevated reactive 
oxygen species, and recognition of pathogens by the RIG-I and NOD family of proteins. All of 
these stimuli converge on the activation of the IκB kinase (IKK) complex.  
The IKK complex comprises of two catalytic subunits (IKKα and IKKβ) and one 
regulatory subunit (NEMO or IKKγ) (Figure 1.5). There is a 52% overall sequence identity 
between the catalytically active kinase subunits IKKα and IKKβ, while the  catalytic domain are 
65% identical. Amongst the two catalytic subunits of IKK, IKKβ contributes more than IKKα 
towards IκB kinase activity in most cell types and thus seems to be the more important catalytic 
subunit. Loss of IKKβ leads to lethality, thus IKKα cannot compensate for the IκB kinase 
activity in absence of IKKβ [96] However, loss of IKKα has little effect on net IKK activity as 
IKKβ can compensate for IKKα [97].  
There is a plethora of clear genetic evidence pointing to the essential role of all the three 
subunits of IKK [98]. Mice lacking IKKβ resemble p65 knockouts. This is expected since IKKβ 
plays a profound role in the canonical activation of p65-containing dimers [72, 99, 100]. The 
embryonic lethality can be rescued by deletion of TNFR1, demonstrating a crucial role for IKKβ 
in TNF-mediated signaling [72, 99, 101]. IKKα knockout mice die soon after birth because of 
severe morphological defects in the skin and the limbs [102-104]. Initially, there was little 
evidence for IKKα playing a role in NF-κB activation. However, subsequent reports 
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demonstrated the central importance of IKKα in the noncanonical NF-κB pathway and in certain 
canonical pathways as well [105]. NEMO is essential in the canonical pathway; hence NF-κB 
cannot be activated via the canonical pathway in NEMO deficient cells. In addition, mice lacking 
NEMO die from severe liver degeneration.  [67, 70, 106].  
It is now understood that almost all NF-κB-stimulating ligands act via the IKK complex 
[107] as there is no NF-κB activity mice lacking both IKKα and IKKβ [107].  Surprisingly, many 
of the components upstream of IKK are similar, and also show significant mechanistic overlap 
(even in pathways that are functionally divergent). However, even 15 years after the initial 
characterization of the IKK complex, it is still not entirely known how IKK gets activated. One 
of the major reasons for this is that, in general, the receptors that lead to IKK activation lack 
enzymatic activity [108].  
What is known is that the activation of IKK depends on the phosphorylation of serines in 
the activation loop of the IKKs. Thus IKKα is activated upon phosphorylation of Ser 176 and Ser 
180 while IKKβ is activated upon phosphorylation of Ser 177 and Ser 181. This phosphorylation 
of active loop serines is essential for inducing kinase activity of the IKK complex. Treatment 
with phosphatases decreases kinase activity in vitro, and mutating the serines to alanines 
abolishes signal responsiveness. Conversely, mutation to glutamic acid results in IKK that is 
constitutively active [109], [110], [111], [112], [113].  
Thus, although receptors leading to IKK activation lack kinase activity, it is evident that 
some kinase has to be responsible for phosphorylating and activating IKK. As described before, 
there is both biochemical and genetic evidence for NIK acting as the kinase to directly 
phosphorylate and activate IKKα in the non-canonical pathway [112], [114], [94]. For the 
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canonical pathway, it is hypothesized that IKK could either be activated by autophosphorylation 
or phosphorylation by an upstream kinase [108]. While multiple kinases can act as an IKK 
kinase in vitro ((IKK-K), they have all failed the genetic test. It has been found that many 
molecules that have kinase activity act as adaptor proteins in the activation of IKK. Currently, 
the only acceptable candidate kinase to phosphorylate IKK is TAK1. Indeed, the failure of 
multiple potential kinases to satisfy the gene-knockout test has supported the theory that IKK 
might activate itself by autophosphorylation. 
Recent resolution of the crystal structure of IKKβ suggests that a dimer of IKKβ could 
not phosphorylate itself. This is because the active site of the one IKKβ would be distant from 
the ‘serine activation loop’ of the second IKKβ of the dimer [115]. However, the active site and 
activation loop are much closer in related higher-order structures that would mediate IKK 
activation [115]. Hence, while it seems that IKKβ could not undergo cis-autophosphorylation; 
there is indeed a possibility that two dimers could autophosphorylate and activate each other by a 
process known as trans-autophosphorylation [116]. For this to happen, the two dimers need to be 
in close induced proximity with the right conformation [117], [113].  
These recent structural insights are in line with documented evidence suggesting that 
large oligomeric signaling complexes need to assemble for IKK activation. Thus, NF-κB 
activation might be mediated by recruitment of IKK to the receptor by adaptor proteins and 
signaling complexes from the TRAF/RIP (Receptor-interacting protein) family members [113], 
[117], [118], [119]. Upon recruitment of the IKK complex to the receptor, it either activates itself 
by autophosphorylation or is phosphorylated by another kinase like TAK1. 
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Different pathways leading to IKK activation share multiple signaling intermediates 
upstream of the IKK complex. These molecules are often the non-kinase adaptor molecules like 
the RIP and TRAF proteins.  It is still an open question whether IKK activation in the canonical 
pathway is mediated by autophosphorylation or TAK-1. However, there is no doubt that a 
kinase-independent organization of adaptor molecules leading to formation of receptor signaling 
complexes is necessary for either of these possibilities and therefore, in the downstream 
activation of NF-κB [108]. 
 
1.5: Ubiquitination and NF-κB 
Ubiquitin is a small protein made of 76-amino-acid that is covalently linked to its target 
protein [120, 121]. The protein is highly conserved across eukaryotes from yeast to humans. 
Ubiquitin is encoded in the genome as ‘ubiquitin precursors’ with ubiquitin fused with a 
ribosomal subunit or two ubiquitins fused together. There are four such genes encoding for 
‘ubiquitin precursors' [122]. Ubiquitination may affect a protein’s half-life, localization or 
function. Ubiquitination is a post-translational modification by which the epsilon amine of a 
particular lysine of a protein can be covalently linked through an isopeptide bond with the 
carboxylic acid of the C-terminal glycine of ubiquitin. The process occurs in three consecutive 
steps catalyzed by three classes of enzymes. These enzymes are the Ub-activating enzymes (or 
E1), Ub-conjugating enzymes (or E2) and Ub ligases (or E3) [123] (Figure 1.7). 
There are only two E1 enzymes in the genome. They catalyze the transfer of a thio-
ubiquitin intermediate to a cysteine residue of a specific E2 enzyme. This transfer is an energy-
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intensive process and proceeds by hydrolysis of an ATP. Thus ubiquitination requires energy and 
the cell uses it to mostly degrade its substrates. There are over 50 E2 enzymes which transfer the 
ubiquitin to an E3 ligase. There are around 700 E3 ligases and the specificity of ubiquitination 
partly comes from the E2-E3 interaction. Additionally, the E3 binds to the specific substrate and 
ligates the carboxyl terminus of the ubiquitin to the ϵ -amino group of the lysine (Lys) residue of 
that specific substrate [124]. Subsequently, multiple rounds of ubiquitination result in the 
formation of polyubiquitin chains. There are seven lysine residues in ubiquitin (K6, K11, K27, 
K29, K33, K48, K63), and any one of these can participate in elongation of the polyubiquitin 
chain. Thus, polyubiquitin chains may have different linkages. A linear ubiquitin chain may also 
be formed by attachment of N-terminal amine of one ubiquitin to the C-terminal carboxyl group 
of another ubiquitin.  
The E2-E3 combinations play a major role in determining the specific linkage of the 
ubiquitin chains. For example, a particular E2 (UBC5) complexes with another E3 ligase 
(SCFβTrCP) to trigger the formation of K48 linked polyubiquitin chains. Similarly, complexing of  




Figure 1.7: Ubiquitination and functions. (A) Three-step cascade that leads to ubiquitination; 
functions of diverse ubiquitin chains (B) Structure of ubiquitin (PDB code: 1UBQ), seven lysine 
residues are highlighted. [123] 
 
These different kinds of polyubiquitin linkages have different structures and topologies. 
Ubiquitin chains are recognized by proteins having an ubiquitin binding domain (UBD). Thus, 
different proteins with distinct UBDs bind the specific ubiquitin linkages. There are more than 
20 different types of ubiquitin binding domains (UBDs) that have been identified till now [126] 
[127], [128], differing substantially in their sizes (20-150 amino acids). For example, the 
proteasome subunits Rpn13/ARM1 and Rpn10/S5a have ubiquitin-associated (UBA) domains 
that preferentially bind K48 linked chains, while NEMO has a UBAN (UBD in ABIN and 
NEMO) motif that binds with both K63 and linear polyubiquitin chains (but not K48) [129]. 
Hence, different ubiquitin chains can potentially confer different fates to the substrate protein 
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(Figure 1.7). K48-linked ubiquitination (and K11) is known to dictate proteasomal degradation, 
while K63-linked chains have been proposed to function as scaffolds to assemble the different 
signaling complexes, thereby regulating different processes like DNA repair, chromatin 
remodeling, or activation of NF-κB. Thus, K63 ubiquitination is also known as regulatory 
ubiquitination [129], [130], [131].  UBDs can act as receptors for ubiquitin, thus in principle, it is 
possible for proteins that have UBDs to potentially transduce signals from substrates that are 
ubiquitinated to other components of the signaling pathway [128]. 
Like phosphorylation, ubiquitination is also a reversible post-translational modification. 
Thus, ubiquitination can be reversed by deubiquitination. The process of deubiquitination is 
carried out by proteases specifically known as deubiquitinating enzymes or deubiquitinases 
(DUBs). There are close to 100 DUBs in the human genome [132]. These DUBS can be 
subdivided into five broad families by the presence of various protease domains: they may be 
metalloproteases, papain-like cysteine proteases (i.e, a carboxy-terminal hydrolase), ubiquitin 
specific protease, joseph disease proteases or an ovarian tumor containing protease (OTU 
deubitinase).  
The specificity of DUBs is determined by their UBDs and other protein interaction 
motifs. This directs them to specific ubiquitinated substrates containing a particular type of poly-
Ub chain linkage [133]. If K63 linked polyubiquitin chains positively regulate NF-κB signaling, 
then their deubiquitinases would be expected to be critical regulators of the pathway. Indeed, 
A20 and CYLD have been reported to be two such critical proteins with deubiquitinase activity. 
However, what is not known is if the deubiquitinase activity of these proteins is actually 
responsible for their function, or if these proteins act by a different mechanism. Mice lacking 
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A20 are perinatal lethal, suffering from uncontrolled multi-organ inflammation as a result of 
persistent NF-κB activity [134]. Additionally, mutations or organ-specific deletions of TNFΑIP3 
(the gene encoding for A20) is associated with different kinds of lymphomas [135], [136], [137], 
[138]. Moreover, patients with the autoimmune disorder systemic lupus erythematosus also have 
been found to have polymorphisms in their TNFΑIP3 locus [139]. CYLD is another 
deubiquitinase that acts as a tumor suppressor and negatively regulates NF-κB signaling. Patients 
with familial cylindromatosis have been found to have multiple somatic mutations in CYLD and 
deletion of CYLD may cause colonic, hepatocellular, and renal carcinomas, in addition to 
multiple myeloma [140].  
 
1.6: Degradative ubiquitination in canonical and non-canonical NF-κB signaling 
Aaron Ciechanover, Avram Hershko and Irwin Rose elucidated the ubiquitin pathway 
and characterized the various enzymes (E1, E2, E3) and deubiquitination enzymes (DUBs) 
[141], [142]. For this, they were jointly award the Nobel Prize for Chemistry in 2004. 
Subsequently Alex Varshavsky and colleagues showed that ubiquitination targets proteins 
degradation in vivo [143], [144]. While there is room for abundant skepticism for the role of 
K63-linked polyubiquitination, there is no doubt that K48-linked ubiquitin chains play a 
prominent role in NF-κB signaling. Activation of NF-κB is defined by IκB degradation or by the 
proteasomal processing of NF-κB precursor proteins and this is mediated by degradative 
ubiquitination [145] (Figure 1.8).  
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Canonical NF-κB signaling may be defined as those pathways which lead to ‘degradation 
of IκB’. These pathways are mostly activated by proinflammatory stimuli including bacterial 
PAMPSs like LPS and cytokines like interleukin (IL)-1β and TNFα.  Stimulation leads to the 
activation of the IKK complex which phosphorylates the IκB proteins. This targets the 
phosphorylated IκBs for K48-mediated polyubiquitination by a K48-specific ubiquitin ligase 
complex that consists of Skp1, Cul1, Roc1 and βTrCP [146].  The ubiquitinated IκB undergoes 
degradation by the 26S proteasome. This allows NF-κB to translocate to the nucleus and begin 
transcription of target genes.  
The noncanonical pathway is defined as the pathway that leads to the ‘proteasomal 
processing’ of precursor-p100 to its mature p52 subunit [145].  This happens when some 
receptors (such as B-cell activating factor receptor and CD40) are stimulated in B lymphocytes. 
Upon stimulation, NIK activates IKKα, which in turn phosphorylates p100. p100 is now 
ubiquitinated by the βTrCP ubiquitin ligase complex. Under most circumstances, K48-
polyubiquitination results in complete proteasomal degradation. However the ubiquitinated p100 
is not complete degraded but the C-terminal ankyrin repeats are selectively degraded by the 26S 
proteasome. This leaves the N-terminal portion intact, and this is the mature p52 subunit.  This is 
because a glycine-rich region in the N-terminus of p100 prevents it from degradation [147]. 
Additionally, the N-RHD domain is tightly folded and forms a stable dimer, making this region 











1.7: Oligomerization in activation of IKK 
A cursory look at any of the three major NF-κB activation pathways (TNF , Toll/IL-1 or 
T cell receptor) show that oligomerization is a shared theme in NF-κB signaling [25] (marked in 
red in Figure 1.9) and recruits the IKK complex to the receptor.  Dimerization of the recruited 
IKK has been shown to be necessary and sufficient for activation of IKK [63], [117], [149].   
The dimerization of IKK is mediated by NEMO, which can form higher order structures 
in vitro (dimers, trimers, and tetramers) and in vivo [150], [151], [152]. RIP1 was shown to have 
a major role in inducing oligomerization of NEMO [119], and activating IKK [118].  Mutations 
in the NEMO oligomerization domain can prevent IKK function. Moreover, mutated NEMO acts 
as a dominant negative [151], [153]. Additional proof of the role of IKK oligomerization in 
induction of NF-κB comes from the observation that viral proteins that activate NF-κB also 
proceed via oligomerization of NEMO [154], [155]. Thus, oligomerization of NEMO is essential 
for inducible assembly and activation of the IKK complex. 
How does IKK/NEMO oligomerize following signal induction? There are two models 
that could explain the formation of oligomeric signaling complexes that recruit the IKK subunits 
and thereby facilitates IKK activation [108].  
According to the first model, receptor engagement causes upstream adapter proteins like 
the RIPs, TRAFs, or various CARD-containing proteins to oligomerize and form higher-order 
structures. IKK is now recruited and binds to these adapter proteins. This causes IKK 
oligomerization. It has been reported that oligomerization of RIP or BCL10 and consequent 





Figure 1.9: Assembly of adaptor proteins in major signaling pathways that lead to NF-κB 
activation (modified from [116]) 
 
According to a second model, ubiquitin chains provide the oligomeric platform and 
recruit the TAK1 and/or IKK complexes, thereby activating them. There are two conceivable 
ways in which these ubiquitin chains may act.  
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The ubiquitin chains may provide the oligomeric platform for another kinase to 
phosphorylate the proximal IKK or the chains may assist proximity-induced trans-
autophosphorylation. Alternatively, ubiquitin chains may directly activate the IKK complex.  
The nature of the linkage of these ubiquitin chains has been proposed to be quite diverse. They 
may be K63-linked or linear. Traditionally, the ubiqutitin chains have been known to be attached 
to a substrate. However, in addition to these traditional ubiquitin chains, free ubiquitin chains 
(K63 linked) not attached to any substrate have also been proposed to activate the IKK complex. 
Interestingly, while K63 linked polyubiquitin chains have been proposed to play a non-
degradative role in NF-κB activation, in vitro experiments reveal that proteins modified with 
K63-linked polyubiquitin chains are actually degraded by the proteasome [156]. However, 
quantitative mass-spectrometry suggests that following proteasomal inhibition, K48-linked but 
not K63-linked polyubiquitin chains accumulate in yeast cells [157]. 
In fact, one area in the NF-κB signaling field that has attracted much attention recently is 
the area of ‘regulatory’ ubiquitination (or signaling mediated by K63-lined and linear ubiquitin 
chains).  Initial work showed that IKK could be activated by polyubiquitination via a 
proteasome-independent mechanism (thus, these polyubiquitin chains were not K48-linked) [76]. 
However, this publication was met with considerable skepticism as it was difficult to appreciate 
how these unique polyubiquitin chains would respond to a physiological stimulus. Besides, the 
claim was based only on in vitro biochemical experiments [158], and it was not clear if E2 or E3 
enzymes existed that could make non-K48-linked ubiquitin chains. Then, however, TRAF6 was 
characterized as an E3 ligase while Ubc13/Uev1A was identified to be the E2 complex 
responsible for catalyzing the formation of K63-linked ubiquitin chains and inducing IKK 
activation in vitro [159]. The conclusions were partly supported when a homologous 
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Ubc13/Uev1A E2 complex was found in yeast and was shown to be involved in DNA repair by 
catalyzing the formation of K63 polyubiquitin chains [160]. This jump-started the work in the 
field of regulatory ubiquitination. Interestingly though, mice deficient in TRAF6 develop 
osteoporosis, but do not show any drastic phenotype as would be expected of mice lacking any 
of the crucial components of the NF-κB signaling pathway [161, 162].  
Thus, mechanistically speaking IKK could be activated either by oligomerization of 
adapter proteins or by ubiquitin scaffolds. However, these two mechanisms may not be mutually 
exclusive.  Indeed, proteins that play a role in assembling the signaling complexes (as adaptors) 
may also get ubiquitinated (like RIP1 or TRAFs). This makes it difficult to ascertain whether the 
ubiquitin-independent adaptor property of these proteins or the ubiquitin chains on the adaptor 
proteins is responsible for downstream IKK activation. Examples of adaptor proteins that get 
ubiquitinated include RIP1, NEMO and TRAF6, as discussed below. 
RIP1 oligomerization leads to inducible interaction with NEMO and subsequent 
activation of the IKK complex [119]. However, RIP1 is also ubiquitinated at Lys-377 after TNFα 
stimulation and it has been proposed that it is through these ubiquitin chains that RIP1 binds to 
NEMO, thus recruiting IKK to the receptor complex (via the ubiquitin binding domain of 
NEMO) [163], [164]. The authors show that the K377R mutant cannot be ubiquitinated and 
prevents the recruitment of IKK complex to the TNF receptor. They claim that this observation 
demonstrates the importance of ubiquitin chains in the recruitment process. Their conclusion is 
however compromised by the fact that the same report reveals that K377R-RIP1 is structurally 
altered and cannot itself be recruited to the receptor.  
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NEMO oligomerization can lead to NF-κB activation [150], [151], [152]. NEMO has also 
been reported to be ubiquitinated in several pathways at K399 as well. However, mutation of this 
site did not lead to complete NF-κB inactivation [165]. Additionally, a knock-in mouse 
containing a mutation at this site was found to be largely normal [166]. NEMO also contains a 
ubiquitin-binding domain and could interact with ubiquitin chains [129]. However, it is difficult 
to accurately determine the domain required for interaction as the NEMO oligomerization 
domain overlaps with the NEMO K63-ubiquitin-binding domain (UBD).   
Another protein whose autoubiquitination might lead to the activation of a possible IKK-
activating kinase (TAK1) is TRAF6. TAK1 has, in turn, been proposed to be activated by 
TRAF6 catalyzed K63-linked ubiquitin chains [167]. TAK1 exists in a complex with TAB1 and 
TAB2. TAB2 and TAB3 have ubiquitin binding domains (UBD), which bind the K63 chains. An 
elegant mechanism was proposed in which the TAK1-TAB2-TAB3 complex bound to K63-
polyubiquitin chains via the UBD of TAB2 and TAB3, resulting in activation of TAK1. TAK1 
subsequently phosphorylated IKK in the two serines in the activation loop, resulting in IKK 
activation. Another report by the same group subsequently showed that TAK1 could also be 
activated by unanchored K63 linked polyubiquitin chains (these chains are not linked to any 
substrate but are free) [168]. From their findings, the authors proposed that K63 ubiquitin chains 
directly [169] regulate NF-κB activation. However, their model is not substantiated by genetic 
evidence. Analysis of mice deficient in TAK1, TAB2 and TAB3 shows that while TAK1 plays 
an essential role in vivo, TAB2 and TAB3 are dispensable. While TAK1 knockouts exhibit 
embryonic lethalality, TAB2 knockouts and TAB3 knockouts show normal NF-κB activation 
[169]. It is important to note that the proposed dependence on regulatory ubiquitination comes 
from the binding of TAB2/TAB3 to the K63 liked ubiquitin chains. This binding is important as 
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TAK1 does not itself have a UBD. In theory, the data with the TAB2 and TAB3 knockouts 
suggests that TAK1 could also be activated by recruitment to the receptor complex by various 
adaptors proteins; such an alternative model would preclude the requirement of the K63 
ubiquitin chains. Of course, it is possible that the TAB2 is compensating for TAB3 and vice 
versa, but double knockouts of TAB2 and TAB3 have not yet been reported. 
Many other components of the NF-κB signaling pathway have been showed to be 
modified by K63 linked ubiquitin chains [170]. However, what is not understood is the role these 
chains play in signaling. One issue with the theory of regulatory ubiquitination is with the 
delayed kinetics of ubiquitination, and the consistent observation that regulatory ubiquitination 
only targets a minuscule fraction of any protein. Thus, the hypothesis is that regulatory 
ubiquitination may result from aggregation of substrates with adaptors exhibiting E3 ligase 
activity. There are some examples of proteins that are ubiquitinated in a robust manner. But even 
for these substrates like IRAK1 and MALT1, it is not clear if the regulatory ubiquitination 
actually precedes IKK activation and IκBα degradation, as would be expected if the K63-linked 
ubiquitination is indeed “regulatory” [171, 172].  Since it is not clear if these substrates actually 
get ubiquitinated before IKK activation, there is skepticism as to whether the K63-linked 
ubiquitin chains are indeed necessary for IKK activation.  
Thus, it has been rather challenging to understand the importance of “regulatory 
ubiquitination” in activating NF-κB. The central problem has been the lack of genetic data. A 
broad aim of my theses is trying to decipher the relevance of K63-linked regulatory ubiquitin 




1.8 Negative regulation of NF-ΚB signaling 
Most of the pathogen-sensing receptors of the innate immune system activate NF-κB and 
both the innate and adaptive immune system is critically dependent on NF-κB. The importance 
of this transcription factor can be gauged from the range of receptors that engage the pathway 
(receptors for proinflammatory cytokines and PAMPS, antigen receptors on T cells and B cells). 
Thus, the prompt activation of this transcription factor is essential for host defense. Activated 
NF-κB translocates to the nucleus and induces the transcription of genes responsible for survival, 
differentiation and proliferation of immune cells, as well as proinflammatory cytokines that 
provide the initial protective response against pathogens. However, since the pathway leads to 
the expression of multiple inflammatory genes, it is critical that the activation is transient and 
tightly controlled after the initial protective response, as persistent inflammation can lead to 
tissue damage and other autoimmune diseases. Indeed persistent NF-κB activation is one of the 
main causes for chronic inflammation and cancer [173], [174], [175]. Hence, multiple negative 
regulatory systems have evolved at different molecular levels to attenuate and terminate 
signaling [69], [176]. 
The mammalian NF-κB family consists of several members that have the transactivation 
domain (TAD) and are thus competent to drive transcription on their own –RelA (p65), RelB and 
c-Rel proteins. The family also includes the transcriptionally inactive members like NF-κB1 
subunit (p50 derived from p105 precursor) and NF-κB2 subunit (p52 derived from p100 
precursor) [25]. p50 and p52 need to form heterodimers with the TAD containing members to be 
transcriptionally active.  The subunits form various homodimers and heterodimers. It is critical 
that NF-κB is inactive under resting conditions, otherwise the host would be overwhelmed with 
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inflammatory cytokines which have the potential to cause unlimited tissue damage and even 
death [17].   
One method of negative regulation is the synthesis of more inhibitory IκB proteins. 
Alternatively, since the pathway converges on IKK, turning off upstream signaling molecules 
that activate IKK is another method of negative regulation of the pathway [116, 177]. As shown 
in Figure 1.10, activation of NF-κB induces expression of negative regulators IκBα and A20. 
The newly synthesized IκBα protein bind to the NF-κB dimers in the nucleus and shuttle them 
back into the cytoplasm. The newly synthesized A20 protein act upstream of IKK by 




Figure 1.10: Inhibition of canonical activation of NF-κB by IκBα and A20 [176] 
 
1.9: Inhibition of NF-κB activity by classical IκB proteins 
An overwhelming amount of data points to the biological significance of IκBs as the 
main negative regulators in NF-κB signaling.  
Upon stimulation, a cascade of events activates IKK, which then phosphorylates the 
inhibitory IκB proteins (IκBα, IκBβ and IκBε) at specific serine residues. The IκBs are now 
 41 
 
proteasomally degraded. Interestingly, though the three IκBs are degraded with distinct kinetics. 
Moreover, their transcriptional regulation by NF-κB following degradation is substantially 
different [37], [60]. IκBα is rapidly degraded while IκBε undergoes the slowest degradation [37], 
[60]. Unlike IκBβ, genes encoding for IκBα and IκBε are under the direct control of NF-κB, 
enabling the two to function as negative feedback inhibitors [50], [178], [179].  
Activated NF-κB induces the expression of IκBα and IκBɛ. The newly synthesized IκB α 
goes to the nucleus and associates with the NF-κB dimers which are located in the nucleus [180]. 
IκBα has a nuclear-export sequence, hence the IκB-NF-κB translocates from the nucleus to the 
cytoplasm. This constitutes a classic negative feedback loop. IκBε production is also induced by 
NF-κB but the expression of IκBε expression is significantly delayed as compared to IκBα 
expression [179]. The newly synthesized IκBɛ seems to dampen IκBα-driven NF-κB oscillations, 
as the induction of its mRNA occurs out of phase with that of IκBα  
Deletion of the main inhibitor of NF-κB (IκBα) expectedly results in early lethality 7-10 
days after birth. The cause of death is hyperinflammation, highlighting the importance of NF-κB 
in the expression of inflammatory genes [73]. Further evidence of IκBα inhibition is provided by 
the observation that mice which have a mutated IκBα promoter (mutated κB enhancers of the 
IκBα gene) and consequently produce less IκBα, have a shortened life span (13-15 months), are 
more sensitive to LPS-mediated septic shock and exhibit abnormal development and activation 
of T-cells [181]. While deletion of IκBɛ does not result in lethality, it does result in the increased 
production of cytokines [182]. Double knockouts of IκBα and IκBɛ exhibit a more drastic 
phenotype than the single knockouts alone. Deficiency of both inhibitors causes neonatal 
lethality.  B and T cells are completely absent and the number of NK cells is significantly 
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reduced [183]. Thus, the host has evolved these two inhibitors with overlapping functions. This 
is also proven by the upregulation of IκBɛ in IκBα -deficient cells. This upregulation disappears 
upon IκBα reconstitution, thereby demonstrating that a certain amount of these two inhibitors is 
biologically ideal [184]. 
Traditionally, the IκB family of proteins has been thought of as sequestering-agents of 
various NF-κB complexes in the cytoplasm [185]. However, it is now clear that the functions of 
the individual IκBs do not quite fit into this simplistic criterion. It is probably better to think of 
the IκB family of proteins as chaperones/cofactors of NF-κB, associating with and stabilizing the 
NF-κB dimers both in the cytoplasm and nucleus. The binding of IκB to DNA-bound NF-κB 
potentially influences the recruitment of other coactivators and the resulting transcriptional 
response. Thus, association of IκB with NF-κB dimers may lead to an increase or decrease of 
transcription, depending on the context. 
An example of an IκB that serves to both activate and inhibit inflammatory gene 
expression is IκBβ [186]. While IκB generally inhibits NF-κB activation, IκBβ has been found to 
prolong the expression of certain genes like TNFα or interleukin 1β (IL-1β) [186, 187] as it 
serves as an essential cofactor for the expression of these genes. It might be counterintuitive to 
think that the same proteins can perform two opposite functions. However, this is possible as 
IκBβ exists in two forms that perform opposite functions: a basal phosphorylated form and an 
hypophosphorylated form that appears upon stimulation.  
When cells are stimulated with LPS, the basally phosphorylated IκBβ is slowly degraded 
(as compared to IκBα). After this, IκBβ is resynthesized as a hypophosphorylated form and can 
be found in the nucleus [34, 35, 188, 189] with p65-cRel dimers.  Thus unlike IκBα, which can 
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dislodge the NF-κB dimers from the DNA, IκBβ cannot promote the spontaneous dissociation of 
NF-κB dimers from DNA [190]. The two inhibitors are structurally different as IκBβ does not 
have a NES. Hence, the IκBβ-p65-cRel trimeric complex does not readily export to the 
cytoplasm. Additionally, the hypophosphorylated form does not mask the NLS of p65. Hence, 
the trimeric complex is found bound to the DNA [35, 188, 191]. This binding of the 
hypophosphorylated form of IκBβ to the DNA in association with NF-κB dimers is also 
supported by the crystal structure of IκBβ bound to homodimers of p65 [192]. In contrast, the 
phosphorylated IκBβ can mask the p65 NLS, thereby inhibiting binding to DNA under basal 
conditions [35, 188, 191].   
The NF-κB:IκBβ complexes bound to the DNA are stable and resistant to newly 
synthesized IκBα (and IκBɛ). Hence, it was hypothesized that nuclear, hypophosphorylated IκBβ 
may actually be a transcriptional activator of specific genes [35]. This was directly in contrast to 
the traditional thinking of IκBs only role as cytoplasmic inhibitors of NF-κB. 
After nearly a decade, the genetic evidence has substantiated the hypothesis. The IκBβ 
knockout (made in our lab) indeed shows that IκBβ has distinct functions in the cytoplasm and 
nucleus [186, 187]. In the cytoplasm, phosphorylated IκBβ acts as a traditional NF-κB inhibitor 
sequestering p65-cRel heterodimers. However, upon stimulation the cytoplasmic IκBβ is 
degraded and the heterodimers translocate to the nucleus. Hypophosphorylated IκBβ is newly 
synthesized and found in the nucleus bound to the   p65-c-Rel heterodimers at specific κB 
promoter sites, accentuating expression of certain proinflammatory genes like TNF [186] and IL-
1β [187]. Mice deficient in IκBβ consequently express less TNFα (or IL-1β), rendering them  
resistant to LPS-induced septic shock and collagen-induced arthritis.  
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Thus, both genetic and biochemical experiments have demonstrated that IκBβ behaves 
substantially differently as compared to the other IκB inhibitors. 
 
1.10: Inhibition of NF-κB activity by deubiquitinases upstream of IKK 
A plethora of biochemical work, in conjunction with mass-spectrometry, has 
demonstrated that multiple adaptors upstream of IKK are decorated with K63 linked 
polyubiquitin chains. Hence, it has been suggested that K63 linked polyubiquitin chains are 
essential for the activation of NF-κB. The proposition holds that ligand binding to different 
receptors leads to the recruitment of E3 ligases that polymerize nondegradative K63-linked 
polyubiquitin chains on specific adaptors [25, 125]. This leads to the activation of IKK in 
multiple pathways. 
For example, stimulation of the TNF receptor results in recruitment of the TRADD 
adaptor protein, and the consequent assembly of a signalosome consisting of RIP1 and multiple 
E3 ubiquitin ligases like cIAP1, cIAP2 and TRAF2. This leads to the polyubiquitination of RIP1 
by K63-linked polyubiquitin chains [193]. These polyubiquitin chains on RIP1 might play a role 
in recruiting kinases like TAK1 and IKK (via the UBD of NEMO) [163], [164].  
It has been conclusively demonstrated that activation of other receptors also recruits 
intermediates that have E3 ligase activity. For example, TLRs recognize PAMPs and activate 
IKK by using various intermediates including  MyD88, TRIF, TAK1 and E3 ligases like TRAF6 
and IRAK1 [194]. TCR mediated signaling, on the other hand, proceeds via the recruitment of 
adaptor proteins like CARD11, Bcl-10, MALT1, TAK1 along with E3 ligases like TRAF2 and 
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TRAF6 [195]. However there is no genetic evidence to show that the ligase activity is integral to 
NF-κB activation. 
Ubiquitination is a reversible, post-translational modification, thus deubiquitinases could 
disassemble the ubiquitin chains and potentially downregulate NF-κB activation. Indeed, 
deubiquitinases (DUBs) have been shown to be important for the downregulation of NF-κB 
[120]. It is important to note that by a process known as ‘ubiquitin editing’, DUBs can 
potentially collaborate with E3 ligases to initially inactivate and then degrade essential mediators 
of IKK activation. Thus, the DUB could initially deubiquitinate the K63 linked polyubiquitin 
chains, thereby disassembling the ubiquitin scaffold that organizes the signaling complex.  After 
this, the ligase could add K48 linked polyubiquitin chains to the same protein thereby targeting it 
for proteasomal degradation [196], [197], [198].   
As shown in Figure 1.11, activation of various pathways leads to recruitment of 
signaling complexes possibly coordinated by the K63-linked polyubiquitination of IRAK1, RIP1 
and TRAF6 (grey circles). Linear ubiquitin chains may also be formed by the action of the 
heterodimeric LUBAC complex (linear ubiquitin chain assembly complex; a ubiquitin ligase that 
catalyzes formation of linear ubiquitin chains) in response to TNF-mediated signaling (tan 
circles). Free, unanchored Lys63-linked polyubiquitin chains may also directly activate IKK. 







Figure 1.11: Activation of NF-κB by regulatory ubiquitination and inhibition by deubiquitinases 
[199] 
 
Three common deubiquitinases are A20, Cezanne and CYLD, and mutations or deletions 
of these genes lead to inflammation or tumorigenesis, as would be expected if these were to 
function as NF-κB inhibitors. However, as with the ligases, there is no evidence that the 
deubiquitinase activity of these enzymes is actually responsible for downregulating NF-κB. 
1) A20 (TNFΑIP3): The best known deubiquitinase is A20. A20-knockouts die from 
unrestrained inflammation [134], [200]. Multiple autoimmune diseases like systemic lupus 
erythematosis are associated with polymorphisms in the A20 locus (Table 1.1 and Figure 1.12). 
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A20 also acts as a tumor suppressor in B-cell lymphoma. Recent evidence also implicates 
dysfunction of A20 as a risk factor for multiple autoimmune diseases [135], [136], [139], 
[138],[201]. Thus, A20 is essential for terminating inflammatory responses. Hence, it is very 
important to understand the mechanism by which A20 functions. A20 is virtually absent under 
resting conditions and is then rapidly induced by NF-κB [202]. In fact, A20 is also called 
TNFΑIP3 or ‘TNFα induced protein 3’ as it was initially identified following induction with 
TNFα [203]. Expression of A20 mRNA is under the direct control of NF-κB (much like IκBα). 
Thus upon stimulation, A20 rapidly accumulates and negatively regulates NF-κB by potentially 











Disease Mutation in A20 or SNPs identified 
Atherosclerosis in mice E627A (mouse) 
Diabetes rs 5029930 
 rs 610604 
Crohn's disease rs 7753394 
Coeliac disease rs 2327832 
Rheumatoid arthritis rs 10499194/rs 13207033 
 rs 6920220 
 rs 5029937 
Systemic lupus erythematosus rs 5029939 
 rs 10499197 
 rs 7749323 
 rs 13192841 
 F127C (rs 2230926) 
 rs 6922466 
Type 1 diabetes rs 10499194 
 rs 6920220 
Psoriasis rs 610604 
Table 1.1: Polymorphisms of A20 associated with autoimmune diseases. [201] 
 
 
A20 has a DUB domain followed by a number of C2-C2 zinc-finger domains and the 
fourth zinc-finger domain (ZF4) is known to have E3 ubiquitin ligase activity [196], [204].  This 
should, in theory, allow dual ubiquitin-editing function, i.e, A20 should be able to act both as a 
ligase and a deubiquitinase. It has been biochemically demonstrated that upon stimulation with 
TNFα, A20 accumulates and disassembles the K63-linked polyubiquitin chains from RIP1, 
attenuating NF-κB signaling (the deubiquitinase function is mediated by Cys103 in the OTU 
domain). In the next step, the E3 ligase domain adds degradative K48-linked polyubiquitination 
chains to RIP1, leading to proteasomal degradation of RIP1 and terminating NF-κB signaling 
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[196]. Incidentally, the DUB activity of A20 is not specific to RIP1 as A20 generally 
deubiquitinates other substrates upstream of IKK. These include TRAF6 [200], NEMO [205], 
RIP2 [206] and MALT1 [207] (Figure 1.13).  
The deubiquitinase activity of A20 has been proposed to be essential in downregulating 
NF-κB on the basis of in vitro work. However, certain critical biochemical data are also difficult 
to reconcile with this. For example, overexpression of a deubiquitinase mutant of A20 has been 
shown to inhibit NF-κB [204], [208]. It is also paradoxical in the light of the proposed 
mechanism that the deubiquitinase activity has been found to be non-specific for K63 chains. 
Indeed A20 has been shown to only weakly deubiquitinate K63 polyubiquitin chains, while it 
robustly disassembles K48 polyubiquitin chains [209], [210].  
Recently, the crystal structure of the OTU domain of A20 has been solved [209], [210] 
and it is not clear how A20 would distinguish between K48 and K63-linked chains. A20 reacts 
with polyubiquitinated TRAF6 to yield polyubiquitin chains but not monoubiquitin linkages 
[210]. This shows that A20 might derive specificity from directly interacting with TRAF6. 
However, A20 does not cleave monoubiquitinated TRAF6. Thus understanding the mechanism 




Figure 1.13: Mechanism of action of A20 [211] (modified) 
 
2) Cezanne: Along with A20, there is another cysteine-protease DUB called Cezanne 
(cellular zinc finger anti-NF-κB) which also attenuates NF-κB signaling by deubiquitinating 
K63-linked chains from RIP1 [212]. Like A20, the expression of Cezanne increases after TNF-α 
stimulation. The deubiquitinase action of Cezanne may be biochemically important as the 
catalytically inactive mutant cannot inhibit NF-κB activation. However Cezanne is not specific 
to K63 chains and preferentially deubiquitinates K11-linked polyubiquitin chain [213]. Thus, the 
biological significance of the deubiquitinating activity of Cezanne is unclear. 
3) CYLD: The third well known deubiquitinase is CYLD (cylindromatosis gene). The 
deubiquitinase action of CYLD is mediated by the conserved Cys601 and mutating this residue 
leads to persistent NF-κB signaling [214]. It has been biochemically established that CYLD 
negatively regulates NF-κB [215], [214], [140]. However, CYLD is a promiscuous 
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deubiquitinase as it removes ubiquitin chains from multiple substrates including RIP1, TRAF2, 
TRAF6, TAK1 and IKKγ [216], [217], [140], [214], [218]. In this regard, CYLD lacks 
specificity and cleaves both K63-linked polyubiquitin chains as well as linear ubiquitin chains 
[219], [220]. It can also cleave K48-linked chains from adaptor Lck in T cells [221]. 
The expression of CYLD is not directly induced by NF-κB (unlike A20 and Cezanne) 
[222]. Thus, CYLD is present at basal levels and might play a role in suppressing NF-κB 
activation in resting cells. In contrast, A20 is expressed at low levels under basal conditions and 
rapidly induced in response to proinflammatory stimuli to downregulate excessive NF-κB 
activation. This may be the reason why the two DUBs do not compensate for each other as their 
mechanisms of action are temporally distinct. The activity of CYLD has to be depressed for the 
cells to become activated. Hence, its activity is controlled by subcellular localization in addition 
to phosphorylation on multiple serine residues by IKK (in a NEMO dependent manner) [223], 
[224]. 
Since CYLD deubiquitinates multiple upstream activators of IKK, the expectation was 
that the CYLD knockout would show a drastic phenotype. Accordingly, multiple groups 
embarked on the project and mice deficient in CYLD were generated independently by various 
groups. Contrary to expectations, Cyld-/- mice show no obvious defect in growth or survival 
[221]. However, they do develop some defects in the immune system with age. Additionally, the 
knockouts generated by different groups sometimes have conflicting phenotypes. In general, 
these genetic knockouts show that CYLD plays a role in immune cell development, 
osteoclastogenesis and spermatogenesis. Thus, Cyld−/− mice made by one group have reduced 
numbers of CD4(+) and CD8(+) single-positive T cells in the thymus and periphery [221]. 
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Cyld−/− mice spontaneously develop inflammation in the colon[218], osteoporosis [225], B cell 
hyperplasia and lymphoid organ enlargement [226]. Studies also show that CYLD plays an 
important role for survival of immature NKT cells [227] and spermatogenesis [216]. However 
conflicting genetic data from another group showed that development of T cells and myeloid 
cells was normal in CYLD-knockouts [217]. A third group showed that Cyld deficient mice are 
more prone to skin tumors [223]. Mice expressing a naturally occurring variant of CYLD that did 
not express exon 7 and 8 (thereby lacking binding sites to TRAF2 and NEMO) were found to 
have enlarged spleens as a result of dramatic accumulation of mature B cells [228].  
 
1.11: Perspectives on inhibitors of NF-κB and broad aims of this thesis 
25 years of research has made it clear that appropriate down-regulation of NF-κB 
signaling is as important as NF-κB activation. IκB proteins are the most well documented 
inhibitors of NF-κB in the physiological setting, as borne out by both biochemical and genetic 
studies. However along with the IκBs, there is a plethora of biochemical evidence to suggest that 
deubiquitinases may also function as negative feedback regulators of NF-κB signaling. This 
thesis examines the mechanism of two inhibitors of NF-κB: (i) A20, which downregulates 
activation of NF-κB upstream of IKK in stimulated cells and (ii) IκBβ which downregulates NF-





1st broad/specific aim: Examine the role of regulatory K63-linked polyubiquitin 
chains in NF-κB activation (specifically, I examined the role of deubiquitinase activity of 
A20 by generating knock-in mice selectively lacking the K63-deubiquitinase function)  
While multiple adaptor proteins have been shown to be covalently linked with K63-
linked polyubiquitin chains, it is not clear if such regulatory polyubiquitination is essential for 
activation of IKK in the physiological context. This is because of an acute lack of genetic 
complementation experiments. Ultimately, the importance of regulatory ubiquitination mediated 
by K63-linked polyubiquitin chains has to be demonstrated in knock-in mouse models (that have 
point mutations selectively disrupting regulatory ubiquitination).  The need for this genetic 
evidence can be understood by studies done on NEMO. NEMO knockouts are embryonically 
lethal, thus demonstrating that NEMO is clearly essential for NF-κB activation [229], [70]. 
Biochemical experiments showed that K63-linked polyubiquitination of Lys-399 was essential 
for NF-κB activation [165], and it was believed for some time that this ubiquitination would play 
an important role in animals. However, a knock-in mouse with a point mutation at this site was 
found to be largely normal with respect to NF-κB activation [166]. This shows that K63-linked 
polyubiquitination of Lys-399 is not important for NF-κB activation. 
Traditionally, putative targets that have been proposed to modulate NF-κB activation by 
regulatory ubiquitination were identified by overexpression of proteins mutated at specific 
lysines. However, mutating a positively charged residue like lysine might change the protein 
conformation leading to incorrect protein folding, thereby altering other functional attributes of 
the protein. For example, the ubiquitination of RIP1 at K377 [163], [230] in response to TNFα 
was demonstrated by overexpression and knock-down studies to be essential in activating IKK. 
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The K377R mutant is not ubiquitinated; however it also does not get recruited to the activated 
TNF receptor complex [163]. This may be because of altered conformations in the mutated 
protein. In fact, a subsequent study by the same group has shown that cells which have 
endogenous ubiquitin genetically replaced with K63R ubiquitin do not show impaired IKK 
activation in response to TNFα [231]. One lesson to draw from this discrepancy is that knock-
down and overexpression studies have limitations.  The level of protein depletion affects 
experimental outcomes in knock-down studies, while overexpression of signaling components 
such as ubiquitin ligases or adaptor proteins (like the TRAFs and cIAPs) may lead to 
promiscuous oligomerization and signaling. 
In order to evaluate the effect of regulatory ubiquitination on the NF-κB pathway, we 
examined various genes that are involved in regulatory ubiquitination based on previously 
published genetic and biochemical data. Specifically, we looked for two criteria: 
1) The knock-out of this gene should result in a phenotype consistent with a profound 
dysregulation of NF-κB signaling, thus this gene would have to be non-redundant in terms of its 
effects on NF-κB signaling. 
2) Biochemical and in vitro complementation studies of the gene in cell-lines (using 
different methodologies) would have to clearly point to an amino-acid that is involved in 
regulatory ubiquitination, such that mutating this residue would disrupt regulatory ubiquitination 
and NF-κB signaling. 
Based on these criteria, we planned to generate a knock-in mouse with a point-mutation 
for the identified residue of interest. If regulatory ubiquitination is indeed important for NF-κB 
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signaling, then this knock-in mouse would be expected to resemble the knock-out (at least 
partially). If not, then some other property of the protein (apart from the ability to mediate 
regulatory ubiquitination) would be expected to be involved in NF-κB signaling. 
The candidate genes that we considered included E2 enzymes (Ubc13), E3 enzymes (like 
TRAFs and cIAPs), adaptor proteins that are ubiquitinated by K63-linked ubiquitin chains (like 
RIP1) and deubiquitinases like A20. 
1) E2 enzyme Ubc13: Two groups reported that Ubc13 deficiency causes embryonic 
lethality; however it is not clear if this lethality results from defective NF-κB signaling [232], 
[233].  
2) E3 ligases like TRAF and cIAP proteins: TRAF proteins are highly redundant. There 
are a total of seven TRAF proteins, all of which have a common C-terminal coiled-coil TRAF 
domain. TRAFs2-7 also contains a N-terminal RING finger domain that is involved in ligating 
ubiquitin chains to substrates; thereby enabling these TRAFs to act as E3 ligases. Amongst them, 
TRAFs2, 5, and 6 have been shown to be important adaptors for IKK activation. TRAF6 plays a 
role in LPS-mediated signaling, and TRAF6 knockouts develop osteoporosis [161, 162]. TRAF2 
and TRAF5 act downstream of the TNF receptor. TRAF2 knockouts are born normal and do not 
show any major defect in NF-κB signaling [234]. This might be expected as TRAF5 may 
compensate for TRAF2. Indeed, TRAF5 knockouts are also relatively normal because of 
compensation by TRAF2 [235]. However, TRAF2/5 double-knockouts are embryonic lethal 
[236]. It is not clear though if the RING domain of the TRAFs is essential for NF-κB activation 
([237]. Additionally, along with the E3 ligase action, the RING domain of TRAF2 is also 
essential for recruiting IKK to the receptor complex. Hence, it would be difficult to ascertain if 
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any observed signaling defect would be because of ‘RING-mediated regulatory ubiquitination’ 
or ‘RING-mediated adaptor function’.  
Similar to the TRAFs, cIAP1 and cIAP2 are also redundant and compensate for each 
other. None of the single knockouts show a phenotype [238], [239], because of compensation by 
the other isotype.  Cells deficient in both the isotypes are sensitized to apoptosis resulting from 
decreased activation of NF-κB [193], [240]. 
3) Adaptor proteins like RIP1: Mice deficient in RIP1 die within a couple of days after 
birth from tissue apoptosis as the anti-apoptotic NF-κB pathway cannot be activated in these 
animals [241]; thus RIP1 clearly satisfies the ‘genetic criteria’ above. Moreover, RIP1 has been 
shown to be polyubiquitinated by both K48 and K63 chains using linkage specific antibodies 
[197] and by mass-spectrometry [242], [243], [244] in response to TNF signaling (mass-spec 
analysis additionally shows evidence of K11 and linear ubiquitination). K377 of RIP1 was 
identified as the site modified with K63-linked ubiquitination; however as explained above, the 
mutated protein (K377R) is inactive as does not get recruited to the receptor complex. Other 
reports though have shown that RIP1 can also be ubiquitinated at Lys115, Lys570, Lys603 and 
Lys626 when overexpressed [245], and also at Lys115, Lys163–167 and Lys671 under 
endogenous conditions [246]. Moreover, there have been conflicting reports which suggest that 
RIP1 may not be needed for TNF-mediated NF-κB activation [247], [248]. Hence, we decided to 
forgo RIP1 as the ‘biochemical criteria’ is not clearly satisfied [249]. 
3) Deubiquitinase protein (A20): A20 is a deubiquitinase that downregulates NF-κB 
signaling and completely satisfies both the criteria outlined above. In fact, the genetic and 
biochemical work done on A20 suggests that K63-linked polyubiquitination may indeed play a 
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role in NF-κB signaling [170]. A20 knockouts die prematurely from rampant inflammation of 
multiple organs and cachexia as these animals are unable to downregulate persistent NF-κB 
signaling [134]. Hence, it is clear that A20 is non-redundant in terms of downregulating NF-κB. 
A20 has been extensively characterized as a protein that acts on both K48 and K63-linked 
polyubiquitin chains.  Multiple biochemical evidences have shows that it may act by first 
removing K63 linked ubiquitin chains from adapter proteins such as RIP1, thereby attenuating 
NF-κB signaling. After this, A20 adds K48-linked polyubiquitin chains to RIP1 and targets it for 
proteasomal degradation, resulting in a complete block of NF-κB induced signals [196] (Figure 
1.13). The initial deubiquitinase function is mediated by Cys103, and the subsequent E3-ligase 
function is mediated by Cys624/Cys627. Mutating any of these residues leads to persistent 
activation of NF-κB in vitro. 
Hence, to broadly ascertain the physiological significance of regulatory K63-linked 
polyubiquitination, our specific aim is to generate the C103A knock-in mouse and 
characterize the effects of the deubiquitinase activity of A20. If Cys103 is indeed the catalytic 
residue responsible for the function of A20, then these mice would be expected to resemble the 




Figure 1.14: Aim1: Determining physiological contribution of deubiquitinase function of A20 
(modified from [250]) 
 
2nd broad aim: Examine the cause of functional differences between the structurally 
similar IκBα and IκBβ (specifically, determine the site of constitutive phosphorylation in 
IκBβ, the kinase that phosphorylates IκBβ, and the functional consequence of this 
phosphorylation) 
While IκBα and IκBβ are structurally similar, they have different functions (Table 1.2 
and Figure 1.15). This is partly because IκBα, but not IκBβ, is an NF-κB dependent gene.  IκBα 
is the main inhibitor of NF-κB and suppresses inflammation by a negative feedback loop. Thus 
mice deficient in IκBα die within a week of their birth from hyperinflammation [73]. In contrast, 
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IκBβ knockouts are not only viable but are surprisingly resistant to LPS shock [186], [187]. This 
would not be expected in mice deficient for an inhibitor of NF-κB. It was determined from the 
study of the IκBβ knockouts that while IκBβ serves as a basal inhibitor of inflammation, it also 
enhances the inflammatory response by augmenting the expression of certain genes like TNFα  
[186] and IL-1β [187].   
There are other differences between IκBα and IκBβ as well. IκBβ, but not IκBα, is 
constitutively phosphorylated in resting cells. It has been found that IκBα–NF-κB complexes 
shuttle between the nucleus and cytoplasm in quiescent cells while IκBβ–NF-κB complexes 
reside entirely in the cytoplasm [191], [251], [252]. Almost all NF-κB activating stimuli induce 
the rapid degradation of IκBα, which is then briskly resynthesized. Constitutively phosphorylated 
IκBβ on the other hand is degraded in a delayed fashion only by ligands (like LPS or IL-1β) that 
are known to cause persistent activation of NF-κB.  IκBβ is then slowly resynthesized as an 
unphosphorylated protein in stimulated cells [35], [253]. The unphosphorylated IκBβ forms a 
complex with the p65:cRel heterodimer, and together they bind the κb2 promoter in the nucleus 
and enhance the transcription of genes like TNFα  [186] and IL-1β [187]. This mechanism 





Figure 1.15: Primary structure of IκBα and IκBβ 
 IκBα IκBβ 
Effect on inflammation Inhibits Inhibits (and activates) 
Basal phosphorylation  No phosphorylation Constitutively phosphorylated 
Degradation Kinetics Rapid (15min) Slow (1-2hr) 
Table 1.2: Differences between IκBα and IκBβ 
 
We hypothesize that the functional differences between IκBα and IκBβ mainly arise from 
the constitutive phosphorylation of IκBβ. This allows the IκBβ to exist in two states: a 
phosphorylated, inhibitory form and an unphosphorylated, activating form. Hence, to broadly 
understand the differences between IκBα and IκBβ, our specific aim is to discover the site 
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of phosphorylation on IκBβ, the kinase that phosphorylates IκBβ, and the biological effects 
of phosphorylation (Figure 1.16). 
 


















Regulation of NF-κB signaling by regulatory ubiquitination: 


















2.1: Regulatory ubiquitination and NF-κB 
Given the importance of IKK in phosphorylating IκBs, it is imperative to understand how 
IKK is activated. There is no doubt that degradative ubiquitination of the IκBs (and other 
molecules) plays a profound role in NF-κB activation. One of the first clues that unconventional 
ubiquitin chains may also have a role to play in activating IKK came when it was found that IKK 
was activated by an E2 of the Ubc4/5 family [254], and that this activation was independent of 
proteasomal activity and the K48 residue of ubiquitin[76]. While this suggested the involvement 
of a proteasome-independent mechanism, the cellular relevance of this finding was unclear as the 
specific E3 ligase had not yet been identified. It was later determined that the ubiquitin ligase 
was TRAF6 [159], a protein that also functions as an adaptor molecule in the IL-1 and Toll-like 
receptor pathways [255], [256].  
Subsequently though (and as detailed below), it has been shown that autoubiquitination 
of TRAF6 is not required for activation of NF-κB and MAPK pathways [237], [257]. While it is 
theoretically possible that the ubiquitin chains may provide a docking site for formation of the 
TAK-TAB signaling complex, it was shown using a TRAF6-RING mutant that ubiquitination 
was dispensable for the recruitment of the TAK-TAB complex. Thus, the activity ofTRAF6 as an 
adaptor protein (independent of ubiquitination) is enough to recruit the complex. The authors 
concluded that while TRAF6 ubiquitination may be a marker for activation, it is unlikely to play 
an essential role for downstream activation. Recent findings, mostly in vitro work, have 
advanced the proposition that K63-linked polyubiquitin chains may have a role to play in 
activating IKK in multiple pathways that activate NF-κB [123], [120]. 
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The physiological targets of K63-linked polyubiquitination have not yet been identified 
[121]. The physiological context of regulatory ubiquitination can be clarified by generation of 
RING-mutant or deubiquitinating-mutant knock-in mice [120], something that has not been done 
for any of the enzymes involved in these pathways. In spite of the overwhelming biochemical 
evidence, genetic evidence that points to the specific role of regulatory ubiquitination is lacking. 
This is partly because all the experiments have been done either by knocking-down or 
overexpressing the relevant proteins. This has been ineffective as it could lead to oligomerization 
of TRAFs, and/or, induce promiscuity in these enzymes.  
An example of this limitation is highlighted by knock-in studies in NEMO. 
Polyubiquitination of K399 in NEMO was shown to be essential for NF-κB activation by an 
experiment based on overexpression with BCL10. The K399R mutant was not ubiquitinated and 
NF-κB was only partially activated in NEMO deficient cell lines complemented with K399R 
[165]. However a murine knock-in model carrying this mutation was found to be largely normal 
with respect to NF-κB and MAPK activation [166]. While outlining the various signaling 
pathways below, I will be highlighting such discrepancies in order to have an accurate 
understanding of the present status of the field.  
2.2: IL-1R/TLR signaling pathways 
TLR (Toll like receptors) are PRRs that recognize various PAMPs that are present in 
different microbes (bacteria and viruses) including bacterial LPS and viral nucleic acids. 
Interluekin-1 (IL-1) is a family of cytokines secreted by cells during the inflammatory process 
and this serves as a defensive response during pathogenic invasion [258].  Upon ligand binding, 
both pathways activate subsets of pro-inflammatory genes. Both TLR and interleukin-1 receptor 
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(IL1R) are transmembrane proteins that have a common cytosolic domain called Toll-IL-1R 
(TIR) domain. Following stimulation, this domain helps recruit TIR-domain adaptor proteins that 
can bind to the TIR domain of TLR and IL1R. The most common example of such an adaptor is 
the myeloid differentiation primary gene 88 (MyD88). MyD88 then recruits two kinases to the 
IL1R, IRAK4 and IRAK1. IRAK1 binds TRAF6, which together with Ubc13/Uev1A catalyzes 
the formation of K63-linked polyubiquitin chains. Both IRAK1 and TRAF6 have been reported 
to be modified by K63-linked chains. The polyubiquitin chains on TRAF6 recruits the TAK1-
TAB2-TAB3 complex (a protein complex of TGF-β activated kinase 1 with adaptor proteins 
TAB1 and TAB2) [259], [167]. The complex binds the ubiquitin chains with the UBD of the 
TAB proteins. This recruitment of the TAK-TAB complex leads to the activation of TAK1 
[260]. Subsequently, TAK1 phosphorylates other downstream kinases like IKK (leading to NF-
κB activation) or MKKs (leading to the JNK and p38 activation).  
Similar pathways are also activated in binding of TLR ligands. As an example, let us 
consider the binding of LPS to TLR4 as the mechanistic details have been confirmed by multiple 
studies. LPS binding activates two branches downstream of TLR4, both of which lead to 
activation of TAK1, which subsequently phosphorylates and activates IKK. In one branch, 
receptor binding   leads to the recruitment of TRAM and TRIF proteins to TLR4, which then 
recruits both TRAF6 and RIP1 to the signaling complex. In the other branch, receptor binding 
leads to Myd88 recruitment which then promotes the assembly of IRAK proteins, TRAF6 and 
TAK-TAB complexes as described above. It has been proposed almost entirely on the basis of in 
vitro evidence that K63-linked polyubiquitination of TRAF6 and RIP1 play an essential role in 
downstream activation of NF-κB [120]. 
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However the genetic evidence is unsatisfactory as TAB proteins have not been found to 
be physiologically essential, as would be critical if the activation of TAK were indeed to depend 
on TAB binding to ubiquitin chains [261]. Additionally, it has been showed that Ubc13 
knockouts have impaired activation of JNK and p38 kinase, but normal activation of IKK [233]. 
Thus NF-κB signaling is normal in UBC13 deficient B cells, bone marrow-derived macrophages, 
or MEFs when stimulated with IL1-β or multiple TLR ligands including LPS, bacterial 
lipopeptide and CpG DNA.  Subsequently though, in another study, UBC13 was shown to be 
important in IKK activation [231, 262-264]. The reason for this inconsistency has been 
speculated to be incomplete deletion of Ubc13 by Cre recombinase in the first study. Indeed, 
titrating the Cre retroviruses and studying the effects of variable Ubc13 depletion, the authors 
concluded [263] that a minor amount of residual Ubc13 was enough to activate IKK. This 
however raises doubts on whether the K63 chains indeed play an actual role in IKK activation or 
if the ubiquitin chains results from aggregation of residual Ubc13 with TRAF6 during NF-κB 
activation. In this regard, multiple proteins that associate with TRAF6 have been showed to be 
ubiquitinated by K63 chains [167], [265], [266], [172], [214]. It is not clear if their ubiquitination 
is actually intrinsic for the act of signaling. 
Along with a lack of genetic evidence, certain biochemical studies have also suggested 
that ubiquitination of TRAF6 may not be essential. For example, a study found that a ligase-
mutant of TRAF6 (i.e, TRAF6 with RING domain deleted) [237] did not block IKK activation 
by IL-1β. However, this mutant failed to activate JNK and TAK1.  In addition to demonstrating 
that the ubiquitin ligase activity of TRAF6 is not required for IKK activation, this study also 
suggested that TAK1 may not be the kinase for IKK, and that IKK could activate itself by 
autophosphorylation. A second independent study confirmed that NF-κB (and MAPK) pathways 
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could be activated by IL-1 and that this does not require TRAF6 autoubiquitination. Thus, 
complementation of TRAF6-knockout MEFs with a TRAF6 mutant that lacks lysines, and hence 
cannot be ubiquitinated, shows normal IKK activation. This mutant TRAF6 is physiologically 
active and rescues osteoclastogenesis when retrovirally transduced in TRAF6-knockout bone 
marrow macrophages.  This may be because the lysine-deficient TRAF6 mutant could serve as 
an adaptor protein and interact with the TAK1-TAB1-TAB2 complex [257]. Subsequently, other 
conflicting studies have demonstrated the importance of the RING domain of TRAF6 in IKK 
activation via the IL-1 mediated pathway [263], [267], [268], [269], [265].  
Additional evidence for the proposed mechanism of IKK activation was obtained by an 
elegant system which replaced endogenous ubiquitin with K63R mutant ubiquitin following 
tetracycline treatment. The authors show that in cells having the K63R ubiquitin, IKK cannot be 
activated by IL-1β. This demonstrates the importance of K63-linked polyubiquitin chains in 
mediating IKK activation. Intriguingly though, the same study also shows that IKK can still be 
activated normally in response to TNFα even when only K63R ubiquitin is present, suggesting 
that IKK may be activated by TNFα by a K63-polyubiquitin independent mechanism [231]. 
Recently it was demonstrated that free, unconjugated K63-polyuniquitin chains (not 
bound to any substrate) could also activate TAK1 [168]. The authors synthesized the K63-linked 
polyubiquitin chains by treatment with TRAF6 and Ubc13/Uev1A. As expected, the UBD 
domain of TAB2 associated with these chains, bringing the TAK1 in close proximity. 
Subsequently, TAK1 was activated by phosphorylation at Thr-187.  Activated TAK1 then 
phosphorylates IKKβ, leading to activation of IKK complex in a NEMO dependent manner. It is 
not clear how the TAK1 would distinguish between polyubiquitin chains freely floating within 
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the cell and polyubiquitin chains that are attached to TRAF6 (or for that matter, any other 
protein). This concern for specificity seems to be a recurring issue in the case of K63-linked 
polyubiquitin chain mediated activation of IKK. 
NF-κB activation is reversible; and the case for positive regulation by K63-linked 
regulatory ubiquitin chains is supported by the activity of deubiquitinases like CYLD and A20 
that disassembles these chains, thereby negatively regulating NF-κB. There is much biochemical 
evidence, often based on the overexpression of the DUB, that shows that deubiquitinases may 
block the activation of IKK by cleaving K63 chains. An example is the familial cylindromatosis 
tumor suppressor (CYLD), which specifically removes K63 chains from TRAF6 [215, 270], 
[140], [214]. Another example of a deubiquitinase is A20, which prevents NF-κB activation 
mediated by IL-1β or LPS by preventing the interaction between TRAF6 and Ubc13 [271], 
[272], [273]. While knockouts of A20 and CYLD show dysregulated NF-κB activation, it has not 
been demonstrated by making knock-ins that their deubiquitinase function is actually responsible 
for NF-κB regulation [134], [221], [218]. 
Figure 2.1 shows how regulatory ubiquitination could potentially regulate the NF-κB  




Figure 2.1: Ubiquitin-mediated activation of TAK1 and IKK in IL-1R/TLR pathways [132] 
 
2.3: TNF receptor (TNFR) signaling pathway   
The pathway is demonstrated in Figure 2.2. Discovered in 1975, tumor necrosis factor-α 
(TNF-α) was so named as it caused necrosis of murine tumors [274]. TNF-α also has potentially 
protective roles as a proinflammatory cytokine that stimulates multiple responses and activates 
NF-κB signaling. Dysregulation of these responses results in a whole host of inflammatory and 
autoimmune diseases [275]. 
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TNF-α binds to two receptors that are responsible for mediating its functions. The 
receptors are TNFR1 and TNFR2. While TNFR1 is expressed ubiquitously in almost all 
mammalian cells, TNFR2 is expressed mostly in lymphocytes [276]. For the purposes of this 
discussion, we will only focus on signals emanating from the TNFR1 pathway. TNF-α exists in 
two forms: a membrane bound form and a soluble form. The membrane bound form is converted 
to the soluble form by TNFα converting enzyme (TACE). Both forms are capable of binding to 
the receptor. Binding of TNF-α causes trimerization of TNFR1 and consequent recruitment of 
TNFR1-associated death domain protein (TRADD). Remarkably, TRADD can assemble two 
complexes that mediate potentially opposing functions downstream. Complex1 mediates the 
activation of NF-κB, which has an antiapoptotic and proinflammatory role, while Complex 2 
initiates apoptosis [277]. However, TNF-α normally does not cause apoptosis as NF-κB is 
rapidly activated with the consequent production of multiple anti-apoptotic proteins like cIAPs 
and c-FLIP. Promotion of the degradation of cIAPs leads to apoptosis [278], [279]. 
Complex I is composed of TRADD, RIP1 (or receptor-interacting protein kinase 1) and 
multiple RING domain containing E3 ligases like TRAF2, TRAF5, cIAP1 and cIAP2. cIAP1 and 
cIAP2 catalyze K63 polyubiquitination on RIP1 [231], [193, 280]. However, cIAPs are 
promiscuous ubiquitin ligases and ubiquitin chains added by cIAPs are not confined to K63 
alone [280], [193]. Consequently, ubiquitin chains with other linkages have been found on RIP1 
(detected using antibodies specific for K48 and K63 chains) [281], and this could potentially 
affect the specificity of the downstream pathway.  
RIP1 has indeed been shown to be essential for TNF mediated NF-κB activation and 
RIP1 knockouts die early (1-3 days) from extensive apoptosis of lymphoid and adipose tissue 
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because of their inability to access the NF-κB pathway [241]. While these animals do survive 
longer than mice deficient in IKKβ or p65, this difference may be because of the involvement of 
RIP1 in NF-κB independent death-pathways like necroptosis [282], [248]. However, there are 
conflicting studies that have reported that RIP1 may not be universally essential in all cases of 
TNF-induced activation of NF-κB [247], [248], and that NF-κB can still be activated in the 
absence of RIP1. It is possible, though, that this residual NF-κB activity is a result of the 
activation of the noncanonical pathway [283]. 
Experiments in cell lines showed RIP1 is associated with NEMO and this association is 
essential for TNFα-induced IKK activation [284], [285], [248], [241]. RIP1 is a kinase and given 
the phenotype of RIP1 knockouts, it would be a satisfactory candidate for a kinase that could 
activate IKK. However, the kinase activity has been shown to be dispensable for NF-κB 
activation [286], [285], [241]. This provided an impetus to uncover the mechanism by which 
RIP1 mediates the TNFα pathway.  
Since RIP1 mediates the TNF-pathway in a kinase independent manner, it is tempting to 
speculate that it serves as an essential adaptor molecule. NEMO can bind directly to both 
positive and negative regulators of the NF-κB pathway. Indeed, it has been known for some time 
now that RIP1 can recruit IKK to the TNFR signaling complex by directly binding with NEMO 
[287]. NEMO can also bind with A20, which is known to negatively regulate the TNF signaling 
pathway [287]. There are multiple reports that the function of RIP may be to assemble a scaffold 
for recruitment and activation of IKK [284], [285], [288].  
Ubiquitin chains may also serve as a scaffold for recruitment of receptor complexes. 
RIP1 ubiquitination has been proposed to be important for downstream activation of TAK1 and 
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IKK. The TAK-TAB complex and IKK complex is recruited to Complex1 by the binding of 
TAB2 and NEMO to the polyubiquitin chains respectively [163]. It has been shown that RIP1 
gets ubiquitinated at K377 and the K377R-RIP1 mutant fails to activate NF-κB [163]. However, 
the K377R-NEMO also does not get recruited to Complex1 upon receptor stimulation. 
Recruitment to the receptor is a pre-requisite for participation in signaling. Hence, while it is 
clear that the K377R mutant is functionally compromised, this may not be because it cannot be 
ubiquitinated. It could also be because the mutant cannot serve as an effective adaptor protein. 
RIP1 is indeed decorated by K63-linked polyubiquitin chains upon stimulation with TNFα, and 
this has been directly [197] verified by using a K63-specific antibody. However, it is not known 
if this ubiquitination is essential for the NF-κB pathway. 
There are other examples in the pathway where it is unclear as to whether the adaptor 
function or regulatory ubiquitination is actually required for downstream singling. Both the 
TNFα and IL-1 mediated pathways seem to activate TAK1 and IKK. They also both use TRAF 
family adaptor proteins (TRAF2 and 5 for TNFα mediated pathway and TRAF6 for IL-1β 
mediated pathway). Given that TRAF2 and TRAF6 are structurally similar, it might be 
speculated that the TNF pathway could also use TRAF2 or/and TRAF5 to catalyze the ubiquitin 
chains, just like TRAF6 in the IL-1β pathway. Indeed TRAF2 is essential in the context of TNF-
α-stimulated NF-κB activation [234], [289].  Absence of TRAF2 decreases RIP1 ubiquitination. 
This was seen using TRAF2 RNAi [196] and by gene ablation [290]. Genetic evidence showed 
that TRAF2 and TRAF5 double-knockouts have impaired TNFα signaling (but not IL-1β 
signaling). Additionally, the MEFs of the double knockouts are more susceptible to TNF induced 
cytotoxicity [236]. However, TRAF2 cannot bind to E2 enzymes like Ubc13, as the structure of 
its RING domain is different from the TRAF6 RING domain [291] and it cannot catalyze 
 73 
 
synthesis of K63-linked ubiquitin chains. Hence, it can be interpreted that the important role of 
TRAF2/5 in the TNFα mediated pathway is a consequence of its adaptor function. Of course, it 
is possible that the adaptor function of TRAF2 acts to recruit another ligase (like cIAP) to RIP1. 
In order to ligate ubiquitin chains on to RIP1, both the TRAFs and cIAPs would need to 
collaborate with the E2 enzyme UBC13. It has been reported that a dominant–negative mutant of 
UBC13 blocks TNFα and TRAF2 mediated NF-κB activation [159]. Ubc13 knockouts are 
embryonic lethal; however it is not entirely clear if this is because of dysregulation of NF-κB 
signaling [232], [233]. There is conflicting genetic data on this topic: while one group showed 
reduced activation of NF-κB in UBC13+/− macrophages and splenocytes [232], another group 
demonstrated that UBC13−/− MEFs have normal NF-κB signaling in response to TNFα [233]. 
These discrepancies may be attributed to the different cell lines used by the researchers or to 
redundancy with another E2 enzyme. In this regard, it has been shown that another E2 enzyme 
(UBC4/5) can also activate IKK (the ligase is as yet unidentified) [76]. It is safe to conclude that 
much more work needs to be done to identify the physiologically relevant E2 enzyme and E3 
ligase, if K63-linked regulatory ubiquitination indeed plays a central role in the NF-κB pathway. 
In a more recent finding, another E3 ligase which catalyzes the formation of linear 
ubiquitin chains [292] has been shown to be recruited to the TNFR1 upon receptor stimulation 
[244]. This E3 ligase complex is known as LUBAC and is composed of HOIP, HOIL-1 and 
Sharpin [293]. The E3 ligase activity has been verified in vitro as LUBAC and Ubc5 have been 
shown to add linear polyubiquitin chains to NEMO [293]. This linear polyubiquitination of 
NEMO has been proposed to be important for NF-κB activation. However, the recruitment of 
LUBAC to TNFR requires only the TRADD, TRAF2 and cIAP1/2 proteins. It does not require 
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NEMO or RIP1, thus it is difficult to understand how linear ubiquitination of NEMO might 
activate NF-κB in a cellular setting. Indeed, there is no evidence of linearly ubiquitinated NEMO 
in cells.  
Additionally, RNAi of HOIP only partially inhibits TNFα induced activation of IKK. A 
naturally occurring mutant mouse (called cpdm) that has a stop codon in the sharpin gene and is 
deficient for sharpin expression shows chronic proliferative dermatitis and reduced IKK 
activation [242, 294, 295].  Surprisingly though, others reported that these mice have normal 
IKK or NF-κB activation (the data even shows a somewhat enhanced IKK activity) [296].  Even 
if these mice were to show an inflammatory phenotype, it clearly does not resemble the lethality 
that is associated with knockouts of IKK components [297]. Crossing the cpdm mice with the IL-
1 receptor accessory protein (IL-1RAcP)-deficient mice rescues the inflammatory phenotype; 
thus the inflammation is caused by enhanced IL-1β signaling [298]. Treatment of cpdm mice 
with a proteasome inhibitor like bortezomib also ameliorates the inflammation, which is further 
evidence that the inflammation in these mice results from excessive NF-κB activation (and not 
decreased NF-κB activation as the model would suggest). Other factors might also be involved in 
the cpdm mice as Sharpin is also known to inhibit activation of integrins [299].  
While the knockouts of the various components that mediate regulatory ubiquitination do 
not all exhibit phenotypes expected to result from knocking out essential member of the NF-κB 
pathway, genetic ablation of A20 indeed resulted in a drastic phenotype and mice that die from 
multi-organ inflammation and cachexia [134]. This is because A20 knockouts show persistent 
and hyperactivated NF-κB signaling.  A20 has a unique mechanism of action; it has been shown 
to first remove K63-linked polyubiquitin chains from RIP1 to attenuate NF-κB signaling, and 
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then ligate K48-linked polyubiquitin chains on RIP1 to completely inhibit NF-κB [196].  As I 
will show in my thesis, the deubiquitinase activity of A20 is actually dispensable in the 
physiological context. This is quite remarkable given the wealth of biochemical data stating 
otherwise. A number of other deubiquitinases of RIP1 have also come to light. A prominent 
example is CYLD which deubiquitinates RIP1 and inhibits NF-κB in response to TNF [140]. 
Another DUB is Cezanne which resembles A20, has an OTU domain, and deubiquitinates RIP1 
upon TNFα stimulation [212]. Figure 2.2 shows how regulatory ubiquitination could potentially 
regulate the NF-κB pathway downstream of TNFR. 
 




2.4: Deubiquitinases and NF-κB 
The process of ubiquitination can be reversed by the action of deubiquitinases (DUBs) 
just like phosphorylation can be reversed by phosphatases. Thus, deubiquitinases can reverse the 
effect of E3 ligases.  Bioinformatic estimates predict around 100 deubiquitinases in the genome 
[300], [301]. While some DUBs are metalloproteases, most are cysteine proteases. The cysteine 
proteases may be classified by the presence of distinct protease domains. They may be ovarian 
tumor (OTU) proteases, ubiquitin-specific proteases (USP), Machado-Joseph disease proteases 
(MJD) or ubiquitin C-terminal hydrolases (UCH). 
A20 and CYLD are the common deubiquitinases in the NF-κB pathway. While A20 is a 
OTU deubiquitinase, CYLD is a USP deubiquitinase. Nevertheless, they share many of their 
substrates. Since A20-knockouts die from multi-organ inflammation and cachexia, it is clear 
there is no functional redundancy with CYLD. This is probably because of temporal reasons, as 
they target the substrates at two different times during the inflammatory process [211]. CYLD 
prevents spontaneous activation of NF-κB in quiescent cells while A20 is essential to terminate 
NF-κB signaling in activated cells. 
CYLD is constitutively active and is inactivated in stimulated cells by IKK mediated 
phosphorylation (in a NEMO dependent manner) [224]. However, it is unclear from the data if 
the transient phosphorylation happens before TRAF2 ubiquitination and NF-κB activation, as 
would be expected if CYLD was regulating the process [224]. A20 on the other hand is basally 
expressed at very low levels but rapidly induced by proinflammatory stimuli to downregulate 
NF-κB after an initial inflammatory phase [222]. Unlike CYLD, A20 is a NF-κB dependent 
gene. While expression of A20 is mainly controlled by NF-κB mediated transcription, it is also 
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post-translationally modified by IKKβ induced phosphorylation at Ser381 [302]. 
Phosphorylation of A20 increases its ability to downregulate NF-κB. Considered together, 
phosphorylation and inactivation of CYLD by IKK provides a window for NF-κB activation 
before it is inducibly turned off by A20 by a negative feedback mechanism. Hence A20 and 
CYLD serve precise and temporally distinct roles in downregulating NF-κB [222]. 
It is worth noting that while the proposed deubiquitinase activity of both A20 and CYLD 
is predicated on K63-linked polyubiquitin chains, they both promiscuously cleave other chains as 
well. CYLD has been shown to deubiquitinate linear polyubiquitin chains (besides K63-linked 
polyubiquitin chains) [220]. For specificity, CYLD has been proposed to require various adaptor 
molecules like p62 in osteoclasts (selectively binds to and recruits CYLD to deubiquitinate 
TRAF6 downstream of RANK) [225]. In vitro, A20 has been shown to have a greater reactivity 
towards K48-linked polyubiquitin chains and deubiquitinates K48-linked chains better than K63-
linked polyubiquitin chains [219], [210]. To achieve this preference for K63-linked chains in 
vivo, A20 forms a complex with other proteins like TAX1BP1 [303]. 
Just as there is strong biochemical evidence implicating E3 ligases in NF-κB activation, 
there is also similar evidence that implicates deubiquitinating enzymes in downregulation of NF-
κB. Additionally, complete genetic knockouts show that deletion of these DUBs indeed lead to 
rampant inflammation. Thus, both CYLD and A20 are very important in negatively regulating 
NF-κB activation. However, to conclusively prove the physiological requirement of the 
deubiquitinase function, mice containing knock-in mutations which destroy the deubiquitinase 
function would be necessary. Given the clear physiological importance of A20 and CYLD, it is 
essential to decipher the mechanism of action for these two proteins. 
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Since this thesis studies the mechanism of action of A20, this deubiquitinase is discussed 
in detail below. 
2.5: A20 (TNFΑIP3 or TNFα Induced Protein 3 gene) 
2.5.1: Structure and proposed mechanism of action 
A20 was discovered in human umbilical vein endothelial cells (HUVEC) as a zinc finger 
protein that is rapidly induced upon stimulation with TNFα, hence it is also called ‘TNFα 
Induced Protein 3 [202], [304]. The function of A20 was to provide protection from TNF 
mediated cytotoxicity [304]. It was shown that A20 is virtually absent at basal levels, but rapidly 
induced by a plethora of PAMPS, mitogens or proinflammatory cytokines [202] in a NF-κB 
dependent manner. While cells of the innate immune system (dendritic cells, macrophages) show 
inducible expression of A20 [202], thymocytes have constitutive expression of high levels of 
A20 that is downregulated upon TCR stimulation [305], [211]. 
An analysis of the structure of A20 (Figure 2.3) shows a N-terminal OTU domain 
followed by seven C-terminal zinc finger domains. A cysteine residue at position 103 (in the 
OTU domain) has been shown to be important for the deubiquitinase activity [196, 204]. 
Multiple studies based on overexpression have demonstrated that A20 downregulates NF-κB 
signaling downstream of the TNFR and TLRs [208], [306], [272]. Upon TNFR stimulation, A20 
is inducibly expressed and targets ubiquitinated RIP1 in an enigmatic two-step sequential process 
to downregulate NF-κB [196]. A20 acts as a dual ubiquitin-editing enzyme that can act both as a 
deubiquitinase and an E3 ligase. The Cys103 residue in the OTU domain first deubiquitinates 
K63-linked polyubiquitin chains from RIP1, thereby attenuating NF-κB activation. After this, the 
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Cys624/Cys627 in the fourth zinc finger domain (ZNF4) ligates K48-linked polyubiquitin chains 
to RIP1, thereby triggering proteasomal degradation of RIP1 and completely inactivating NF-κB 
[196].  E3 ligases are typically characterized by the presence of a RING or HECT domain; 
however, the E3 ligase function of A20 is uniquely mediated by a zinc finger domain. A 
considerable fraction of cellular A20 has been found to localize to lysosomes. This localization is 
mediated by zinc finger domains and has been found to lead to degradation of TRAF2 [307, 
308]. Surprisingly though, a deubiquitinase mutant of A20 (C103A) has been shown to inhibit 
IKK both in vitro and in vivo, leading to normal activation of NF-κB [309]. 
A20 can also inhibit NF-κB in response to LPS stimulation. However, it does so by a 
different mechanism. Once induced, A20 attenuates NF-κB activation by preventing further 
K63-linked ubiquitination by disrupting interactions between Ubc13 (E2 enzyme) and TRAF6 
(E3 ligase) [271].  At later time points, A20 abrogates NF-κB signaling by adding K48-linked 
polyubiquitin chains to Ubc13 targeting it for proteasomal degradation. This process is also 
dependent on ZNF4 (C624/C627) and Cys103. Another publication showed that A20 directly 
inhibited LPS-mediated NF-κB signaling by deubiquitinating TRAF6 [200]. 
The mechanisms are elegant and C624/C627 and C103 have been shown to be important 
in downregulating NF-κB both in response to TNF and LPS stimulation. However the 
experiments are based on overexpression and knock-down of the protein. This thesis will 
characterize knock-in mice in which the Cys103 residue is mutated to test the physiological 





Figure 2.3: Structure of A20 [211] 
 
2.5.2: Function of A20 
The anti-apoptotic and NF-κB inhibitory role of A20 was elucidated after the generation 
of A20-knockout mice. A20-knockouts are perinatally lethal. They die because of spontaneous, 
extensive multi-organ inflammation and cachexia, resulting from persistent, unabated NF-κB 
signaling [134]. As would be expected, they also succumb to different pro-inflammatory stimuli 
including sub-lethal doses of TNF-α or LPS [134]. A20-knockout MEFs show persistent 
activation of NF-κB in response to TNF-α, LPS and IL-1 stimulation and are more sensitive to 
apoptosis as compared to wild type MEFs [134].  
The inflammation in A20-knockouts is mediated by myeloid cells and is independent of 
the adaptive response. This was found by deleting A20 in mice lacking B and T cells (Rag1−/− 
mouse). Thus, inflammation is not rescued in a TNFAIP3−/−Rag1−/− double deficient mice [134]. 
Surprisingly, even though A20 was considered a feed-back inhibitor of TNF mediated signaling, 
the inflammation in A20-knockouts is independent of TNFR signaling. Thus the inflammation 
also continues unabated in TNFAIP3−/− TNFα−/− and TNFAIP3−/− TNFR1−/− double-knockouts 
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[200]. While the deubiquitinating property of A20 is certainly important in vitro, this observation 
casts serious doubts on the physiological relevance of this function. This is because the 
deubiquitinase role has been implicated in downregulating TNF signaling, and the physiological 
relevance of A20 is clearly not dependent on TNF signaling. 
The inflammation in A20 knockouts is recued by crossing with Myd88−/− mice. Thus, the 
spontaneous inflammation in A20 knockouts is triggered by TLR-mediated signaling, and the 
TNFAIP3−/− Myd88−/− double-knockouts are normal [200], [310]. Consistently, A20-deficient 
mice can be successfully treated with broad-spectrum antibiotics and cured of the severe 
inflammation [310]. Hence, it can be inferred that A20-knockouts have constitutive TLR 
signaling driven by commensal intestinal flora. Thus, A20 is essential to maintain intestinal 
immune homeostasis. 
A20 has also been specifically deleted from various organs and these conditional-
knockouts have been used to determine the role of A20 in these organs (Table 2.1). Thus, A20 
was specifically deleted from intestinal epithelial cells (IECs) by crossing with Villin-Cre mice 
[311]. The A20 IEC conditional knockout (A20IEC-KO) mice were found to be healthy. However, 
they have a greater propensity of developing colitis when induced with dextran sulphate sodium 
(DSS). This colitis is rescued by crossing with TNFR-knockouts [311]. Thus, TNFR signaling is 
responsible for the systemic, intestinal pathophysiology.  
A20 plays a profound role in the innate immune system. Specific ablation of A20 in 
myeloid cells causes spontaneous development of rheumatoid arthritis accompanied by 
osteoclastogenesis [312]. This is caused by a higher level of proinflammatory serum cytokines, 
as would be expected from protracted activation of NF-κB [312]. The pathology was shown to be 
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dependent on TLR4-MyD88 and IL-6 signaling but independent of TNF [312].  Upon 
stimulation with LPS, both macrophages [200] and dendritic cells (DCs) [313] deficient in A20 
produced more proinflammatory cytokines (IL-6 and TNF-α) and showed an enhanced 
expression of co-stimulatory molecules [313]. siRNA based silencing of A20 in DCs triggered 
constitutive NF-κB activation and antigen presentation [313]. Thus, A20 seemed to be important 
in not only determining the activation threshold of DCs, but also in regulating antigen 
presentation. Indeed when A20 is selectively deleted from DCs by crossing with CD11-Cre 
transgenic mice, the mice develop autoimmunity and show spontaneous proliferation of T cells 
and expansion of plasma cells. They have symptoms of systemic lupus erythematosus (SLE) 
[314]. The DCs were resistant to apoptosis probably because of upregulation of Bcl-2 and Bcl-x 
[314]. In this regard, patients of SLE [315] have multiple SNPs associated with A20. 
The importance of A20 in mediating antigen presentation of DCs might imply that A20 
may also be important for adaptive immunity. In fact, A20 has been determined to be essential 
for terminating NF-κB signaling in both T and B lymphocytes. The expression pattern of A20 in 
these lymphoid cells is different from myeloid cells. In lymphoid cells, A20 is constitutively 
expressed. The basal levels of A20 are particularly high in T cells [305]. Experiments based on 
overexpression reveal that A20, but not the deubiquitinase mutant, can downregulate NF-κB 
signaling in response to CD3 and CD28 receptor stimulation [316].  A20 acts by removing K63-
linked polyubiquitin chains from MALT1 to downregulate NF-κB [207]. Conversely MALT1 
has paracaspase activity to cleave A20 and facilitate NF-κB activation [317]. This balance 
between ‘MALT1 mediated A20 cleavage’ and ‘A20 mediated MALT1 deubiquitination’ fine-
tunes NF-κB activity in T cells. 
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A20 is constitutively expressed in B lymphocytes as well. Intriguingly though, CD40 
signaling further increases the expression of A20 [318]. This would suggest that A20 plays an 
important role in downregulating NF-κB in these cells. Indeed, selectively deleting A20 in B 
cells (by crossing with CD19-Cre mice) results in autoimmunity mediated by production of 
autoantibodies [319].   The (A20CD19-KO) mice show normal development and growth. However, 
they have more immature and germinal center (GC) B cells as compared to their littermates.  
Their splenic B cells also proliferate more upon stimulation with α-CD40, LPS or CpG [319]. 
They show enhanced non-canonical and canonical NF-κB signaling as evidenced by 
phosphorylation of p100 and degradation of IκBα respectively [319]. Thus, A20 maintains B cell 
homeostasis by inhibiting both canonical and non-canonical signaling in B lymphocytes. 
However, one observation in these mice (A20CD19-KO) does not correlate with the well 
documented anti-apoptotic effects of A20. The B cells in these mice are surprisingly resistant to 
Fas-mediated apoptosis. This is because of the higher expression of antiapoptotic molecules like 
Bcl-x in these mice. 
The cross-regulation of A20 and MALT1 is not unique to T cells alone, but is present in 
B cells as well. Dysregulation of this cross-regulation may result in B-cell lymphoma. In B-cell 
lymphomas, the paracaspase activity of MALT1 is constitutively active. This deactivates A20, 





Table 2.1: Phenotypes of cell type-specific deletion of A20 [20] 
 
2.5.3: Regulation of A20 by ubiquitin-binding proteins and adaptors 
A20 exists in a complex with many other proteins (like Tax1 binding protein 1 
(TAX1BP1), Itch, Ring finger protein (RNF) 11, and possibly ABIN-1 and YMER, and this 
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“A20 ubiquitin-editing complex” has been proposed to be important for inhibiting NF-κB 
signaling [211]. Thus, the interaction of A20 with RIP1 or TRAF6 is mediated by TAX1BP1 
[321] while another E3 ligase (Itch) is essential for A20 promoting K48-linked 
polyubiquitination of RIP1 [250]. ABIN-1 has been shown to be important in terminating the 
NF-κB response by deubiquitinating NEMO [322], [205]. 
TAX1BP1 was discovered using the HTLV-I Tax oncoprotein as bait in a yeast two-
hybrid screen [323]. Later, TAX1BP1 was shown to bind A20 and cooperatively promote cell 
survival [303]. TAX1BP1 knockouts have been generated using two methods, by gene trapping 
and by a conventional gene targeting method. The resulting phenotypes are different for 
unknown reasons. The knockout generated using gene trapping is embryonically lethal because 
of cardiac defects at E13.5 [324]. The knockout generated using gene targeting [321] developed 
normally till four months. After this, they succumbed to inflammatory cardiac valvulitis. While 
the first phenotype resembles the A20-knockout and suggests that TAX1BP1 could be an 
essential ‘adaptor protein for A20’, the second phenotype does not readily comply with the 
mechanism of cooperative-action.  
However both the A20 and the TAX1BP1 knockouts are hypersensitive to 
proinflammatory cytokines because of enhanced activation of NF-κB [321], [324]. They also 
succumb to sub-lethal doses of IL-1β and TNF-α. RIP1 is persistently ubiquitinated in 
Tax1bp1−/− MEFs upon TNF stimulation, similar to the A20-knockout MEFs [324]. This 
suggests that A20 and TAX1BP1 act in a complex to reduce RIP1 ubiquitination. Since 
TAX1BP1 does not have deubiquitinating activity, it probably inhibits RIP1 ubiquitinating by 
acting through A20 [324].  
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TAX1BP1 has two zinc finger (ZnF) domains in the C-terminus and one of them is 
known to harbor a UBD. This UBD recognizes the K63-linked polyubiquitin chains of RIP1, 
serving as the adaptor domain for TAX1BP1 to recruit A20 to the receptor complex [324], [321].  
The ZnF domains of a TAX1BP1 have a ‘PPXY’ motif (P-Proline, X-variable amino acid, Y-
tyrosine’). Such motifs preferably interact with ‘WW’ (W-tryptophan) motifs in other proteins 
[325]. This motif is important for a functional TAX1BP1 molecule as TAX1BP1 mutants lacking 
this motif have persistent NF-κB activation [250]. It was later discovered that Itch contains the 
‘WW’ motif and interacts with TAX1BP1 [250].  The TAX1BP1/Itch complex is inducibly 
formed upon TNF stimulation and is responsible for recruiting A20 to the receptor complex and 
deubiquitinating RIP1 [250].  
Itch-knockouts also show hyperactive NF-κB signaling, however the inflammation in 
these mice is confined to the lungs and skin alone [326] as compared to A20-knockouts, which 
show inflammation throughout the body. Additionally, unlike A20—knockouts, the 
inflammation in Itch-deficient mice depends on the adaptive immune system and is recued by 
crossing with Rag1−/− mice [250]. Thus, it is probable that Itch has functions independent of 
A20. 
RNF11 also interacts with A20, TAX1BP1, Itch and NEMO as identified in a high-
throughput yeast two-hybrid screen [327].  RNF11 is an E3 ligase and is overexpressed in 
cancers of different tissues (breast, pancreas, etc) [328], [329]. This suggested a possible link 
with the NF-κB pathway and it was subsequently demonstrated that RFN11-TAX1BL1-Itch 
complex is inducibly formed upon stimulation  with TNF-α or IL-1 [330].  Overexpression of 
RNF11 negatively regulate NF-κB signaling, while knockdown of RNF11 using siRNA 
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increases activation of NF-κB [330]. Furthermore, cells deficient in RFN11 showed increased 
ubiquitination of RIP1 and TRAF6 [330]. Hence, it has been suggested that A20 acts in a 
complex with RFN11, TAX1BL1 and Itch. RNF11 is also known to participate in TGF-β 
signaling [331], [332]. Hence, RNF11 clearly plays a complex role and delineation of its 
physiological function will have to await the generation of knockout mice. 
ABIN-1 is another A20-interacting protein identified by a yeast two-hybrid screen [306], 
whose overexpression inhibits NF-κB signaling in response to a wide range of stimuli [306], 
[333]. ABIN1 has been proposed to be an adaptor molecule essential for the interaction of A20 
and NEMO, leading to deubiquitination of NEMO by A20 [205]. Interestingly, a pathogenic E3 
ligase IpaH9.8 found in Shigella cooperates with ABIN-1 to add K48-linked polyubiquitin 
chains to NEMO, thereby targeting it for proteasomal degradation and inactivation NF-κB in the 
process [334]. However, a major discrepancy is that MEFs deficient in ABIN-1 show normal 
NF-κB activation [335].  
Similarly, the yeast two-hybrid screen identified another A20 interaction protein named 
YMER [336]. YMER was also identified in a protein array using a polyubiquitin bait [337], and 
this polyubiquitin binding domain of YMER is essential for inhibition of NF-κB signaling [336].  
Overexpressing YMER downregulates NF-κB, while YMER knockdown cells shows augmented 
NF-κB activation [336]. YMER interacts with RIP1 and hence has been proposed to act in a 




2.5.4: The role of A20 in autoimmune diseases and cancer 
Polymorphisms of the TNFΑIP3 gene (Figure 2.4) has been implicated in a number of 
autoimmune diseases (rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, 
psoriasis, SLE, coronary artery disease, celiac disease, and SLE) [338], [135], [136], [139], 
[138],[201], [339], [340], [341], [342]. Based on murine studies, it could be rationalized that 
these polymorphisms affect the expression and/or function of the expressed A20 protein [211]. A 
mutation in the coding region of the OTU domain (A125V) has been found in the African 
population [343]. The data tentatively suggests that this affects A20-mediated deubiquitination of 
TRAF2. Two other mutations (V377M and P656L) are associated with lung cancers. The 
mechanistic effect of these two mutations on A20 is not clear.  
 
 




A20 acts as a tumor suppressor for many different B-cell lymphomas. A20 is on 
chromosome 6, and deletion of chromosome 6q is often associated with non-Hodgkin 
lymphomas [344]. Several point mutations that could inactivate A20 lead to marginal zone 
lymphoma, Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL) or MALT lymphoma 
[345], [136], [135], [138]. A reduction in the levels of the A20 protein (by methylation of 
promoter) could lead to MALT lymphoma [346]. The tumor suppressor function of A20 has 
been conclusively proven by demonstrating that B-cell lymphomas can be rescued by expressing 
A20 in lymphoma cell lines that lacks both A20 alleles [136], [135]. 
It is interesting to note that oncogenic transformation of MEFs has been found to be 
associated with reduction of expression of A20 protein. For example, Ras-mediated 
transformation of primary MEFs leads to the upregulation of most NF-κB-controlled genes. It, 
however, reduces levels of A20 [347].  
A20 inhibits TNF mediated cytotoxicity [304] and has prosurvival activity in this context. 
Hence, it is conceivable that A20 may be an oncogene in certain circumstances. This is indeed 
the case in breast cancer and glioma. A20 is estrogen-regulated in breast cancer and protects 
against the apoptotic effects of tamoxifen [348]. A20 is needed for glioma stem cell survival 
[349]. Indeed overexpression of A20 is a hallmark of breast tumor and glioma and may serve as 




2.5.5: Pathogens modulating A20 activity 
Since A20 is an essential regulator of NF-κB, oncogenic viruses often inactivate it, thus 
promoting chronic activation of NF-κB [211]. A few examples are outlined below. They 
highlight the critical role that A20 plays in controlling excessive immune responses. 
The genome of Human T-cell leukemia virus type I (HTLV-I) encodes an oncogenic 
protein called Tax which mediates activation of NF-κB and has been hypothesized to be 
associated with adult T-cell leukemia (ATL) [350]. Tax binds to TAX1BP1 [323], [351], and 
hinders the association of A20 and Itch with TAX1BP1 adaptor protein [323], [324]. As a result 
the “A20 ubiquitin editing complex” is not formed and A20 cannot be recruited to RIP1 [323]. 
By a similar mechanism, upon IL-1 stimulation, Tax does not allow recruitment of A20 to 
TRAF6 receptor complex [271]. In response to TNFα, Tax prevents association of Ubc13 with 
A20, thereby preventing the consequent degradation of Ubc13 [271]. In this way, Tax inhibits 
A20 (by binding to TAX1BP1) and activates NF-κB [211]. 
The human papillomavirus virus (HPV) E2 protein also interacts with TAX1BP1. It is 
currently unclear if this interaction affects NF-κB signaling during infection with HPV [352]. 
Epstein Barr Virus (EBV) encodes an oncogenic protein called LMP1. This protein interacts with 
A20 to promote constitutive activation of NF-κB [353], [354]. A20 also deubiquitinates IRF7 in 
Raji cells infected with EBV virus [355]. Thus, the infection is not mediated solely through the 
inactivation of the NF-κB pathway.  
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In addition to encoding for proteins that hijack the cellular role of A20, some viruses and 
bacteria have also evolved to directly encode for a DUB that resembles A20. This could in 
theory allow the pathogen to inhibit NF-κB [211] and reduce the proinflammatory response by 
the host.  In effect, this would provide the pathogen a strategy for ‘immune evasion’. The 
Crimean Congo hemorrhagic fever virus (CCHFV) causes hemorrhages and 30% of infections 
are lethal [356].  It encodes a protein named L protein which has a N-terminal OTU domain (just 
like A20). This is not unique to CCHFV, but also found in Nairobi sheep disease virus and 
nairoviruses Dugbe virus (DUGV). This protein deubiquitinates NF-κB activators, thereby 
attenuating TNF-α-mediated activation of NF-κB. The bacteria Yersinia (causes plague) has 
evolved to encode a gene called YopJ. This virulence factor could potentially deubiquitinate 
TRAF2 or TRAF6, leading to inactivation of NF-κB and reduced expression of proinflammatory 
cytokines [357].  Much like mammalian DUBs, pathogenic DUBs also seem to lack specificity. 
Thus, YopJ has been found to cleave both K63-linked and K48-linked polyubiquitin chains 
[357]. In this way, by mimicking the DUBs, pathogenic bacteria and viruses can find a way to 
escape the host immune response.   
 
2.5.6: Regulation of A20 deubiquitinase activity 
Recently, the crystal structure of the OTU domain was solved independently by two 
groups [210], [209]. The structure is similar to other cysteine proteases, and the architecture of 
catalytic cysteine (C103) and accompanying histidines is conserved [209]. The C103 
(responsible for deubiquitinase function) is located in an alpha helix, which may provide the 
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platform for binding of ubiquitin chains [210]. However biochemical evidences by other groups 
have suggested that the seventh zinc finger motif is important for ubiquitin binding [309].  
A20 cleaves K48-linked polyubiquitin chains rather than K63-linked polyubiquitin chains 
in vitro, and this is at odds with the proposed mechanism of disassembling K63-linjed chains 
from RIP1 and TRAF6 [210], [219]. Additionally, unlike most of cysteine proteases of OTU 
family, A20 deubiquitinates K63-linked chains from the TRAF6/ubiquitin interface [210]. While 
some groups have confirmed the importance of the deubiquitinase activity of A20 [196], [200], 
[324], others have found that that this property of A20 is dispensable for downregulating NF-κB 
[204], [307]. Moreover, inhibition of antiviral signaling requires the ZF domains [358] but not 
the DUB domain of A20 [359], [360], [358]. These discrepancies may be attributed to distinct 
experimental designs employed by different groups (cell lines, varying levels of overexpression, 
etc).  
2.6: Conclusion and Perspectives  
Despite the large body of literature implicating A20 in inflammatory responses, the 
mechanism by which A20 downregulates inflammation has remained elusive. Multiple 
biochemical and knockdown approaches in cell culture have suggested that A20 functions as a 
deubiquitinase by disassembling regulatory K63-ubiquitin chains on upstream signaling 
molecules such as RIP1. In the next chapter, we report the creation and characterization of a 
knock-in mouse that expresses a mutated form of A20 that lacks the deubiquitinase activity. The 
knock-in mouse that we have generated abrogates the deubiquitinase function of A20 in vivo, 
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Ubiquitination of multiple signaling adaptor molecules by K63 linked ubiquitin chains have been 
proposed to be a key regulatory mechanism in NF-κB activation. Deubiquitinase enzymes such 
as A20 have been suggested to limit the persistence of NF-κB activation by removing regulatory 
ubiquitin chains from ubiquitinated substrates. A20 has garnered significant interest as mice 
lacking A20 die prematurely from multi-organ inflammation and cachexia, as a result of 
increased NF-κB signaling. Thus, it is evident that A20 is non-redundant in its ability to limit the 
persistence of NF-κB signaling. A20 is believed to function by first removing K63 linked 
ubiquitin chains from adapter proteins such as RIP1, and then polyubiquitinating the same 
substrates with K48 linked ubiquitin chains that trigger proteasomal degradation. However the 
exact role of the deubiquitinase function of A20 in its ability to downregulate NF-κB signaling, 
had not been examined in a physiological setting. To understand the physiological relevance of 
A20-mediated deubiquitination, we generated a knock-in mice that lacks the deubiquitinating 
function of A20 (A20-OTU mice). We hypothesized that these mice would have an 
inflammatory phenotype because of increased, persistent NF-κB signaling. However our results 
show that A20 OUT mice display normal NF-κB activation and no inflammatory phenotype, 






NF-κB is an ubiquitously expressed, inducible transcription factor that regulates the 
expression of numerous target genes, particularly in the immune system. In unstimulated cells, 
NF-κB is sequestered in the cytoplasm through its binding to inhibitory IκB proteins that mask 
the nuclear localizing signals on the NF-κB proteins. NF-κB can be activated upon stimulation of 
cells with a wide variety of inducers including pro-inflammatory cytokines such as TNFα and 
IL-1β, or components of pathogenic microbes (PAMPs) such as bacterial lipopolysaccharide 
(LPS). Upon engagement of cognate receptors e.g. TNF-receptor or Toll-like receptor 4, 
signaling pathways are triggered that lead to the activation of a protein kinase complex known as 
the IκB kinase (IKK). The activated IKK phosphorylates the IκB proteins on specific serine 
residues that lead to their polyubiquitination with K48-linked ubiquitin chains, and consequent 
degradation by the proteasome. The released NF-κB then migrates to the nucleus where it binds 
to promoters of target genes and activates transcription [108]. 
 
Besides the well-characterized K48-linked polyubiquitination that triggers proteasome-
mediated degradation of substrate proteins such as IκBs, polyubiquitination of signaling adapter 
proteins with K63-linked chains have been proposed to have critical regulatory function in NF-
κB activation pathways. RING-finger proteins such as TRAFs are believed to act as 
ubiquitinating enzymes and molecules such as RIP1 are well-characterized substrates that 
undergo K63-linked ubiquitination. Similar to kinases and phosphatases, deubiquitinating 
enzymes have been proposed to act to limit the consequence of regulatory ubiquitination by 
removing the polyubiquitin chains. Amongst the various deubiquitinases that have been 





 A20 was initially identified as a TNFα-inducible zinc-finger protein that protects cells 
from TNFα induced cytotoxicity [304]. A20 is expressed at very low levels in most cell types but 
is rapidly induced in response to various PAMPs or proinflammatory cytokines [304]. 
Subsequently, many studies, mainly in overexpression systems, have demonstrated that A20 
downregulates NF-κB signaling in multiple pathways including the tumor necrosis factor (TNFα) 
and Toll-like receptor (TLR) pathways[208], [306], [272]. Mice deficient in A20 die prematurely 
from multi-organ inflammation and cachexia as a result of increased NF-κB signaling as would 
be predicted from the in vitro studies. These mice are also sensitive to proinflammatory stimuli 
and cannot withstand even sub-lethal doses of TNFα or LPS. Additionally, the A20 deficient 
MEFs show persistent NF-κB signaling as evidenced by increased IκBα degradation [134].  
Intriguingly, although A20 was initially identified as a TNFα-inducible gene, the 
spontaneous inflammation in A20 deficient mice continues unabated even in A20(TNFΑIP3)-/-
TNFα-/- and A20(TNFΑIP3)-/-TNFR1-/- double mutant mice. Thus, the spontaneous inflammation 
in A20 deficient mice results from TNFα-independent signaling. Instead the inflammation in 
these mice in largely eliminated by removal of MyD88, and the TNFΑIP3-/-Myd88-/- mice do not 
show the severe inflammation characteristic of A20 deficient mice, indicating that TLR signaling 
drives the spontaneous inflammation in these mice [200]. Consistently, treatment of A20 
deficient mice with broad-spectrum antibiotics rescues the inflammatory phenotype, thereby 
indicating that a dysregulated intestinal flora contributes to the constitutive TLR signaling which 
results in perinatal lethality in these mice [310]. Thus, it has been clearly demonstrated that A20 
is essential and non-redundant in restricting persistent TLR mediated activation of NF-κB and 
subsequent lethality. Therefore while many studies have focused on the role of A20 in response 




It has been shown by various biochemical assays that A20 can function both as a 
deubiquitinase (DUB) and as an ubiquitin ligase. A20 has a N-terminal OTU domain followed 
by seven C-terminal zinc finger domains. Cys-103 in the OTU domain has been showed to be 
essential for the deubiquitinating function of A20 [204], [196] . Previous biochemical studies 
using recombinant A20 has demonstrated that A20 is a unique ubiquitin modifying enzyme 
regulating both the activity (by removing K63 linked chains) and stability (by adding K48 linked 
chains) of signaling molecules such as RIP and TRAF6 (Nature, 2004, 430, 694-699) [196]. 
These studies showed that in response to TNFα stimulation, A20 acts by first deubiquitinating 
the regulatory K63-linked polyubiquitin chains from RIP1, thereby initially attenuating NF-κB 
signaling. Subsequently, A20 acts as an E3 ubiquitin ligase adding K48-linked polyubiquitin 
chains to RIP1 leading to degradation of RIP1 and terminating any residual NF-κB signaling. In 
the TLR and the IL-1R pathway, A20 inhibits NF-κB signaling by disrupting the binding of the 
E3 ligase, TRAF6, with E2 ubiquitin conjugating enzymes like Ubc13 or UbcH5c. The 
deubiquitinase activity mediated by C103 residue has been shown to be essential in mediating 
this interaction as well [271]. 
Despite the A20 C103A mutants being completely deficient in DUB activity, some 
studies have shown that overexpression of A20 C103A can also inhibit NF-κB signaling  [204, 
208, 307]. We were intrigued by these observations because they suggested that the ability of 
A20 to inhibit NF-κB activation might not be due to the ability of A20 to deubiquitinate K63-
ubiquitinated substrates. Therefore, to accurately delineate the physiological ramifications of 
A20’s deubiquitinating function, we generated a gene-targeted mouse with a C103A point 
mutation to eliminate the DUB activity of A20. Given the severe multi-organ inflammation in 
A20-/- mice that led to perinatal lethality [134], we hypothesized that these A20-C103A knock-in 
deubiquitinase mutant mice would show a phenotype similar to the A20 knock-out mice.  
Furthermore since dysregulation of A20 has been implicated in a host of diseases [20], these 
knock-in mice could prove to be a potential model for studying these disorders in a 
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physiologically relevant setting. However, as described in this report, the A20 C103A KI mice 
do not show any aberrant pro-inflammatory mice and demonstrate normal lifespan without any 
observable phenotype. Analysis of NF-κB signaling in cells isolated from these mice show no 
discernible difference from normal, wild-type cells, including the degree of ubiquitination of 
signaling adapter proteins. Therefore our studies reveal that the deubiquitinase function of A20 is 
not important for the well-described role of A20 in NF-κB signaling. 
 
3.3: Results 
3.3.1: Generation of A20-OTU knock-in mice.  
In order to evaluate the physiological contribution of A20’s deubiquitinating function, we 
decided to create a mouse with a mutation in the OTU domain to abolish the deubiquitinase 
activity. We used a BAC based approach, as described in the methods section, to generate a 
knock-in mouse that harbors a point mutation at position 103, namely a change from cysteine to 
alanine (Figure 3.1A). Heterozygous A20 knock-in mice (C103A or C/A) were intercrossed to 
generate the homozygous A20-OTU knock-in mice (or A/A mice). Sequencing of genomic DNA 
from both C/A and A/A mice confirmed the presence of the correct C103A point mutation 
(Figure 3.1B). The sequencing chromatogram of the genomic DNA isolated from heterozygous 
mice shows both cysteine and alanine at position 103, while the homozygous mice encodes for 
only alanine. The genotyping strategy and the photographs of the respective littermates are 
shown in Figure 3.1C. In this thesis, we refer to the wild type littermates as C/C meaning they 
have a cysteine in both alleles at position 103; the heterozygous mice as C/A as they have a 
cysteine and alanine in the two alleles; and the homozygous knock-in mice as A/A as they have 
only the mutated alanines on both alleles. 
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We next isolated BMDMs from both WT and A/A littermates and found roughly equal 
levels of A20 mRNA and protein (Figure 3.1D) following LPS and TNFα stimulation. A20 was 
initially found at relatively low levels but is rapidly induced upon LPS stimulation in both the 
C/C and A/A littermates.  
3.3.2: Characterization of A20 OTU knock-in mice 
Although A20-/- mice were runted by 1 week of age and die perinatally of multi-organ 
inflammation and cachexia, the homozygous A/A knock-in mice were normal (Figure 3.1E) and 
did not display any external signs of inflammation (for the observed period of 10 months after 
birth). They were born in Mendelian ratios and both the C/C and A/A littermate adults weighed 
the same (Figure 3.1E). Histological examination of 6 week old  A20-/- mice had revealed severe 
tissue damage in multiple organs. However histology of major organs (kidney, liver, spleen, 
thymus, lung and heart) of WT (C/C), heterozygous knock-in (C/A) and homozygous knock-in 
(A/A) littermates did not reveal any differences (Figure 3.2A). Hence, the deubiquitinating 
function of A20 is not important for maintaining basal tissue homeostasis. 
3.3.3: Characterizing the cells of immune system of C103A knock-in mice in the steady 
state 
Unlike A20 -/- mice that have increased numbers of myeloid lineage cells in the bone 
marrow and spleen, the C/C, C/A and A/A littermates had comparable frequencies of myeloid 
lineage cells (CD11b+). Within the myeloid compartment, the frequencies of monocytes 
(CD11b+Ly6c+Ly6G-) and granulocytes (CD11b+Ly6c+Ly6G+) were similar across all 
indicated genotypes (Figure 3.2B). Similarly, analysis of B cell development indicated that the 
differentiation pattern of CD19+B220+ and CD19-B220+ cells in heterozygous and homozygous 
knock-in mice was comparable to the WT littermates. In addition, analysis of surface IgM and 
IgD expression in CD19+ B cells of the bone marrow indicated similar expression patterns 
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amongst wild type, heterozygous and homozygous knock-in mice (Figure 3.2C).  Consistently, 
analysis of erythroid (Ter119+) and megakaryocyte (CD41+) lineage cells suggested comparable 
frequencies in the bone marrow (Figure 3.2D). 
In mice, T cell development occurs in the thymus and undergoes distinct stages of 
differentiation including the, earliest, double negative  (DN) stage (CD4-CD8-), double positive 
(DP) stage (CD4+CD8+) and subsequently into CD4+CD8- and CD4-CD8+ single positive cells 
[361]. Analysis of thymus of the three genotypes indicated a roughly equal differentiation of 
CD4 and CD8 cells between the genotypes as shown in Figure 3.2E. Consistent with the normal 
differentiation of myeloid, lymphoid and erythroid lineages in the BM and thymus, the spleen 
also showed normal proportions of B cells (Figure 3.2F), T cells (Figure 3.2G), dendritic cells 
(Figure 3.2H) and myeloid cells (Figure 3.2I).  Therefore these results suggest that the 
deubiquitinase function of A20 does not play a role in differentiation and maintenance of 
immune cell types. 
As mice age to 6 months, the A/A deubiquitinase mutant mice develop splenomegaly and 
their spleens weigh around 145 mg as compared to their age and sex-matched wild-type C/C 
littermates whose spleen weight around 65 mg. Both the wild-type and mutant mice weight 
around the same (Figure 3.2J). Analysis of the bone marrow and spleen of older mice showed 
that the homozygous mutant mice showed an increase in myeloid cell population (Figure  3.2K).  
 
3.3.4: Activation of wild type and mutant BMDM and BMDCs in response to LPS and 
TNFα in vitro 
A20 is negligibly expressed in the basal state but is rapidly induced upon stimulation by 
LPS and TNFα, and the newly synthesized A20 helps down-regulate NF-κB activity. Hence, we 
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wanted to test the contribution of the deubiquitinating function of A20 in inhibiting NF-κB 
activation following stimulation with LPS and TNFα. 
We differentiated bone marrow cells of wild type (C/C), heterozygous (C/A) and 
homozygous (A/A) mice into dendritic cells and macrophages in the presence of either GMCSF 
or MCSF respectively. After seven days of in vitro culture, we stimulated them with either TNFα 
or LPS. ELISA analysis revealed that LPS stimulation produced roughly equal amounts of 
TNFα, IL-6 and IL-12 by BMDM and BMDCs of both C/C and A/A mice (Figure 3.3A). 
Similar results were obtained following TNFα stimulation (IL-6 and IL-12 were roughly similar 
for both C/C and A/A littermates) as shown in Figure 3.3B.  
In addition, we also analyzed the DCs and macrophages by flow cytometry for their 
activation status (as determined by upregulation of CD40, CD80, CD86 and MHC-Class II) after 
48 hours of stimulation with LPS and TNFα. While both DCs and macrophages showed 
upregulation (of CD40, CD80, CD86 and MHC-Class II) upon stimulation, the levels of 
expression were comparable amongst C/C, C/A and A/A littermates (Figure 3.3C and Figure 
3.3D). 
Taken together, these data indicated that the C103A deubiquitinase domain is not 
involved in limiting inducible NF-κB activation.  
 
3.3.5: Response of A20 OTU knock-in mice to LPS shock 
The perinatal lethality manifested by lack of A20 is largely mediated by TLR based 
signaling. Thus, A20 is important for restricting LPS induced inflammation in vivo and we 
wanted to determine the physiological contribution of the deubiquitinase activity of A20 in LPS 
dependent responses. We therefore challenged the C/C and A/A knock-in mice with LPS using 
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established protocols and observed that both WT and the A/A knock-in mice succumbed to LPS 
shock (Figure 3.3E). We also analyzed the serum levels of the key acute phase cytokines 
(TNFα, IL-6 and IL-12) after LPS injection and found that while TNFα peaked after 1 hour, IL-6 
and IL-12 peaked later in agreement with previous studies. However, there was no significant 
difference in the levels of the cytokines between WT and the A/A mice after LPS shock (Figure 
3.3F). Hence, the deubiquitinating function of A20 does not play an important role in limiting 
inflammatory responses in vivo following LPS administration. 
3.3.6: Similar activation of NF-κB  in BMDMs from both wild type and homozygous mice 
Before biochemically testing the activation of NF-κB in  wild-type and homozygous mice 
, we first showed that the C103A mutation eliminates deubiquitinase activity in A20 (Figure 
3.4A). A20 analogs (wild type and C103A-A20) were immunoprecipitated from LPS-stimulated 
BMDMs of wild-type and homozygous A/A mice and an in vitro deubiquitinase assay was 
carried out with recombinant K48 or K63-linked polyubiquitin chains (Figure 3.4A). Our results 
clearly demonstrate that the C103A mutation eliminates DUB activity of A20, as C103A-A20 is 
unable to deubiquitinate either K48-linked or K63-linked ubiquitin chains in the in vitro DUB 
assay.  
Next, we then wanted to test the role of the A20 deubiquitinase activity in NF-κB 
activation in cells stimulated with TNFα. We isolated and cultured BMDMs from C/C and A/A 
knock-in mice, stimulated them with TNFα, and prepared nuclear fractions to test NF-κB binding 
to DNA by EMSA (Figure 3.4B). Both the WT and the A/A BMDMs showed elevated (but 
similar) binding of p65-p50 heterodimers to the DNA following stimulation. The nuclear extract 
isolated after stimulating the WT BMDMs for 30 minutes was used for the super-shift assay and 
analysis with the unlabeled probe. Western blotting showed similar activation of NF-κB as 
tracked by degradation of IκBα. pJNK, p38 and pERK signaling were also found to be similar 
between wild-type and A/A littermates. As RIP1 in stimulated cells has been suggested to be 
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deubiquitinated by A20, we immunoprecipitated RIP1 from stimulated cells and tested it for 
ubiquitination. Both the WT and the C103A-A20 was recruited to RIP1 in roughly equal 
amounts and similar kinetics following TNFα stimulation (Figure 3.4C). Intriguingly, we also 
found roughly equal amounts of ubiquitinated RIP1 in the BMDMs of both genotypes following 
TNFα stimulation. These results suggest that the deubiquitinase activity of A20 does not affect 
RIP1 ubiquitination in cells.  
Similar results were also obtained upon stimulation of BMDMs with LPS. Both the wild 
type and the homozygous mutant showed similar activation of NF-κB as analyzed by EMSA 
(Figure 3.4D). The result is consistent with the kinetics of disappearance of IκBα as analyzed by 
western blotting (Figure 3.4E). Since TRAF6 has been shown to be deubiquitinated by A20 in 
response to stimulation with LPS, we immunoprecipitated TRAF6 from stimulated cells and 
found that the levels of ubiquitination (and K63-linked ubiquitination) of TRAF6 is more in 
BMDMs derived from A/A mice as compared to their wild-type littermates after stimulation with 
LPS. The kinetics and amounts of WT and the C103A-A20 recruited to TRAF6 was similar after 
stimulation with LPS (Figure 3.4E), showing the structural integrity of C103-A20 protein. 
 
3.4: Discussion  
Ubiquitination is a reversible post-translational modification that involves the attachment 
of one or more ubiquitin monomers to the substrate. This reversible post-translational 
modification involves the activity of ubiquitinating enzymes (like kinases) that add ubiquitin 
chains to the substrate, and deubiquitinases (like phosphatases) that disassembles these ubiquitin 
chains. While ubiquitination is best known to target the substrate protein for proteasome-
mediated degradation, recent studies have suggested various nonproteolytic consequences of 
ubiquitination. K48-linked ubiquitination of substrates targets them for degradation, while 
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regulatory K63-linked ubiquitination has been shown to activate various kinases including IKK 
in vitro leading to activation of NF-κB. Thus ubiquitination has emerged as a mechanism 
whereby covalent attachment of diverse polyubiquitin chains lead to different biological 
outcomes. However while it is clear that K48-linked polyubiquitination leads to proteasomal 
degradation, the physiological consequences of regulatory K63-linked ubiquitination remains to 
be established in animal models [123]. 
A20 is one of the best characterized of all enzymes that acts on K63-linked ubiquitin 
chains. It is believed to deubiquitinate K63-linked ubiquitin chains and this deubiquitinase 
activity has been proposed to be essential in the downregulation of NF-κB signaling for both 
TNFα and LPS mediated pathways. However, this is difficult to reconcile with the observation 
that the OTU domain of A20 disassembles K48-linked polyubiquitin chains much more potently 
as compared to K63- linked polyubiquitin chains in an in vitro setting [209, 210]. This is an 
intriguing discrepancy as the deubiquitinating function of A20 would be expected to be specific 
to K63-linked ubiquitin chains for it to play such a profound role in a tightly regulated process 
such as NF-κB activation. 
While the physiological role of the deubiquitinating property of A20 requires further 
study, there is no doubt that A20 is essential in limiting inflammation, very likely through NF-κB 
activation. Dysregulation of A20 has now been implicated in various autoimmune diseases and 
cancer. Polymorphisms in the A20 locus increases disease susceptibility in multiple autoimmune 
diseases including type I diabetes, psoriasis, rheumatoid, arthritis, systemic lupus erythematosus, 
etc. [20] Recently, an A20 polymorphisms (A125V and F127C) were discovered in the DUB 
domain which increases susceptibility to autoimmunity by impairing A20 mediated 
deubiquitination [343]. It has been speculated that the Cys103, the residue primary important for 
deubiquitinating property could be important in the physiological mechanism of A20. 
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To directly ascertain the contribution of the deubiquitinating role of A20 in its biological 
function, we replaced the wild-type A20 gene with a mutant form that lacks deubiquitinating 
activity. Our studies of these knock-in mice show that abolishing the deubiquitinase activity of 
A20 does not affect its ability to be recruited to RIP1 or TRAF6, and hence the mutation does 
not affect the protein structure. Furthermore, it is important to appreciate that the phenotypes 
observed in the knock-in mice are the result of the C103A mutation regulated by endogenous 
mechanisms as compared to previous in vitro experiments that relied on overexpression systems 
and exogenous gene regulatory mechanisms.   
The mutant protein in the homozygous mouse and the wild type protein in the wild type 
littermate are induced in equal amounts following inflammatory stimuli. This is what is typically 
expected in a gene targeted knock-in system. However, as A20 expression is directly induced by 
NF-κB signaling, A20’s capacity to downregulate NF-κB signals exemplifies a negative 
feedback mechanism. Moreover, previous studies of hypomorphic A20+/- cells suggest that the 
ability of A20 to negatively regulate NF-κB signaling is directly dependent on the amount of 
A20 in the cells [319, 362]. Thus if Cys103 was indeed important for restricting NF-κB 
signaling, it would be expected that the levels of the mutant protein would be increased in the 
homozygous mice. This was the first hint that Cys103 may not be a playing an important role in 
downregulating NF-κB signaling in a physiological context. This is not surprising as the 
deubiquitinase activity mediated by Cys103 has been shown to promiscuously cleave 
unanchored K11-, K48- and K63-linked polyubiquitin chains in addition to disassembling K63-
linked chains from in vitro substrates [196, 200, 209, 210, 363]. 
A20’s Cys103 residue has been proposed to be crucial for down regulating NF-κB 
signaling in vitro [196, 271]. Thus, it was expected that the A20-C103A mice would at least 
partially resemble the A20-/-mice [134]. However, while A20-/-mice develop spontaneous multi-
organ inflammation and perinatal lethality, the A20-C103A mice are grossly normal in the basal 
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state. While A20 -/- mice have an increased number of myeloid lineage cells in the bone marrow 
and spleen, we found an overall normal population of both myeloid and lymphoid cells in the 
bone marrow, spleen and thymus in the C/C, C/A and A/A littermates. Thus, the deubiquitinating 
activity of A20 does not play a major role in the maintenance of basal immune homeostasis. 
Moreover even following LPS stimulation, the response of the AA knock-ins were similar to 
wild type littermates.  
Our results are in agreement with a recent study that also found that mice lacking the 
deubiquitinating activity of A20 are grossly normal for at least four months and contained 
normal number of lymphocytes, however older mice (6 months) develop splenomegaly and show 
increased number of myeloid cells [281]. It is therefore possible that Cys103 plays a role in older 
mice.  However as our data shows, it does not play a role in directly inhibiting NF-κB. In this 
regard, defects in the NF-κB pathway would manifest itself in much younger mice. For example, 
it is worth pointing out that complete knockouts of A20 are perinatally lethal from persistent 
inflammation resulting from NF-κB activation. In agreement with the previous study, we also 
find that in addition to NF-κB signaling, other pathways like pJNK, p38 and pERK signaling 
were also comparable in BMDMs derived from wild-type and A/A littermates. Thus, the 
deubiquitinase function of A20 is not responsible for inhibiting TNF-induced cell death. 
The study also found RIP1 to be slightly more ubiquitinated in A/A cells as compared to 
our study [281]. The discrepancy in the levels of RIP1 ubiquitination might be explained by the 
different cell lines and experimental conditions used by them and us. While they used MEFs, we 
used BMDMs for our study. Experimentally, we checked ubiquitin levels of total cellular RIP1 
while they examined ubiquitin levels of RIP1 recruited to the TNFR complex. The slightly 
different levels of ubiquitination of RIP1 in the two studies might be attributed to these causes. 
We found that the levels of ubiquitination (and K63-linked ubiquitination) of TRAF6 is 
more in the A/A mice following LPS stimulation. Importantly, both the wild-type and the 
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C103A-A20 was recruited to TRAF6 in roughly equal amounts and with similar kinetics 
following stimulation with LPS, showing that the C103A-A20 is not structurally altered. 
However, the kinetics of degradation of IκBα as determined by western-blotting is not affected in 
the A/A mice. This shows that while the Cys103 might play a role in deubiquitinating TRAF6, it 
does not play a role in inhibiting NF-κB. It is also possible to argue that regulatory ubiquitination 
of TRAF6 is not intrinsic to the activation of NF-κB following LPS stimulation. 
These investigators also concluded, similar to our observations, that the deubiquitinase 
activity of A20 was not required for prevention of spontaneous cachexia and premature death. 
Surprisingly however, this study focused exclusively on the role of Cys103 in limiting TNFα 
induced NF-κB activation, despite previous reports from the same group that A20 functioned in 
vivo in limiting TLR/MyD88-dependent pathways [200, 310]. Hence, our study focusing on the 
role of A20 C103 on LPS/TLR-mediated responses is vital for understanding the physiological 
role of the deubiquitinating property of A20 in restricting persistent TLR mediated activation of 
NF-κB. 
As our studies clearly demonstrate, the C103A mutation eliminates DUB activity of A20. 
Inspite of that, NF-κB activation is not altered in A/A mice. Hence, it is safe to conclude that the 
deubiquitinase activity of A20 is dispensable for its well-documented role in NF-κB signalling. 
However, the E3 ligase function of the ZnF4 domain could partially compensate for the lack of 
deubiquitinating function in vivo, even though A20 is only supposed to ubiquitinate substrates 
such as RIP1 after first deubiquitinating them. Interesting, a recent study with mice lacking the 
E3 ligase activity demonstrated that neither of the C103 or the ZnF4 motif were singly 
responsible for all of A20’s functions in restricting TNFα signaling, and in the ZnF4 motif 
appeared more important than the deubiquitinase activity in restricting TNFα signaling in 
embryonic fibroblasts (MEFs). The mechanism underlying such an observation remains unclear, 
but also casts doubt on the importance of A20 as a deubiquitinating enzyme. As we know that 
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the A20 protein is important in inflammatory signaling, these studies suggest that A20 plays a 
more important role that does not involve ubiquitination/deubiquitination in exerting its 
regulatory function in inflammatory signaling. In this respect, the seventh zinc-finger motif 
(ZnF7) of A20 was recently proposed to be involved in direct inhibition of IKK by a non-
catalytic mechanism [309]. Thus, it is probably fair to say that significant additional studies will 
be needed to determine the actual role that A20 plays in regulating inflammatory/NF-κB 
signaling.  
 
3.5: Materials and Methods 
3.5.1: Generation of A20C103A knock-in mice 
 The A20C103A mice were generated using conventional gene-targeting approaches. In brief, 
exon 3 harboring Cys103 was PCRed out using a bacterial artificial chromosome (BAC) bearing 
the A20 gene and cloned into a PL452 plasmid having a Lox-Neo-Lox cassette. Standard site-
directed mutagenesis using Stratagene kits was used to mutate Cys103 to Alanine. The relevant 
part of the A20 construct was then transferred from PL452 plasmid to the BAC using 
homologous recombination. This BAC construct which now harbors the Lox-Ne0-Lox cassette 
along with a C103A mutation was retrieved into a pMCS_DTA plasmid (with diphtheria toxin 
selection gene) which was linearized and electroporated into CSL2J2, albino C57BL/6J ES cells. 
Correctly screened ES cell clones were injected into blastocysts derived from C57BL/6 mice to 
give rise to chimaeras (in the Columbia University Transgenic Core facility). Genetic 
transmission of the allele was confirmed by PCR and subsequent sequencing to confirm the 
presence of the C103A mutation. The LoxP flanked neomycin sequences were deleted by 
crossing the transgenic mice with the EIIA-Cre deleter mice. The C/A heterozygous mice were 




Bone marrow cells of 6-8 weeks aged matched wild type (C/C), heterozygous (C/A) and 
homozygous (A/A) mice were differentiated into dendritic cells and macrophages in the presence 
of either GMCSF or MCSF respectively. In the in vitro experiments, BMDMs were stimulated 
with 10ng/ml TNFα or 1ug/ml LPS 
3.5.3: Biochemical experiments 
 Immunoprecipitations and western blotting were performed as has been described previously 
[196]. For the in vitro DUB assay, immunoprecipitated A20 was incubated 37 °C with 
recombinant K48 or K63-linked polyubiquitin chains in 20µl of DUB buffer (25 mM Hepes pH 
7.4, 1 mM DTT, and 5 mM MgCl2) for 1 hour. Samples were then subject to western-blot 
analysis with the indicated antibodies. Gel shift assay was done using the Li-cor EMSA kit as per 
the user manual. The κB probe was purchased from Li-cor while the Oct1 probe was custom-
made. Antibodies used in this study include anti-murine RIP monoclonals (BD Bioscience, clone 
610458), ubiquitin (Santa Cruz, sc-8017), (IκBα (Santa Cruz, sc-371), A20 (Imgenex, 161A), 
βtubulin (Abcam), . 
3.5.4: LPS-induced shock 
LPS was injected intraperitonially at a concentration of 50 mgkg-1 of mice body weight. The 
mice were monitored for survival every eight hours. In a separate experiment, the mice were bled 
1 h, 2 h and 6h after LPS treatment and the serum cytokine levels measured by ELISA [186]. 
3.5.5: Flow cytometry, ELlSA and qRT–PCR 
Cell preparations, flow cytometric and ELISA analyses were performed as previously described 
[186], [319]. ELISA was performed with kits from BD Biosciences.  Cells were analyzed by 
flow cytometry using LSRII and Flowjo software (Tree Star).  
 110 
 
BMDMs were stimulated and RNA was isolated using the RNA Easy kit (Qiagen). RNA was 
reverse transcribed (SuperScriptIII reverse transcriptase; Invitrogen-Life Technologies), and 
SYBR Green master mix (QuantiTect SYBR green; Invotrogen) was used to quantify relative 
gene expression of the corresponding mRNA with normalization to β-actin (by using the formula 




Figure 3.1A: Gene targeting strategy for generating the A20OTU/OTU mice: The plasmid 
construct was linearized using Not1 and chimeras were obtained after homologous 








Figure 3.1B: Sequencing of genomic DNA from homozygous (A/A) and heterozygous 
littermates (C/A). (Schematic of sequencing strategy: Blue denotes the LoxP sequence and the 
plasmid sequences of the targeted locus; purple denotes the genomic sequence; red ‘X’ demotes 
the C103A mutation in the targeted locus. The sequencing primer used has a genomic sequence. 
Hence, sequences of the DNA from the homozygous A/A mice show only the ‘alanine’; while 






Figure 3.1C: Genotyping strategy and photograph of wild type, heterozygous and homozygous 
littermates (Schematic of genotyping strategy: Red denotes the LoxP sequence and the plasmid 
sequences of the targeted locus; purple denotes the genomic sequence. Forward primers used are 
Lox (red) and wild-type primer (purple); hence the homozygous gives a slow migrating upper 
band while the wild type yields the lower band) 
 
 
Figure 3.1D: Relative A20 mRNA and protein expression in macrophages from littermates. Error 
















Figure 3.2B: Characterizing the myeloid cells of the bone marrow 
 




Figure 3.2D: Characterizing the megakaryocytes and erythroid cells of the bone marrow 
 
 







Figure 3.2F: Characterizing the B cells of the spleen 
 




Figure 3.2H: Characterizing the dendritic cells of the spleen 
 
 





Figure 3.2J: A) Photograph of 6-month old C/C (WT) and A/A (Homo KI) mice B) Photograph 







Figure 3.2K:  6-month old A/A (Homo KI) mice show increased numbers of myeloid cells as 






Figure 3.3A: TNFα, IL-6 and IL-12 produced by BMDM and BMDC in response to 1ug/ml LPS 
was measured by ELISA. Error bars represent standard deviation 
 
 
Figure 3.3B: IL-6 and IL-12 produced by BMDM and BMDC in response to 10ng/ml TNFα was 






























Figure 3.3E: Age and sex matched mice (n=5; experiment repeated thrice) were given 





Figure 3.3F: Serum cytokine levels of TNFα, IL-6 and IL-12 in mice injected with 50ug/ml LPS 




Figure 3.4A:  C103A mutation eliminates deubiquitinase activity of A20 as determined by in 
vitro deubiquitinase assay 
 
 
Figure 3.4B: NF-κB   binding to DNA in response to TNFα stimulation was analyzed by 
Electrophoretic mobility shift assay. EMSA was performed with nuclear extracts after 
stimulating BMDMs isolated from wild type and homozygous littermates with 10ng/ml of TNFα 
for the indicated time points. The nuclear extract isolated at 30 minutes from wild type BMDMs 






Figure 3.4C: BMDMs isolated from wild type and homozygous littermates were stimulated with 
10ng/ml TNFα for the indicated time points. The cells were lysed and immunoprecipitated with 









Figure 3.4E: BMDMs isolated from wild type and homozygous littermates were stimulated with 
1ug/ml of LPS for the indicated time points. The cells were lysed and immunoprecipitated with 





























4.1: Inhibitors of NF-κB (IκB) 
The IκBs are the master-regulators of NF-κB activity, and they can inhibit NF-κB activity 
via a negative feedback mechanism [62]. An intriguing historical observation was that the 
activation of NF-κB was transient in nature and that the inhibition of NF-κB required ongoing 
protein synthesis [364]. This correlates with observations that the IκBα protein is rapidly 
regenerated after initial degradation [47] [48, 50, 365]. Additionally, IκBα is transcriptionally 
regulated by NF-κB [48, 50, 178, 365] and indeed, one of the earliest NF-κB target genes 
actually encodes for IκBα [50]. Around this time, it was reported that although IκBα has a strong 
Nuclear Export Signal, it was still found in the nucleus [366] thereby indicating that it is possible 
that IκBα enters the nucleus and dissociates from the DNA-bound p65:p50 heterodimers. This 
leads to the export of the heterodimers from the nucleus to the cytoplasm, an example of a classic 
negative feedback loop [48, 50, 178, 366, 367]. This kind of negative-feedback regulation was 
also supported by genetic data demonstrating that IκBα-deficient mice were dead within a week 
of birth. This was as a result of persistent NF-κB activation upon treatment with TNFα or LPS 
[47, 368]. While IκBα is the most obvious inhibitor of NF-κB activation, it is by no means the 
only inhibitor. 
4.2: Why so many IκBs? 
The accepted paradigm is that the IκB proteins are fundamentally regulatory inhibitors of 
NF-κB. They function by forming an inhibitory complex with NF-κB and keeping NF-κB 
sequestered in the cytoplasm, where it is inactive in the basal state.  The generally accepted 
model is that these IκBs are inducibly phosphorylated by the IκB kinase complex, and that this 
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leads to their stimulus-dependent destruction. This is the key regulatory event required for the 
activation of the inducible transcription factor NF-κB. 
The basic question then is: Why are there so many IκBs?  It may be expected that the 
simple answer to this question would be ‘biological redundancy’, but the answer turns out to be 
much more elaborate than that as the different counterparts have unique functions (Table 4.1). 
Indeed, intense research in the last fifteen years has shown that the family of IκBs does 
not act solely as reversible cytoplasmic inhibitors of NF-κB. The different IκBs are functionally 
heterogeneous and the specific IκB-NF-κB complex is a regulatory module that may act to 
inhibit, or even promote transcriptional activity in response to various stimuli [186]. In this light, 
it is best to modify the traditional idea of IκBs acting as cytoplasmic inhibitors of NF-κB with 
the notion of IκBs acting as chaperones or cofactors of NF-κB. The activity of the IκB cofactor is 
necessary for stabilization of the NF-κB heterodimers not only in the cytoplasm, but in the 
nucleus as well. The binding of IκB also provides an interface to interact with other molecules 
and alter the transcriptional response. It also might facilitate cross talk with other heterologous 
pathways [108].  
The phenotypes of mice deficient in the different IκB proteins are shown in Table 4.2. 
Genetic evidence has also suggested the need to modify the traditionally held model of IκB-
mediated cytoplasmic sequestration of NF-κB [369]. Thus, cells lacking all three IκBs (IκBα, 
IκBβ and IκBe) show increased basal activation of NF-κB, in spite of having a normal 
subcellular distribution of p65 [369]. In brief, there is an intricate relationship between the IκB 
and NF-κB family of proteins which modulates NF-κB-dependent transcription in response to 
the specific physiological environment. 
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1. NF-κB, nuclear factor-κB; n.d., not determined. 
2. *IκBβ can occur as phosphorylated (P) or as hypophosphorylated (HP) species. 
3. †Human splice variant. ↓ and ↑ denote respectively decrease or increase in transcription. 











(P)* + (delayed)/no ++ 
Heterodimeric 
NF-κB – 
Sequesters NF-κB in the 
cytoplasm 
IκBβ1 
(HP)*   n.d. p65:c-Rel ChIP 
Coactivator of p65:c-Rel, 
TNFα↑, IL-1β↑ 
IκBβ2† + (delayed)/no −/+ Heterodimeric NF-κB – 
Sequesters NF-κB in the 
cytoplasm 
IκBε + (delayed)/yes ++ 
Heterodimeric 
NF-κB – 
Sequesters NF-κB in the 
cytoplasm 




Cyclin D1 ↑, MDM2 ↑, 
cytokine expression ↓, gene 
expression profile 
IκBζ ++/yes n.d. p50:p50 ChIP IL-6 ↑, TNFα↓ gene expression profile 
IκBNS ++/yes n.d. p50:p50 DNA-pull-down ChIP 
IL-2 ↑ IL-6 ↓ gene 
expression profile 
IκBη − or +/no n.d. p50:p50 n.d. Cytokines, e.g. IL-1β, IL-6 ↑ 




– Sequesters NF-κB in the cytoplasm 
p100 ++/yes − RelB – Sequesters NF-κB in the cytoplasm 





Table 2.   Knockouts of IκB family proteins  
Knockout Lethality Phenotype 
IκBα−/− 7–10 days after birth 
Severe widespread dermatitis and extensive granulopoiesis; persistent 
NF-κB activation after TNFα or LPS treatment 
IκBβ−/− No Resistant to LPS-induced septic shock and collagen-induced arthritis; increased and prolonged expression of cytokines, e.g. TNF and IL-1β 
IκBε−/− No Increased expression of individual Ig isotypes and cytokines 
IκBα−/−  
IκBε−/− Neonatal 
Severe malfunction of lymphopoiesis; nearly complete absence of B 
and T cells; NK cell number reduced 
Bcl-3−/− No Defects in splenic microarchitecture and T-cell differentiation; severe defects in protective humoral immune responses 
IκBζ−/− No 
Severe atopic dermatitis-like disease with inflammatory cell 
infiltration; impaired expression of specific genes activated by 
TLR/IL-1R signal transduction, e.g. IL-6 
IκBNS−/− No 
High sensitivity to LPS-induced endotoxin shock and intestinal 
inflammation; reduced T-cell proliferation; deregulated cytokine 
production 
p105−/− No Defects in stress response and various immune functions 
p100−/− No Defects in secondary lymphoid organ development; impaired B-cell maturation 
Table 4.2: Phenotypes of murine knockouts of different IκB proteins [19] 
 
IκBs can be broadly subdivided into three categories (Figure 4.1): 
a) proto-typical IκBs, that are expressed in cytoplasm and are known to undergo 
phosphorylation, degradation, and resynthesis upon stimulation. The first member of the IκB 
protein family, IκBα, was cloned in 1991 [370], and is characterized by the conserved ankyrin 
repeat domains. After this, the second member to be identified and cloned was IκBβ [34, 371, 




b) atypical nuclear IκBs, barely expressed at basal levels, but induced upon stimulation. 
Bcl-3, is the first member of the family of atypical IκBs. It was initially cloned and discovered as 
a proto-oncogene in chronic lymphocytic leukemia [374]. Later, it was also identified as an IκB 
family member [375] [371, 372]. Typical of many atypical IκBs, it has been demonstrated that 
Bcl-3 can act as a transcriptional coactivator [376, 377]. Subsequently, many other members of 
this groups have been discovered like IκBζ/MAIL [378-380], IκBNS [381] and, recently, IκBη 
[382]. In contrast to the typical IκBs, all atypical IκBs with the significant exception of IκBη 
have a low level of expression under resting conditions, but are rapidly induced by NF-κB-
stimulators [374, 381-383]. Initially, IκB proteins were assumed to function only as inhibitors of 
NF-κB activity. However, the discovery of these atypical IκB-like family members has 
demonstrated that the functions of IκB are much more complicated than previously imagined. 
The atypical IκBs are located predominantly in the nucleus and may interact with other nuclear 
factors. Such interaction may prevent degradation of DNA-bound NF-κB dimers, which may 
increase or decrease transcription [384]. It is also possible that the atypical IκBs might fine-tine 
NF-κB-dependent gene regulation by competing with the cytoplasmic IκBs for binding DNA-
bound NF-κBs in the latter part of the activation process. 
c) Precursor proteins p105 and p100: they have an N-terminal Rel homology domain 
and C-terminal ankyrin repeats [385-391]. p100 and p105 are known to form stable complexes 
with other NF-κB family members via the N-terminal Rel homology domain and/or the ankyrin 
repeats in the C-terminal end. Thus, they function like IκB in sequestering NF-κB, blocking 
nuclear translocation and eventual DNA binding. [371] [74] [392] [393] [394] [395] [396]. 
Following proteolytic processing, these precursor proteins release NF-κB proteins p50 (from 
p100) and p52 (from p105) using distinct mechanisms [397] [398]. Specifically, p105 is 
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proteolytically degraded under multiple IKK-activating conditions [399] [400] [401]. Like any 
typical IκB, p105 is also phosphorylated by IKKβ at serines 927 and 932, followed by β-TrCP 
mediated degradation [402] [403] [404]. In this way, p50 homodimers may be released in a 
signal-dependent manner. It has been recently shown that noncanonical signaling can also 
liberate p50 from cytoplasmic p100 [405]. Both p105 and p100 knockout mice exhibit defects in 
the immune system [98]. These phenotypes are probably a result of the knockouts lacking the 
encoded precursor protein as well as the IκB-like function of these proteins. There may be a 
feedback regulation for these precursors as they are under the transcriptional regulation of NF-






Figure 4.1: Typical and atypical IκB proteins. [108] 
 
4.3: Ankyrin repeats: signature of IκBs 
The single most important structural feature of IκB proteins is their conserved ‘ankyrin 
repeat domain (ARD)’ [19] (Figure 4.2). The ARD motif is responsible for binding to NF-κB 
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proteins, thereby enabling the IκBs to perform their most important functions. ARDs frequently 
mediate protein–protein interactions in a wide range of proteins with different functions. An 
ankyrin repeat consists of 3 amino acids, and has a broad phylogenetic distribution. They fold to 
a helix-loop-helix conformation [408], [409]. While the typical IκBs (IκBα, IκBβ and IκBε) have 
six ankyrin repeats, the atypical IκB molecules have seven or eight. Structural studies suggest the 
binding of one NF-κB dimer with one IκB molecule. This confirms the 1:1 stoichiometry of 
binding as observed in previous biochemical studies involving cross-linking experiments and 
native gel analysis [410], [411], [412], [413]. 
It has been seen that ARD mediated interaction stabilizes the IκB protein. Interestingly, 
the closer the sequence of the ankyrin repeat in a particular protein is to the bioinformatically 
derived consensus sequence, the more stable is the protein.  This is obviously an empirically 
derived axiom but has been found to be able to explain the low stability of free IκBα [414].  This 
is because only half the primary sequence of the ARD of IκBα matches the theoretical sequence. 
Besides, it has been documented by a number of studies that the 5th and 6th ankyrin repeats is not 
fully folded in free IκBα. They fold fully only in a complex with NF-κB. This explains the 
stability of IκBα-NF-κB complex as compared to free IκBα [415], [416], [417], [418]. 
The N-terminal part of IκBs is unfolded and contains the serines that are phosphorylated 
by IKK. These serines are in a ‘signal response domain’, also known as the ‘degron’ as 
phosphorylation leads to degradation of the IκB molecule. Upon phosphorylation, lysine residues 
located about ten amino acids upstream of the site of phosphorylation undergoes 
polyubiquitination with K48-linked polyubiquitin chains. This ‘signal response domain’ is 
followed by the ARD. The third domain in the C-terminus of IκB is known as the PEST domain. 
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This region is abundant in proline (P), glutamic acid (E), serine (S) and threonine (T) [419], 
[412]. They are arranged in short stretches of more than ten negatively charged amino acids. The 
PEST domain is also found in NF-κB precursor proteins (p105 and p100) [411] and may be 
involved in facilitating protein turnover. The ankyrin and PEST domains of IκBα, Bcl-3, or p105 
have been found to be sufficient in binding the dimerized Rel domain [411], [372]. The N-
terminal ‘signal response domain’ is not required for binding but for being able to respond to 
upstream stimulus. 
While the binding of ARD to the NF-κB dimer imparts stability to the complex [410], 
[413], it is not immediately clear how the ‘de novo’ synthesized IκB molecules displace the NF-
κB dimers from the DNA. The ‘partially folded’ 5th and 6th ankyrin repeats along with the PEST 
domain seem to be playing an important role in dissociating the dimer from the κB site [190], 
[417]. This is because mutations facilitating the stable folding of these ankyrin repeats (without 
affecting the IκB-NF-κB binding affinity) reduce the ability of IκBα to remove the dimers from 
the κB site [190]. A ternary complex comprising of a NF-κB dimer, IκBα, and DNA has been 
found in solution, as determined by NMR based experiments [420]. These experiments also 
provide a mechanism by which IκBα dislodges the p65:p50 dimer from κB site. The first contact 
with the NLS of p65 is made by the ‘well-folded’ ankyrin repeats putatively to obscure the NLS. 
After this, the ‘unfolded’ ankyrin repeats associates with the dimerization domain in p65 and 
p50.  This results in the complete folding of all ankyrin repeats and configures the negatively 




Figure 4.2: Structure and domains of the IκB protein family. [19] 
 
A few of the important IκBs are described below in further detail: 
4.4: IκBα (the prototypical inhibitor of NF-κB) 
IκBα is by far the most well characterized member of the IκB family and has a molecular 
weight of 37-kDa. It is the prototypic IκB, which sequesters the main NF-κB (p65/p50) 
heterodimer in the cytoplasm [421], [370], [422], [423]. It is degraded in response to a range of 
ligands including the various Toll-like receptor (TLR) ligands and the various cytokines (TNFα, 
interleukin-1 (IL-1) etc). Upon stimulation, IκBα undergoes phosphorylation by IKK, and rapid 
subsequent degradation [52], [51], [424] via the proteasome [54], [55], [53]. This results in the 
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release of the heterodimers [38], [370], translocation of active NF-κB dimers (p65-p50) from the 
cytoplasm to the nucleus, and expression of  NF-κB  dependent genes [25].  
Since the IκBα gene is transcriptionally regulated by NF-κB, it forms an autoregulatory, 
negative feedback loop [50], [367], [178], [48]. Thus, in mice deficient in IκBα, NF-κB is 
persistently unregulated [73], [368] leading to embryonic lethality. Lethality can be rescued by 
knocking-in an IκBβ gene downstream of the IκBα promoter [425]. 
The discovery of the negative-feedback mechanism prompted investigations to discover 
the underlying mechanisms. The p65:p50:IκBα complex has been found to undergo cytoplasmic-
nuclear shuttling [61], [180]) and the reason was initially unclear as it was expected that IκBα 
would sequester the heterodimer only in the cytoplasm. However it was soon found that while 
IκBα interacts with p65:p50 in the resting state, it does not completely mask the NLS of p50 
[252], [410]. Hence in the basal state, IκBα is found (in a complex with the heterodimer) both in 
the nucleus and the cytoplasm. It is degraded upon stimulation and then rapidly resynthesized. 
The current model is that the resynthesized IκBα goes to the nucleus. There, it binds the 
deacetylated p65-p50 heterodimers and the trimeric inactive complex moves back to the 
cytoplasm.  
It is not clear why the de novo synthesized IκBα translocates to the nucleus, especially as 
IκBα does not have a NLS (and instead has a nuclear export sequence). One suggestion has been 
that IκBα has a non-classical NLS in its second ankyrin repeat. Another study has proposed a 
‘piggy-back’ mechanism, by which IκBα uses the NLS of another unknown protein [426], [427]. 
IκBα is unique (unlike IκBβ) and can remove heterodimers bound to the DNA. This is because 
the binding of NF-κB with IκBα (KD =40 pM) is much stronger than the binding of NF-κB with 
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DNA (KD =3-10nM). This has been shown using different analytical techniques using NMR, 
stopped flow-fluorescence and surface plasmon resonance [428], [420], [190]. 
The nuclear export sequence (NES) of IκBα, present between residues 45-54, has thus 
been proposed to be very important for translocating the IκBα:p65:p50 complex to the cytoplasm 
[74], [75], [429],  and subsequent termination of NF-κB activation [251]. But mice carrying a 
gene that encodes IκBα with a mutant NES are perfectly viable [430].   
4.5: IκBε (inhibitor of chronic NF-κB signaling) 
IκBε is a 45 kDa protein that also undergoes IKK dependent phosphorylation, 
degradation and resynthesis just like IκBα. Moreover, the IκBe is also a NF-κB dependent gene 
[179], [36]. However, the kinetics of degradation and resynthesis is much more rapid for IκBα as 
compared to IκBe [37]. It is conceivable that that the both IκBα and IκBe inhibit NF-κB at 
distinct time points by a negative feedback mechanism. This may have significant impact in the 
regulation of post-stimulus NF-κB  inhibition, especially in response to TNFα [179]. 
IκBε is predominantly associated with Rel:p65 heterodimers in the basal state [37], [431]. 
It is phosphorylated by IKK at Ser 157 and Ser 161. After this, it is proteasomally degraded by 
β-TrCP [37], [432]. The rapid phosphorylation of IκBα as compared to IκBe may be in part 
because of the higher binding affinity of IKK to IκBα. Additionally, IκBɛ has also been found to 
be associated with the PP6 phosphatase in unstimulated cells. This may also delay the 
phosphorylation [433]. This is supported by the observation that knocking down  PP6R1 
(essential subunit of PP6) has been found to increase the rate of IκBɛ degradation [434]. IκBe is 
predominantly cytoplasmic and does not undergo as much nuclear-cytoplasmic shuttling as 
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IκBα. This may be because IκBe has a noncanonical NES between residues 343 and 352 [431], 
[429], [435]. 
IκBɛ is less ubiquitous than IκBα and it is predominantly found in hematopoietic cells. 
IκBe knockout have minor defects in components of the hematopoietic lineages. This may be 
because IκBα compensates for the loss of IκBe [183], [436]. IκBɛ is expressed at various stages 
of developing B cells and may regulate p65 and cRel containing complexes [437], [438]. Thus, B 
cells deficient in IκBɛ have been found to have increased levels of basal  and induced cRel [439]. 
It is clear though that more in vivo work is necessary to elucidate the temporal behavior of IκBɛ.  
4.6: IκBβ (inhibitor and activator of NF-κB signaling) 
Humans have two splice variants of the protein, the longer isoform IκBβ1 (43 kDa) and 
shorter, C-terminally truncated IκBβ2. The mouse orthologue IκBβ corresponds to human IκBβ1 
and is degraded is response to LPS or IL-1β. There have been reports that in human, IκBβ2 is 
more abundant as it is resistant to stimulus-dependent degradation [440]. Though the promoter of 
IκBβ has a NF-κB-binding site, transcription of IIκBβ does not seem to be regulated by NF-κB 
[34], [441], [442]. 
Unlike any of the other IκBs, IκBβ is constitutively phosphorylated. This phosphorylation 
may be important for inhibition of NF-κB complexes in the cytoplasm [443]. Similar to the other 
IκBs, upon stimulation, IKK phosphorylates IκBβ at Ser 19 and Ser 23 [444] leading to β-TrCP-
mediated proteasomal degradation [445]. However, the kinetics of NF-κB activation is not 
significantly altered in IκBβ deficient cells as compared to the IκBα or IκBe deficient cells [60], 
[179]. Interestingly, the stimuli that degrade IκBβ (LPS or IL-1) are known to cause persistent 
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activation of NF-κB [34]. Multiple groups have reported that there is a significant difference in 
the overall pattern and kinetics of IκBβ degradation [423], [34], [191], [189] as compared to the 
other IκBs. 
After degradation, IκBβ is resynthesized in a hypophosphorylated form. 
Hypophosphorylated IκBβ does not mask the NLS of p65 and can be found in the nucleus in a 
complex with p65:cRel dimers bound to DNA  [34], [35], [188], [189], [191]. Crystallographic 
data has confirmed that IκBβ-bound p65 homodimers can indeed bind the DNA [192]. The 
DNA-bound “hypophosphorylated IκBβ-NF-κB complex” cannot be removed by IκBα. The 
presence of this complex in the nucleus led our group to hypothesize about 15 years ago that 
hypophosphorylated IκBβ might actually be augmenting the expression of certain genes [35], 
though it was unclear at that time if the complex was increasing or inhibiting transcription [191], 
[192], [253]. The idea emerged that IκBβ could act as a chaperone, protecting the DNA-bound, 
functional p65:cRel heterodimer in the nucleus from IκBα.  
The phosphophorylated IκBβ on the other hand masks the NLS of p65 and is found in the 
cytoplasm of unstimulated cells (IκBβ does encode a NES). Acting as a bona fide inhibitor, the 
phosphorylated form inhibits DNA binding in vitro [35], Phillips, 1997 #408}, [191]. Indeed, in 
vitro data suggests that IκBβ might have greater affinity for NF-κB as compared to IκBα, and 
hence completely masks the NLS of NF-κB heterodimers. As a result, IκBβ is exclusively 
cytoplasmic in unstimulated cells (as compared to the nuclear-cytoplasmic shuttling of IκBα) 
[252], [251]. 
In order to understand the contribution of IκBβ to regulation of NF-κB in the 
physiological context, an IκBβ knockout mouse was generated by us (and another group) [186], 
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[187]. These mice are resistant to LPS-induced septic shock as they produce less TNFα [186] 
and IL-1β [187] in response to LPS. They are also resistant to collagen-induced arthritis. It is 
clear from the animal model that IκBβ has distinct functions in the cytoplasm and nucleus. 
Cytosolic IκBβ acts as a traditional inhibitor and inhibits basal activation of NF-κB. It does so by 
sequestering p65:cRel complexes in the cytoplasm of unstimulated cells. Upon stimulation with 
LPS, IκBβ is degraded and the dimer translocates to the nucleus. Consistent with our decade-
long hypothesis, hypophosphorylated IκBβ is synthesized and interacts with p65:cRel in the 
nucleus. The IκBβ-p65-cREl complex binds to the DNA at specific κB sites (κB2 promoter 
region) leading to increased transcription of specific genes like TNFα [186] and IL-1β [187]. 
While it has been speculated for a long time that IκBα and IκBβ are quite different in 
their functions, the physiological relevance of this was unclear. Now both biochemical and 
genetic evidence is available to show that while IκBα inhibits inflammation, IκBβ can both 
activate and inhibit inflammation [186] depending on the context.  
4.7: Conclusion and Perspective 
While their functions may partially overlap, murine genetic models have now 
conclusively established the non-redundant functions of the three typical IκBs in the 
physiological context. IκBα-knockout mice die 7–8 days after birth from severe dermatitis and 
extensive granulopoiesis [368] [446]. Expectedly, upon stimulation with lipopolysaccharide 
(LPS) or tumor necrosis factor alpha (TNFα), these cells show sustained upregulation of NF-κB 
(and IκBε) [37]. These mice have defects in NF-κB signaling in B-cells and in formation of 
secondary lymphoid tissues. In contrast, IκBβ-knockout or IκBε- knockout mice are viable and 
have relatively minor differences in immune cell composition as compared to their wild type 
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littermates. The IκBε-knockout mice show increased expression of certain cytokines and specific 
Ig isotypes [60, 182]. Remarkably, work in our laboratory has shown that mice lacking IκBβ are 
resistant to LPS-induced septic shock and collagen-induced arthritis [186, 187]. This result 
would have been unexpected based on the previous paradigm of inhibitory, sequestering function 
of IκBs. 
It is possible that specific functions of the typical IκBs could be contingent on their 
selectivity of interaction with specific NF-κB homo- or heterodimers. For example, IκBα binds 
to heterodimers containing p50, p65, and c-Rel [447] [448] [422]. Multiple studies reveal that it 
also exhibits the greatest efficiency in removing the active heterodimers from the nucleus, thus 
blocking transcription [373] [252] [191]. In contrast, IκBβ binds preferentially to cRel and p65 
containing heterodimers.  IκBβ is also a relatively weaker inhibitor of NF-κB subunits binding to 
DNA in vitro [34] [252] [191]. Additionally, it is important to understand that the stimulus-
dependent dynamics of degradation and subsequent regeneration of IκBα and IκBβ is 
substantially different. As shown in Figure 4.3, IκBα is degraded and resynthesized within an 
hour of stimulation. In spite of this rapid resynthesis of IκBα, NF-κB continues to stay activated 
possibly as a result of the delayed activity of IκBβ. This difference in the temporal control of 
IκBα and IκBβ might be because IκBβ  is constitutively phosphorylated. The pathway controlled 
by IκBα is well understood. In order to dissect the pathway controlled by IκBβ , it is important to 
know the site of constitutive phosphorylation, the kinase and the biological significance of this 
























GSK-3β constitutively phosphorylates IκBβ at Ser-346 to downregulate 
















It has been shown that unlike IκBα, IκBβ can both inhibit and activate the inflammatory response 
[186]. We hypothesize that this may be because IκBβ exists in two forms, a constitutively 
phosphorylated form and an unphosphorylated form. However the site of phosphorylation and 
the kinase is unknown, hindering a detailed characterization of the pathway mediated by IκBβ.  
Here, by mass-spectrometric analysis of immunoprecipitated IκBβ, we show that IκBβ is 
phosphorylated at Ser-346 in quiescent cells but not in cells stimulated with LPS. The kinase 
phosphorylating IκBβ at Ser-346 is Glycogen Synthase Kinase 3 (GSK3) which is active in 
resting cells, but inactivated upon stimulation with LPS. IκBβ phosphorylated at Ser-346 masks 
the NLS of p65, thereby sequestering the p65:cRel complex to the cytoplasm while 
unphosphorylated IκBβ cannot mask the NLS of p65. Consequently, phosphorylated IκBβ is 
anti-inflammatory while unphosphorylated IκBβ is pro-inflammatory. Additionally, Ser-346 also 
harbors a SNP, and preliminary experiments have suggested that it might be deleterious in 
patients with invasive pneumococcal disease; though the role of the SNP in the disease is not 
clear. It has also been predicted to be “highly damaging” by multiple softwares like Polyphen 
and Sift. We show that mice succumb to sub-lethal doses of LPS if phosphorylation of IκBβ is 
abrogated. The death occurs from increased production of TNFα caused by unphosphorylated 









5.2: Introduction  
NF-κB is an inducible transcription factor and is known to play a critical role in 
regulating multiple biological processes including development, survival and mediates the 
immune response in response to multiple  pathogenic insults [25]. Once activated, NF-κB 
upregulates genes that encode for different kinds of antiapoptotic proteins, cytokines and other 
molecules involved in immunoregulation. The NF-κB family consists of five members: p50, p52, 
p65, cRel and RelB. They can form homodimers or heterodimers that are inactive in the basal 
state, typically sequestered in the cytoplasm in a complex with  the inhibitor of κB (IκB) 
proteins. NF-κB is activated by a wide range of stimuli. It is remarkable that all these stimuli 
converge to activate a single kinase complex, the IκB kinase complex (IKK), which 
phosphorylates the IκBs, targeting them for proteasomal degradation [33]. The NF-κB dimers are 
now to free to enter the nucleus, bind to specific  κB  promoter sites on the DNA, and modulate 
transcription of target genes [187]. NF-κB functions in an intricate and context-dependent 
manner to selectively upregulate specific genes in response to specific stimuli.  
The primary inhibitors of NF-κB in the resting state are the IκB proteins. Consequently, 
ever since their initial discovery [24], much attention has been paid to understanding their 
function and mechanism of action. This has been an arduous task given that there are many 
members in the IκB family, including IκBα, IκBβ, IκBε, IκBγ, p100, p105, Bcl-3 and IκBζ [19], 
all of which have multiple ankyrin repeats in common. Amongst the IκBs, IκBα and IκBβ are the 
major inhibitors that sequester NF-κB to the cytoplasm in quiescent cells [34], [447]. Both IκBα 
and IκBβ also have a carboxy-terminal PEST domain that is rich in proline, glutamic acid, serine 
 147 
 
and threonine. The biggest difference between IκBα and IκBβ  in resting conditions is that IκBβ 
(but not IκBα)  is constitutively phosphorylated in the basal state. Upon stimulation, both the 
inhibitors are inducibly phosphorylated at two conserved serine residues in their N-terminal 
signal-response domain, leading to their degradation and subsequent resynthesis, although with 
markedly different kinetics. Much of the work in the field has focused on understanding the 
mechanism of IκBα which is the prototype inhibitor undergoing rapid degradation and 
subsequent resynthesis (within an hour of stimulation) [48]. However, NF-κB remains induced 
despite the rapid resynthesis and accumulation of IκBα after stimulation [35].  
Thus in spite of their structural similarities, IκBα and IκBβ have different functions [34], 
[191]. While IκBα–NF-κB complexes undergo nuclear- cytoplasmic shuttling under resting 
conditions, IκBβ–NF-κB complexes are entirely cytoplasmic [191], [251], [252]. Almost all 
known stimuli transiently activate NF-κB by rapidly degrading IκBα which is then almost 
immediately resynthesized in a NF-κB–dependent negative-feedback loop. The resynthesized 
IκBα travels to the nucleus, binds to the DNA-bound NF-κB dimer (mainly p65:p50 
heterodimer), exporting it to the cytoplasm [50], [368], [60]. In contrast, IκBβ is not a NF-κB 
dependent gene. Moreover, it is degraded in a delayed fashion (2 hrs) in specific cell-types by a 
subset of stimuli like LPS or IL-1, which are known to cause persistent activation of NF-κB [34], 
[449]. The activation is persistent as the NF-κB dimer regulated by IκBβ (p65/cRel) is 
intransigent to the newly synthesized IκBα [34]. Following degradation of the constitutively 
phosphorylated IκBβ, IκBβ is resynthesized in stimulated cells in an unphosphorylated form 
[35], [253]. The newly synthesized unphosphorylated IκBβ forms a stable complex with 
p65:cRel in the nucleus [34], [191], [189], [423], [35]. Along with biochemical evidence, 
crystallographic studies have suggested that this complex in the nucleus might actually bind 
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stably to DNA  [192]. Since this complex is resistant to IκBα , it was believed that the complex 
might even promote the transcription of certain genes [191], [35], [188]. This idea was indeed 
quite revolutionary at the time, as it suggested that an inhibitor of NF-κB could actually 
chaperone NF-κB dimers and turn on (instead of inhibit) transcription of some genes. 
About a decade later, the IκBβ knockout mouse was generated by two groups, and it was 
found that unphosphorylated IκBβ complexes with the p65:cRel heterodimer; and the complex 
indeed binds to the κB2 promoter in the nucleus to prolong the expression of certain genes like 
TNFα [186] and IL-1β [187]. As a result IκBβ knockouts are resistant to LPS-shock and 
collagen-induced arthritis. Thus, unlike IκBα , IκBβ can both inhibit and activate the 
inflammatory gene response in vivo.   
We hypothesize that this functional difference between IκBα  and IκBβ is because IκBβ 
(but not IκBα ) is constitutively phosphorylated in the quiescent state. Thus, IκBβ can exist in 
two forms: a phosphorylated form (which exists in unstimulated cells and has an anti-
inflammatory role) and an unphosphorylated form (which is pro-inflammatory and appears after 
stimulation). My aim in this chapter in to discover the site of phosphorylation, the kinase 
and the effect of phosphorylation. 
By mass-spectrometric analysis of endogenous IκBβ, we discovered that the constitutive 
site of phosphorylation is Ser-346 in the PEST domain. While determining the kinase, it became 
obvious that the kinase should be active in the basal state under unstimulated conditions but 
inactivated upon stimulation with LPS. Such a kinase is the glycogen synthase kinase 3 (GSK-3) 
[450], [451] (Figure 5.1), which was discovered as the kinase that phosphorylates and 
inactivates the enzyme glycogen synthase, thus having a critical role in the biosynthesis of 
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glycogen. It was originally isolated from skeletal muscle [452], [453], [454]. Since then, GSK3 
has been shown to play a critical role in regulation of many biological processes including 
development, cell cycle control, differentiation, cell motility and microtubule function, cell 
adhesion, proliferation, survival and inflammation [455], [456], [457]. Commensurate with its 
diverse functions, dysregulation of GSK3 has been implicated in many diseases including 
diabetes, cancer and Alzheimer disease. 
 
 
Figure 5.1: Hypothesis of GSK-3β -IκBβ axis 
 
GSK-3 is a serine/threonine kinase and exists as two homologous proteins, GSK-3α and 
GSK-3β (Figure 5.2). These two isoforms have an overall homology of 85%, and their kinase 
domains are 98% homologous [458].  It participates in a myriad of signaling pathways that are 
mediated by different transcription factors like NF-ATc, cyclin D1, cJun and β-catenin [459], 
[460], [461], [462]. It is best known for it’s role in the PI3-kinase/Akt pathway and Wnt 
signaling. In the PI3-kinase pathway, Akt phosphorylates GSK3 thereby inhibiting GSK3 in 
 150 
 
stimulated cells [463]. In Wnt signaling, constitutively active GSK-3β forms a complex with 
adenomatous polyposis coli (APC) protein, axin and β-catenin.  In unstimulated cells, GSK-3β is 
active and phosphorylates β-catenin, leading to the degradation of β-catenin [464], [465]. As a 
result, β-catenin mediated transcript is suppressed in resting cells. Wnt signaling leads to 
inactivation of GSK-3β  and disruption of the complex, stabilizing β-catenin  and inducing 
transcription of β-catenin target genes [466]. 
Although GSK-3α  and GSK-3β  are homologous proteins, they are encoded by two 
distinct genes [458]and are non-redundant. GSK-3β knockout mice are embryonically lethal, and 
GSK-3α cannot compensate for the deficiency of GSK-3β.  The GSK-3β knockout mice die 
around day 16 from TNFα-dependent liver degeneration [467]. The first hint that GSK-3β  may 
cross-regulate the NF-κB pathway came from the fact that these mice closely resemble mice 
deficient in p65 or IKKβ  [73], [72]. The degradation of IκBα  is not affected in these mice, 
suggesting that GSK-3β affects an IκBα  independent pathway.  In contrast, mice lacking GSK-
3α are viable [468], [469]. They are however more sensitive to insulin and have abnormal brain 
structures. The functional differences between the two isoforms have also been  demonstrated  in 
Drosophila where overexpression of GSK-3β, but not GSK-3α, could rescue a mutant lacking a 
GSK3 homolog [470], [471], [450]. 
The crystal structure of GSK-3β has been determined by three independent groups and 
suggests that GSK-3β has a preference for phosphorylating primed substrates (i.e, substrates that 
have been pre-phosphorylated by other kinases) [472], [473], [474]. While not strictly required, 
priming phosphorylation typically increases the efficiency of subsequent phosphorylation by 
GSK-3β by ~100 fold as compared to non-primed substrates [475]. This is because the primed 
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phosphate binds to a positively charged pocket in GSK-3β  (consisting of residues R96, R180 
and K205). This binding orients the kinase domain of GSK-3β  for optimal phosphorylation. 
Mutating Arg96 disrupts the pocket, and inhibits binding and consequent phosphorylation of 
primed substrates [476]. Substrates that do not need priming have negatively charged residues 
that mimic the priming phospho-residue. The site of priming is typically three residues to the C-
terminus of serine/threonine targeted by GSK-3β. Hence, the consensus sequence of substrates 
phosphorylated by GSK-3β is  Ser/Thr—X—X—X-Ser/Thr-P, where the first S/T is the site of 
phosphorylation by GSK-3β; and the last residue is the S/T primed by some other kinase [477]. 
A prototypical priming kinase is casein kinase II (CK2) for the substrate glycogen synthase. This 
initial phosphorylation of glycogen synthase by CK2 is required for subsequent phosphorylation 
by GSK-3β [478], [479]. Other protein kinases that resemble GSK-3β also require primed 
phosphorylation of their substrates. They include ERK2, CDK2 and p38γ [480], [481], [482].  
However, GSK-3β  has many important substrates that do not need priming including axin [483], 
[476] tau [484], APC [485], [486] and presenlin-1 [487]. 
GSK-3β  has been shown to be inhibited by phosphorylation at Ser-9, while GSK-3α  is 
inhibited by phosphorylation at Ser-21. Different kinases can carry out this inhibitory 
phosphorylation including protein kinase A (PKA), Akt/protein kinase B (PKB) and protein 
kinase C (PKC) [463], [488], [489]. The crystal structure of GSK3 shows that GSK3 
phosphorylated at Ser-9/21 resembles a primed pseudosubstrate, and the negatively charged 
phospho-group (at Ser-9/21) can now bind intramolecularly to the positively charged pocket. As 
a result, the substrates of GSK3 can no longer bind to the positively charged pocket. This inhibits 
phosphorylation of substrates. However, the physiological relevance of this inhibitory 
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phosphorylation is not entirely clear as knock-in mice in which these serines are mutated to 




Figure 5.2: Structure of GSK-3α  and GSK-3β  [456] 
 
Biochemical studies using luciferase reporter assays and EMSA on GSK-3β  knockout 
MEFs have suggested that GSK-3β  may be involved in activating NF-κB. Other studies have 
also shown that inhibitors of GSK-3β  decrease the production of proinflammatory cytokines like 
TNFα during acute systemic inflammation [491], in plural exudates [492] and in the colon [493]. 
However, this is rather surprising as several stimuli that activate NF-κB (like TNFα, LPS, IL-1) 
actually lead to the inactivation of GSK-3β  (by Akt mediated phosphorylation) [456]. In 
apparent contrast to reports using GSK3 inhibitors, multiple reports have shown that Akt limits 
the production of proinflammatory cytokines [494], [495], [496], [497].  
Indeed in contrast to results in GSK-3β knockout MEFs, GSK-3β has been shown to 
inhibit IKK thereby inactivating NF-κB in neurons [498], [499]. In addition to neurons, the 
inhibitory regulation of NF-κB has also been demonstrated in other tissues. Overexpression of 
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GSK-3β  has been shown to inhibit expression of TNFα in lungs, hearts and endothelial cells of 
LPS-injected mice [500]. Independent reports have shown that GSK-3β could attenuate TNFα 
expression in response to LPS in cardiomyocytes [501], and IL-6 production  in response to IL-
17 [502]. There have been suggestions that the inhibitory activity of GSK-3β is mediated by 
phosphorylation of p65 [503], [504] or p105 [505]. The authors use a peptide array approach to 
show that GSK-3β phosphorylates p65 at Ser-468 and this leads to downregulation of NF-κB.  
Besides p65, GSK-3β  has also been shown to phosphorylate and stabilize p105 in quiescent 
cells [505], leading to suppression of NF-κB. This phosphorylation also primes the p105 for 
degradation by IKK in response to TNFα signaling. TNFα signaling not only inactivates GSK-3β 
, but also activates IKK leading to proteasomal processing of p105. 
It is possible that GSK-3β specifically affects the expression of only a subset of NF-κB-
target genes. A report has demonstrated the requirement of GSK-3β for the localization of p65 to 
the promoter region of some of the genes regulated by NF-κB using chromatin 
immunoprecipitation assays [506]. Another report has identified 74 early-response genes whose 
transcription is dependent on activation of PI3-kinase in response to stimulation with to growth 
factor [507]. Out of these, 12 genes could be induced by inhibition of GSK-3 even without 
stimulation with growth factor [508]. Computational and biochemical approaches have shown 
that GSK-3β inhibits NF-κB in the resting state. However GSK-3β  may also be required for NF-
κB activation in response to stimulation by different ligands [509]. 
Although GSK-3β is generally considered to be pro-inflammatory, one of the 
confounding findings have been that LPS stimulation activates NF-κB while simultaneously 
inactivating GSK-3β. We report the discovery of a novel pathway mediated by IκBβ, which 
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shows how inactivation of GSK-3β  in response to LPS stimulation can selectively upregulate 
certain NF-κB dependent genes like TNFα. 
5.3: Results 
5.3.1: IκBβ is constitutively phosphorylated at Ser-346 in quiescent cells 
1) IκBβ undergoes degradation and resynthesis in response to LPS stimulation 
To demonstrate stimulus-dependent degradation and resynthesis of IκBβ, 70Z/3 cells 
were stimulated with 1µg/ml of LPS. In agreement with previous results [186], [35], we found 
that IκBβ is constitutively phosphorylated in the unstimulated state (slower migrating upper 
band). Upon stimulation, the phosphorylated IκBβ is degraded followed by the accumulation of 
unphosphorylated IκBβ (faster migrating lower band) as shown in Figure 5.3A. The time points 
were chosen carefully in order to identify a time point where IκBβ is entirely in the 
unphosphorylated state. We determined that IκBβ is almost entirely unphosphorylated at 4.5 
hours. The stimulation with LPS was also carried out in the presence of cycloheximide.  Our 
results agree with previous results [35] and show that the appearance of the unphosphorylated 
IκBβ depends on the synthesis of new unphosphorylated IκBβ protein (as opposed to being 
formed from the degradation of phosphorylated IκBβ).  
As opposed to IκBβ which exhibits a delayed kinetics, IκBα  is degraded and synthesized 
rapidly within an hour (Figure 5.3A). 




Since IκBβ is present entirely in the phosphorylated and unphosphorylated state at 0 and 
4.5 hours, we decided to immunoprecipitate and determine the site of phosphorylation by mass-
spectrometric analysis. 70Z/3 cells were chosen as these are suspension cells, easy to grow and 
has a higher yield of endogenous proteins. Hence, we immunoprecipitated endogenous IκBβ at 
these time points from 70Z/3 cells (Figure 5.3B) and analyzed it by western blot. After this, we 
scaled up the immunoprecipitations reaction and ran it on a 8% SDS-PAGE gel (Figure 5.3B) . 
The bands containing the IκBβ protein was excised and analyzed by mass-spectrometry. Mass-
spectrometric analysis revealed that IκBβ is phosphorylated at Ser-346 in the PEST domain of 
IκBβ only in unstimulated cells, but not under stimulated conditions (Figure 5.3B). Ser-346 is 
conserved in mice, rats, chinese hamster, chimpanzee and humans. Additionally, Ser-346 is the 
site of a SNP (“rs11551804”) in humans (mutated to leucine), and one report has shown that it is 
in patients with invasive pneumococcal disease , though it’s role in the disease is unclear [510]. 
There is another SNP in the PEST domain where arginine at the 339th position is mutated to a 
tryptophan (“rs17886215”). Both these SNPs have been predicted by multiple softwares 
((Polyphen, Sift, etc)  to be “highly damaging” SNPs. This is predictable as the mutated leucine 
cannot be phosphorylated. This confirmed our initial prediction that the site of constitutive 
phosphorylation would have some important downstream functions. In this context, not many 
disease-associating mutations of typical IκBs have been found till date, perhaps because 
redundancy of IκB proteins [16]. 
3)  Characterization of phospho-specific antibody against Ser-346 of IκBβ 
We next generated an antibody against phospho-S346-IκBβ by injecting a peptide 
containing the Phospho-Ser-346-IκBβ peptide in rabbit. The phospho-specific antibody detected 
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a band corresponding to endogenous phospho-IκBβ in wild type macrophages and MEFs (under 
unstimulated conditions) but not in the IκBβ knockout cells as determined by western blot 
analysis (Figure 5.3C). Lambda phosphatase treatment of IκBβ abrogated the recognition by 
phospho-specific antibody, thereby demonstrating the integrity of the phospho-Ser-346 antibody 
(Figure 5.3C). The specific band was also detected in IκBβ–/– MEF transfected with WT IκBβ, 
but not with a S346A-IκBβ mutant (Figure 5.3C).  
We confirmed the LPS-dependent degradation and resynthesis of phospho-IκBβ using the 
phospho-S346 in intact cells. (Figure 5.3D).  
4) Phosphorylation of IκBβ at Ser-346 masks the NLS of p65 
While NF-κB-IκBα complexes shuttle between the cytoplasm and nucleus in resting 
cells, NF-κB-IκBβ complexes are exclusively cytoplasmic. A previous report has suggested that 
the NLS of p65 is exposed in a complex with recombinant IκBβ, but not with mammalian IκBβ 
[35]. Hence, we hypothesized that phosphorylation at Ser-346 may be responsible for masking 
the NLS of p65.    
To test if the unphosphorylated IκBβ exposes the NLS of p65, we incubated recombinant 
or mammalian IκBβ (wt, S346A or S346D analogs) with p65. Immunoprecipitation of p65 was 
carried out using two different antibodies, one that recognizes a 20 amino-acid C-terminal 
peptide of p65 (generic p65 antibody) and another that recognized the NLS of p65. Previous 
reports have showed that the NLS-specific antibody fails to recognize the p65 NLS in a p65-
IκBα  complex [366], [35] as the complex masked the NLS of p65.  
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Figure 5.3E shows that the p65 NLS antibody was able to efficiently immunoprecipitate 
p65 only when incubated with recombinant wild-type or S346A-IκBβ, but not for S346D-IκBβ. 
Hence, this experiment with recombinant IκBβ demonstrates that the phospho-mimetic S346D 
analog indeed masks the NLS of p65. However, we were concerned that this result may be 
because of differences between the two antibodies in binding to IκBβ or enhanced binding of 
S346D-IκBβ to p65. However, both the p65 antibodies pulled down equal amounts of the wt and 
S346A IκB analogs. Additionally, all the three IκB analogs are co-immunoprecipitated equally 
with the generic p65 antibody. This shows that the inability of the NLS-antibody to pull-down 
p65 when incubated with S346D-IκBβ is indeed because the phosphorylation at Ser-346 masks 
the NLS of p65 and not because of  different binding efficiencies between  the two antibodies or 
tighter binding of the S346D-IκBβ with p65. 
 
To confirm that the differences between phospho-S346-IκBβ and unphosphorylated IκBβ 
is not somehow due to anomalous protein expression in bacteria, we repeated the experiment 
with the three IκBβ analogs purified from mammalian cells (Figure 5.3E). In this case, the p65 
NLS antibody was able to efficiently immunoprecipitate p65 only when incubated with the 
unphosphorylated S346A-IκBβ analog, but not the wild-type or S346D-IκBβ. This is because the 
wild-type analog is basally phosphorylated in mammalian cells while the S346D-IκBβ is a 
phospho-mimetic. We confirmed that this was because phosphorylation masks the NLS of p65, 






5.3.2: GSK3 phosphorylates IκBβ at Ser-346 in vitro and in vivo 
1) GSK3 phosphorylates IκBβ in vitro 
Recombinant GST tagged wt, S346A and S346D IκBβ analogs were expressed in BL21 
cells and purified using standard protocols. Both GSK-3α and GSK-3β (Figure 5.4A) 
immunoprecipitated from macrophages and MEFs phosphorylated recombinant IκBβ in vitro in 
the presence of γ32-ATP, and this phosphorylation was blocked by two specific GSK3 inhibitors 
in a dose-dependent manner. The two generic GSK3 inhibitors used are 6-bromoindirubin-30-
acetoxime and  a membrane-permeable GSK-3 peptide inhibitor (Calbiochem). Both have an 
IC50 value in the nanomolar range and are highly specific inhibitors of GSK3 (has a high 
selectivity even for proteins that have a similar structure like CDK1). The inhibitors are used at a 
concentration of 20nM and 100nM [511]. The phosphorylation was inhibited in the presence of 
phosphatase. The negative control using IGG1 isotype antibody could not phosphorylate the 
recombinant IκBβ. Recombinant GSK-3β could also phosphorylate recombinant IκBβ and this 
phosphorylation is decreased in the presence of the GSK3 inhibitors (Figure 5.4B).  
2) IκBβ is an unprimed substrate of GSK3 
WT-GSK-3β , the kinase-mutant analog of GSK-3β  (KM-GSK-3β ) and R96A—GSK-
3β  was reconstituted into GSK-3β  knockout MEFs and the immunoprecipitated analogs was 
used to phosphorylate recombinant IκBβ in the presence of γ32-ATP (Figure 5.4C). While the 
KM-GSK-3β could not phosphorylate IκBβ, both the WT and R996A analog phosphorylates 
IκBβ. The R96A-GSK3β phosphorylates only substrates that do not need priming, but not 
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substrates that need prior priming by other kinases [476], [511]. Hence we conclude that IκBβ 
does not need priming by other kinases to be phosphorylated by GSK-3β. 
3) GSK3 phosphorylates IκBβ at Ser-346 in vitro 
γ32-ATP was not incorporated into recombinant S346A-IκBβ upon incubation with either 
immunoprecipitated GSK3 or recombinant GSK-3β , meaning that the S346A-IκBβ cannot be 
phosphorylated by GSK3. Figure 5.4D shows the kinase assay in the presence of 
immunoprecipitated GSK-3α and GSK-3β  (from two different mammalian cell lines, BMDMs 
and MEFs). Figure 5.4E shows the kinase assay with recombinant GSK-3β which 
phosphorylated the wild-type but not the recombinant S346A-IκBβ. 
Phosphorylation at Ser-346 was also checked using the phospho-Ser-346 antibody. The 
antibody detected phosphorylation of recombinant GST-IκBβ (Figure 5.4F) after incubation of 
GST-IκBβ with GSK-3β immunoprecipitated from MEFs and macrophages in presence of ATP. 
Phosphatase (lambda phosphatase) treatment of GST-IκBβ previously incubated with GSK-3β 
abrogated its recognition by the phospho-Ser-346 antibody. This shows that GSK3 
phosphorylates IκBβ specifically at Ser-346. 
4) GSK3 phosphorylates IκBβ at Ser-346 in vivo 
To directly determine whether GSK3 phosphorylates IκBβ at Ser-346 in vivo, BMDMs 
were treated with two distinct cell-permeable GSK3 inhibitors. The efficient inhibition of GSK3 
was confirmed by the increased levels of β-catenin in GSK3-inhibited BMDMs. The levels of 
IκBβ phosphorylation at Ser-346 decreased in a dose dependent manner (Figure 5.4G). The 
inhibitors did not affect the levels of IκBα , in agreement with previous studies [73], [72], [506], 
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which suggested that the NF-κB modulating activity of GSK3 was independent of IκBα . We 
next used a shRNA that has been reported to deplete both the isoforms of GSK3 [511]. We find 
that the depletion of GSK-3β stabilizes β-catenin, in agreement with multiple previous studies 
[459], [460]. Depletion of both the isoforms using shRNA markedly decreases the amount of 
phosphorylated IκBβ ((Figure 5.4H). Additionally, the phosphorylation of IκBβ at Ser-346 
increases when IκBβ-/- MEFs were co-transfected with IκBβ along with GSK-3β  (Figure 5.4I).  
To determine the levels of phosphorylation and degradation kinetics in WT, GSK-3β-/- 
and GSK-3α-/- MEFs, we stimulated these cells with LPS (Figure 5.4J). We found the presence 
of unphosphorylated IκBβ protein in unstimulated GSK-3β-/- MEFs. While the isoforms may 
partially compensate for each other, GSK-3β seems to be exclusively responsible for 
phosphorylating the newly synthesized, unphosphorylated IκBβ (as determined from the 
presence of unphosphorylated IκBβ six hours after stimulation).  
We also checked the degradation kinetics of IκBβ in MEFs where both the isoforms have 
been depleted using a commercially available inhibitor of GSK3 (6-bromoindirubin-30-
acetoxime at a concentration of 50nM) and shRNA (Figure 5.4K). The amount of 
phosphorylates IκBβ is substantially decreased in both unstimulated and stimulated cells, thereby 
confirming GSK3 as the kinase for IκBβ. 
5.3.3: The β-inhibitory peptide (BIP) selectively abrogates phosphorylation of IκBβ by 
GSK-3β  by decreasing the association of GSK-3β  with IκBβ 




Reciprocal immunoprecipitations of IκBβ with GSK3 and GSK3 with IκBβ shows that 
GSK3α/β and IκBβ physically associate with each other both in unstimulated and stimulated 
cells (Figure 5.5A and 5.5B).  
Co-immunoprecipitation of IκBβ using antibodies against GSK-3α  and GSK-3β  show 
that while GSK-3β associates with IκBβ under both stimulated and unstimulated circumstances, 
the interaction of GSK-3α with IκBβ is markedly decreased in stimulated cells (Figure 5.5A). 
2) GSK-3β  but not GSK-3α  is associated with the IκBβ:p65:cRel complex in stimulated cells 
Previous work has shown that IκBβ exists in a trimeric complex with p65:cRel [186]. We 
performed sequential immunoprecipitations by first immunoprecipitating IκBβ, and then 
immunoprecipitating the eluted IκBβ complexes with anti-p65 antibody. cRel was found to be 
present in the anti-p65 immunoprecipitate both in stimulated and unstimulated cells, confirming 
the existence of the IκBβ:p65:c-Rel complex. None of the GSK3 isoforms interact with the 
trimeric complex in unstimulated cells, thereby suggesting that GS3 does not phosphorylate IκBβ 
in a complex under resting conditions. Only GSK-3β (but not GSK-3α)  selectively associates 
with this complex upon stimulation (Figure 5.5B). This confirms the previous results and show 
that while the two GSK3 isoforms may be redundant in phosphorylating IκBβ in the quiescent 
state, only GSK-3β  associates with the unphosphorylated-IκBβ:p65:cRel complex and 
phosphorylates IκBβ in stimulated cells. 
3) The PEST domain of IκBβ is necessary for interaction with GSK3 
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Next, we mapped the domain of IκBβ required for interacting with GSK3. The full length 
IκBβ, but not the PEST deleted IκBβ, could interact with GSK3; demonstrating that the PEST 
domain of IκBβ is required for association with GSK3 (Figure 5.5C). 
4) β-inhibitory peptide (BIP) selectively inhibits the phosphorylation of IκBβ (but not β-catenin ) 
by GSK-3β  by decreasing the association of GSK-3β  with IκBβ both in vitro and in vivo 
GSK-3β may molecularly regulate NF-κB in various ways as have been suggested by 
different groups in the past. In order to specifically study the effect of the GSK-3β-IκBβ axis, we 
designed a peptide spanning Ser-346 in the PEST domain that abrogated the phosphorylation of 
IκBβ at Ser-346 (by GSK-3β). A phosphorylated version of the peptide (mutant peptide with 
phosphorylation at Ser-346) was also designed and was found to have no effect on the 
phosphorylation. 
Kinase assays showed that the peptide inhibited the phosphorylation of IκBβ at Ser-346 
by GSK-3β  in a dose-dependent manner. GSK-3β (Figure 5.5D) or GSK-3α  (Figure 5.5E) 
were immunoprecipitated from macrophages and incubated with recombinant GST-IκBβ in vitro 
in the presence of γ32-ATP and the peptide. The peptide (but not the mutant-peptide) inhibited 
phosphorylation of IκBβ by GSK-3β  in a dose-dependent manner (Figure 5.5D). However, 
phosphorylation by GSK-3α was only modestly affected in the presence of the peptide (Figure 
5.5E). The peptide also reduced the phosphorylation of GST-IκBβ by recombinant GSK-3β  in 
the presence  of γ32-ATP although it did not affect the autophosphosphorylation of GSK-3β  
(Figure 5.5F). This suggested that the peptide might be a specific inhibitor of IκBβ 
phosphorylation. We confirmed that the peptide was remarkably selective in inhibiting the 
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phosphorylation of GST-IκBβ as it also did not affect the phosphorylation of GST-β-catenin 
primed with casein-kinase (Figure 5.5G).  
We discovered that the peptide acted by abolishing the association of GSK-3β  with IκBβ 
both in vitro and in vivo. The mutant peptide was found to have no effect on the association of 
the molecules either in vitro or in vivo. We first incubated recombinant GSK-3β with 
recombinant GST-IκBβ in presence of the peptide and carried out a pull-down experiment using 
glutathione beads. The association of GSK-3β  with GST-IκBβ was completely abolished at 
higher concentrations of the peptide. Reciprocal pull-down using an antibody against GSK-3β  
also abolished the amount of GST-IκBβ associated with GSK-3β  at similar peptide 
concentrations (Figure 5.5H). 
We also wanted to see if the peptide could inhibit the GSK-3β-IκBβ interaction in intact 
cells. Hence, we made a cell-permeable version of the peptide (and mutant-peptide) by fusing the 
peptide with a sequence derived from the Antennapedia homeodomain that has been shown to 
mediate membrane translocation [512], [513]. Reciprocal immunoprecipitation reactions using 
antibodies directed against both GSK-3β  and IκBβ showed that the interaction was indeed 
abrogated in the presence of the peptide (Figure 5.5I).  The association between GSK-3α  and 
IκBβ was largely unaffected in the presence of the peptide, and is probably the reason why the 
peptide fails to inhibit phosphorylation by GSK-3α . The peptide did not affect the interaction of 
p65 and cRel with IκBβ. While higher doses of the peptide did result in some unphosphorylated 
IκBβ, it is not enough to ablate the phosphorylated form already present. This shows that the 
peptide acts by preventing the phosphorylation of newly synthesized unphosphorylated IκBβ, but 
does not trigger degradation of the pre-formed phosphorylated-IκBβ already present in cells.  
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The levels of β-catenin was not affected by the addition of the peptide, confirming that the 
peptide is not a global inhibitor of GSK-3β  and is a specific inhibitor of the kinase activity 
directed towards IκBβ.  
 
5.3.4: Functional consequences of GSK3β phosphorylating IκBβ at Ser-346 
1) Unphosphorylated IκBβ selectively activates specific NF-κB target genes (like TNFα) while 
inhibiting others in response to LPS stimulation  
Luciferase assay was performed by co-transfecting wt-IκBβ, S346A-IκBβ or S346D-
IκBβ along with pBIIX-luciferase and Renilla luciferase in IκBβ-/- MEFs. All the analogs are 
expressed in equal amounts as determined by western-blot analysis. While both wild type and 
S346D analogs suppressed NF-κB activity, the S346A analog failed to inhibit NF-κB (Figure 
5.6A). 
To explore if S346A-IκBβ positively regulates all NF-κB dependent genes (or only a 
subset), we also did a luciferase assay with the luciferase gene downstream of the promoters of 
TNFα and IL-6 (pTNF-luciferase and pIL6-luciferase) (Figure 5.6B). We first confirmed equal 
expression of the different IκBβ analogs. Remarkably, the results indicate that the S346A-IκBβ 
selectively increases the expression of the luciferase gene downstream of the TNFα promoter, 
but not the IL-6 promoter. In contrast, the phosphomimetic S346D-IκBβ inhibits expression of 
luciferase downstream of both the promoters. 
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These results were confirmed by ELISA analysis. We reconstituted IκBβ-/- BMDMs with 
GFP and wt-IκBβ, S346A-IκBβ or S346D-IκBβ. After confirming that the IκBβ-/- BMDMs 
express equal amounts of the IκBβ analogs, we stimulated them with LPS. Upon LPS 
stimulation, IκBβ-/- macrophages failed to make TNFα (but produced normal IL-6) in agreement 
with previous results [186]. This effect was rescued by expression of wt-IκBβ and increased in 
S346A-IκBβ containing cells; however the phosphomimetic S346D analog suppressed 
production of TNFα. The production of IL-6 was not influenced by the different analogs, 
suggesting that the pathway is specific for TNFα (Figure 5.6C). Since the production of TNFα 
was substantially increased in macrophages expressing S346A-IκBβ and almost completely 
abrogated in macrophages expressing S346D-IκBβ, we hypothesized that the unphosphorylated 
form of IκBβ may be responsible for the selective expression production of TNFα. 
2) GSK-3β inhibits the expression of TNFα via a novel pathway mediated by the inhibitory 
phosphorylation of IκBβ  
Consistent with previous studies [467], [506], total cellular NF-κB activity was strongly 
downregulated (75%) in GSK-3β -/- MEFs as determined by luciferase assay (Figure 5.6D). In 
order to determine if all NF-κB mediated genes were affected similarly, we repeated the assay 
with the luciferase gene downstream of the IL-6 and TNFα promoter (Figure 5.6E). While 
luciferase was also strongly downregulated (~70%) downstream of the IL-6 promoter in GSK-3β 
-/- MEFs, the downregulation downstream of the TNF-promoter was relatively mild (~15%). 
However, overexpressing the phosphomimetic S346D-IκBβ (but not the S346A-IκBβ ) abrogated 
the activation of luciferase downstream of the TNF-promoter. GSK-3β is known to upregulate 
the secretion of TNFα and other pro-inflammatory cytokines (like IL-6) by an IκBβ -independent 
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mechanism. Our results suggest that GSK-3β  might be playing a dual role in selectively 
downregulating TNFα (but not IL-6) via a different pathway mediated by inhibitory 
phosphorylation of IκBβ .  
To confirm the results obtained from luciferase assays, we also measured the cytokines 
secreted by wild-type and GSK-3β-/- MEFs in response to stimulation with 10ng/ml of LPS 
(Figure 5.6F). Not surprisingly, secretion of both TNFα and IL-6 was reduced in GSK-3β-/- 
MEFs (expressing GFP as control) as compared to wild type MEFs (expressing GFP) in 
agreement with previous studies [491]. However, the relative downregulation of IL-6 was six 
times more than TNFα. Co-expression of S346D-IκBβ (but not S346A-IκBβ) was required to 
suppress TNFα to comparable levels.  
Intriguingly, the suppression of TNFα secretion by S346D-IκBβ  was more in GSK-3β -/- 
MEFs as compared to wild-type MEFs. This is because the expression of S346D-IκBβ  in wild 
type MEFs suppresses the secretion of TNFα mediated by the IκBβ  pathway, but not the IκBβ -
independent pathway. However, the expression of TNFα in GSK-3β -/- is caused only by the 
presence of unphosphorylated IκBβ stabilizing the p65:cRel heterodimers at the TNF promoter. 
Hence, expression of S346D-IκBβ  almost completely suppresses the expression of TNFα. 
3) β-inhibitory peptide (BIP) selectively increases the production of TNFα but not IL-6 in 
BMDMs in response to LPS stimulation   
In order to confirm our hypothesis that the unphosphorylated IκBβ selectively increases 
the production of TNFα and study the specific effects of the GSK-3β -IκBβ  pathway, we 
stimulated wt-BMDMs with LPS in the presence and absence of BIP. While administration of 
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the peptide alone was not enough to convert IκBβ entirely to the unphosphorylated form, IκBβ 
was almost exclusively in the unphosphorylated state after stimulation with LPS in the presence 
of the peptide (Figure 5.6G); hence the BIP is a great tool for studying the physiological effects 
of unphosphorylated IκBβ. The stimulation with LPS is required to degrade the ‘preformed’ 
phosphorylated IκBβ already present in cells. While the levels of β-catenin increase upon 
addition of LPS, it does not increase any further upon addition of the peptide.  
The amounts of TNFα produced by LPS-stimulated BMDMs increases with the addition 
of the peptide in a dose-dependent manner (Figure 5.6H). In contrast, the amounts of IL-6 
produced is relatively unaffected. Previous results have suggested that the κB2 site in the TNFα 
promoter is required for optimal transcription of TNFα [186]. Hence, we carried out an EMSA 
using a κB2 probe and found the enhanced recruitment of p65:cRel heterodimer to the κB2  site 
in the presence of the peptide in LPS stimulated BMDMs (Figure 5.6I). Our results confirm 
previous suggestions that unphosphorylated IκBβ associates with p65:cRel and this trimeric 
complex binds  to the κB2 site in the TNFα promoter to augment transcription of TNFα. 
4) Mice succumb to elevated levels of caused by hypophosphorylated IκBβ in response to sub-
lethal doses of LPS  
To test the consequences of the Ser-346 phosphorylation in animals, we challenged mice 
with sub-lethal dose (18mg/kg of animal weight) of LPS in the presence and absence of the 
peptide. Our results show that mice succumb to the sub-lethal dose in the presence of the peptide 
(Figure 5.6J). The mice do not die in the presence of LPS alone or when LPS is injected with 
the mutant peptide. The mice die only when LPS is injected with the peptide. Tunnel-staining of 
liver and spleen (as shown in Figure 5.6K) show increased signs of cell-death. We examined the 
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serum levels of acute phase cytokines like  TNFα, IL-1β and IL-6. TNFα peaked early after an 
hour while both IL-6 and IL-1β peaked around 2 hours, in agreement with previous studies 
[186]. Levels of IL-6 and IL-1β did not change substantially in the peptide-treated mice, but 
production of TNFα was strikingly increased in these animals (Figure 5.6L). Immunostaining 
also shows accumulation of TNFα and IL-6 in the liver and spleen of these animals (Figure 
5.6M).  
To confirm that the effect of the peptide was mediated by IκBβ and not through any non-
specific effects, we also challenged IκBβ-/- mice with peptide in the presence of LPS. The IκBβ-/- 
mice do not succumb to LPS shock in the presence of the peptide unlike the wild-type mice 
(Figure 5.6N). Wild type mice (but not the IκBβ-/- mice) show elevated levels of TNFα in their 
serum as measured by ELISA (Figure 5.6O) and immunostaining (Figure 5.6P). Tunnel 
staining of liver and spleen also confirm increased cell death in wt but not in IκBβ-/- mice 
(Figure 5.6Q). Our results show that unphosphorylated IκBβ is pro-inflammatory and 
specifically upregulates the expression of TNFα. 
5.3.5: A biological pathway for regulation of IκBβ  
To uncover a model by which phosphorylation by GSK3 regulates IκBβ, we examined if 
immunoprecipitated nuclear and cytoplasmic GSK3 can phosphorylate IκBβ under basal and 
stimulated conditions. We extracted the nuclear and cytoplasmic fractions of BMDMs under 
both stimulated and unstimulated conditions as shown in Figure 5.7 (right panel). We 
confirmed the compartmentalization of HDAC1 and β-tubulin to the nucleus and cytoplasm 
respectively. IκBβ is phosphorylated in unstimulated cells and is completely cytoplasmic. In 
stimulated cells, the newly synthesized unphosphorylated IκBβ is localized to the nucleus. Total 
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GSK3 is distributed both in the nucleus and cytoplasm in stimulated and unstimulated cells. LPS 
stimulation inactivates GSK-3β  by phosphorylating it at Ser-9 [463], [488], [489], and this 
inactive GSK-3β is present only in the cytoplasm. While LPS stimulation generally inactivates 
GSK-3β, nuclear GSK-3β is less phosphorylated and more active than cytoplasmic GSK-3β in 
stimulated cells. 
Equal amounts of GSK-3β were immunoprecipitated from whole cell extracts, nuclear 
and cytosolic fractions of both unstimulated and stimulated cells. A kinase assay was then 
performed with GST-IκBβ in the presence of γ32-ATP (Figure 5.7 (left panel).  GSK-3β 
phosphorylates IκBβ to a much greater extent in unstimulated cells in both the nucleus and the 
cytoplasm. This is expected as GSK3 is active in the quiescent state and present almost equally 
in both compartments. However at 4.5 hrs, GST-IκBβ can be phosphorylated only by the nuclear 
GSK-3β. This is because the cytosolic GSK-3β is predominantly phosphorylated (S9) and 
inactive. 
 
5.4: Biological model of GSK-3β  regulating IκBβ 
We propose a model (Figure 5.8) where IκBβ is phosphorylated in the quiescent state by 
GSK-3β (both nuclear and cytosolic) at Ser-346 (Figure 5.8, top-left). Phosphorylated-IκBβ 
masks the NLS of p65, hence the phosphorylated-IκBβ:p65:cRel complex is cytoplasmic in the 
resting state (Figure 5.8, top-left). Upon LPS stimulation, GSK-3β is inactivated and 
phosphorylated IκBβ is proteasomally degraded. IκBβ is resynthesized in the unphosphorylated 
state and cannot mask the NLS of p65. As a result, the trimeric unphosphorylated-IκBβ:p65:cRel 
trimeric complex is found in the nucleus, where it drives the expression of proinflammatory 
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genes like TNFα (Figure 5.8, top-right). Nuclear GSK-3β associates with this complex and 
phosphorylates IκBβ (Figure 5.8, bottom-left). The phosphorylation masks the NLS of p65, 
translocating the phosphorylated-IκBβ:p65:cRel complex back to the cytoplasm (Figure 5.8, 
bottom-right). 
GSK3 does not associate with the phosphorylated-IκBβ:p65:cRel trimeric complex in the 
quiescent state (Figure 5.5B and Figure 5.8, top-left), hence it seems that GSK3 does not 
phosphorylate IκBβ in the complex under resting conditions. However nuclear GSK-3β 
associates with this complex after stimulation (Figure 5.5B and Figure 5.8, top-right and 
bottom panels), suggesting that GSK-3β phosphorylates the newly synthesized, 
unphosphorylated-IκBβ that is associated with p65:cRel heterodimer. 
 
5.5: Discussion 
It had long been known that IκBβ is constitutively phosphorylated [35]. The 
phosphorylated IκBβ is degraded upon stimulation with LPS, and the new IκBβ is resynthesized 
in a hypophosphorylated form. This hypophosphorylated form was hypothesized to be pro-
inflammatory in an in vivo model [186]. We discovered that GSK3 associates with the PEST 
domain of IκBβ and phosphorylates IκBβ at Ser-346 both in vitro and in vivo. IκBβ does not 
need priming by any other kinase. This is not surprising as IκBβ was efficiently phosphorylated 
by both GSK-3α and GSK-3β in the absence of any other kinase (unlike β-catenin which could 
not be phosphorylated at all in the absence of priming by CK2). The presence of two aspartic 
acids at residues 355 and 356 might be providing the negative charges for the ‘positively 
charged’ kinase binding pocket of GSK3. 
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The redundancy of IκBs may be a reason for the dearth in disease-associating mutations 
that have been discovered till date with these proteins [16]. Another reason could be that the 
SNPs associated with the IκB proteins are so drastic that they may result in early lethality. 
Remarkably, a ‘highly dangerous’ SNP was found at Ser-346 of IκBβ and reported in patients 
suffering from invasive pneumococcal disease, though it is not clear if the SNP is linked to the 
disease [510]. 
 We generated a phospho-specific antibody against the site of phosphorylation, and 
showed the degradation and reappearance of endogenous phosphorylated IκBβ in response to 
LPS stimulation. The phosphorylation masks the NLS of p65, thus sequestering it to the 
cytoplasm.  This is why the phosphorylated form is anti-inflammatory. Phosphorylation does not 
affect the binding to p65 and all the three analogs of IκBβ (wild type, S346A and S346D) bind 
equally to p65. This is because the binding of IκBβ to p65 is mediated only by the ankyrin 
repeats of IκBβ and Rel-homology domain of p65 [34], [370].  
While both GSK-3α and GSK-3β can phosphorylate IκBβ in vitro, GSK-3β  is more 
physiologically relevant in vivo. It is not surprising that both the isoforms phosphorylate IκBβ in 
vitro given the high degree of homology (98%) in their kinase domains [458]. Given it’s 
importance in regulating NF-κB, it is also not surprising that GSK-3β would be expected to be 
more important in an in vivo setting. This is additionally borne out by the observation that only 
GSK-3β is associated with the trimeric unphosphorylated-IκBβ:p65:cRel complex in stimulated 
cells. It is possible that GSK-3β downregulates NF-κB in resting cells by phosphorylating p65 
[503], [504],  p105 [505] and IκBβ (according to our findings). 
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We also discovered a peptide (BIP) that selectively abrogates the phosphorylation of 
IκBβ (but not other GSK3 substrates) by inhibiting the association between GSK-3β  and IκBβ, 
and show that IκBβ is unphosphorylated in the presence of the peptide.  BIP does not inhibit in 
vitro phosphorylation by GSK-3α. Administration of the peptide alone does not completely lead 
to the formation of unphosphorylated IκBβ and an accompanying stimulation with LPS is 
required for complete de-phosphorylation. This may be because a sufficiently high dose of the 
peptide (alone) has not been administered. Alternatively, it may be because the peptide only 
inhibits the phosphorylation of newly synthesized unphosphorylated IκBβ. Concurrent 
stimulation with LPS is required to degrade the already phosphorylated IκBβ (Figure 5.8, top-
left).  
Mice succumb to sublethal doses of LPS in the presence of the peptide because of 
increased secretion of TNFα (but not IL-6 or IL1 β). GSK-3β is known to be important for the 
upregulation of TNFα (and other cytokines) by an IκBβ independent pathway; the peptide does 
not affect this pathway. The peptide additionally inhibits the phosphorylation of IκBβ, thereby 
activating TNFα synergistically by the described IκBβ-mediated pathway. This is probably the 
reason why the peptide is so effective and death with accompanying upregulation of TNFα. This 
also demonstrates the importance of unphosphorylated IκBβ in regulating expression of specific 
proinflammatory cytokines like TNFα.  
GSK-3β generally abets inflammation, and GSK-3β-/- mice are embryonically lethal 
resulting from a failure to activate the pro-survival NF-κB pathway [467]. GSK-3β inhibitors are 
increasingly used in therapeutics with the expectation that they would inhibit the production of 
pro-inflammatory cytokines. Our results show that while they are effective in abrogating the 
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production of some inflammatory cytokines like IL-6, they are not as effective in abolishing 
production of TNFα. This is because of our finding that GSK-3β also plays a physiological role 
in inhibiting the production of TNFα in response to LPS, something that might be important in 
inhibiting persistent inflammation (Figure 5.8, bottom panels). Infact, the side-effects of GSK-
3β inhibitors may be manifested by their failure to abrogate expression of TNFα. Developing 
drugs that mimic the effect of S346D-IκBβ in conjunction with these inhibitors might provide 
better therapeutic value as compared to using these inhibitors alone as it will substantially 
decrease the production of TNFα. 
  
5.6: Materials and Methods 
5.6.1: Cell culture, reagents and transfection   
Wild-type, GSK-3α  and GSK-3β null mouse embryonic fibroblasts (MEFs) were kind 
gifts of Prof.  J. Woodgett). MEFs, immortalized BMDMs and HEK293 cells were cultured in 
Dulbecco's modified Eagle's medium-H supplemented with 10% fetal bovine serum. 
Transfection was done using Lipofectamine LTX according to the manufacturer’s protocol. The 
commercial GSK inhibitors used were 6-bromoindirubin-30-acetoxime (Calbiochem) and 
membrane-permeable GSK-3 peptide inhibitor (Calbiochem). The GSK3α/β shRNA was 
obtained Prof. William Snider. 
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5.6.2: Western analysis and immunoprecipitations 
Cells were lysed in RIPA buffer containing protease and phosphatase inhibitors for 20 
min on ice and centrifuged at 13,000 × g for 10 min. Supernatants were quantitated by the BCA 
and 30 μg of protein was denatured in sodium dodecyl sulfate loading buffer and fractionated 8% 
SDS-PAGE gels. Following transfer onto PVDF membranes, the blots were blocked in 5% milk. 
They were then incubated with appropriate antibodies in 2.5% milk overnight at 4°C. For 
immunoprecipitations, cells were lysed in 25mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 
1% NP-40 and 5% glycerol along with the protease/phosphatase inhibitors. For the analysis with 
phospho-Ser-346 antibody, the membranes was blocked in Protein-Free (TBS) Blocking Buffer 
(ThermoScientific) for 2 hours. After this, the antibody was diluted 1:25 (or (1:50) in the 
Protein-Free (TBS) Blocking Buffer and the membrane was incubated overnight. 
5.6.3: Kinase assays 
Lysates were immunoprecipitated overnight with GSK-3α  or GSK-3β  antibody. After 
this Protein-G-Sepharose was added for 2 hours. Immunoprecipitates were washed twice with 
lysis buffer and thrice with kinase reaction buffer (20 mm Hepes, pH 7.2, 10 mm MgCl2, 10 mm 
MnCl2, 1 mm dithiothreitol, 0.2 mm EGTA, and 5 μm ATP). After this, the GSK-3 kinase assay 
was performed at 37 °C for 1 hour in 20 μl of GSK -3 kinase buffer supplemented with 4 μg of 
recombinant GST-IκBβ and 5 μCi of [γ-32P]ATP for each reaction. When the reaction was 
carried out in the presence of peptides, then the peptide was directly diluted out to the reaction 
media. The reaction was terminated by adding 6X sample buffer and boiling for 5 min. The 
entire reaction was resolved on a 8% SDS-PAGE gel, and exposed to a PhosphorImager plate. 
Equal loading of GST-IκBβ and immunoprecipitated GSK-3 was determined by Comassie 
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staining and western-blot analysis respectively. As controls, GSK-3 kinase reactions were also 
carried out without adding the GSK-3 antibody (with the IGG1 isotype). 
5.6.4: Electrophoretic mobility shift assays.  
Gel shift assay was done using the nuclear fractions with the Li-cor EMSA kit as per the 
user manual. The κB2 and  Oct1 probe was custom made.  
 
5.6.5: LPS-induced shock and serum-cytokine measurement 
LPS-induced shock was tested by intraperitoneal injection of a sublethal dose of 18 µg/g 
body weight LPS and monitoring for survival every six hours. In a separate identical experiment, 
the mice were bled at 1 hr and 2 hr after LPS treatment and the concentration of TNF-α, IL-6 and 
IL-1β in the serum was measured by ELISA. Peptide injections were done by intraperitonial 
injection of 200µg of the peptide along with LPS. ELISA analyses were performed as previously 











Figure 5.3A: Degradation kinetics of IκBα  and IκBβ in response to LPS stimulation (boxes 
indicate the early and latter time course of action of IκBα  and IκBβ respectively): 70Z/3 cells 
were stimulated with 1µg/ml LPS for the indicated time points with and without cycloheximide 








Figure 5.3B: Mass-spectrometric analysis shows that IκBβ is phosphorylated at Ser-346 in 
resting cells (70z/3 cells were treated with 1µg/ml of LPS for the indicated time points and 
immunoprecipitated using the generic IκBβ antibody). The MH2+ peak denotes that the serine at 










Figure 5.3C: Characterization of phospho-antibody: i) western blot showing the presence of 
endogenous phospho-Ser-346-IκBβ; wild—type and IκBβ-/- BMDMs and MEFs were lysed and 
200 µgs of lysate was run out on a 8% gel  (ii) Recognition by phospho-antibody abrogated by 
phosphatase treatment (200 µgs of wild-type BMDM lysate was treated with and without 
lambda-phosphatase and blotted with the respective antibodies) (iii) Phospho-antibody 
recognizes phospho-Ser-346 in IκBβ-/- MEFs transfected with wt-IκBβ but not S346A-IκBβ 
(IκBβ-/- MEFs were reconstituted with wt-IκBβ and S346A-IκBβ; cells were lysed and blotted 




Figure 5.3D: Degradation and reappearance of endogenous phospho-Ser-346-IκBβ in response to 
1µg/ml LPS stimulation (BMDMs were stimulated with 100ng/ml of LPS and 200 µgs of lysate 
was run out on 8% gel and blotted with phospo-specific antibody as shown in the top panel; 30 
µgs of same lysate was run out on 8% gel and blotted with pan- IκBβ antibody (sc) as shown in 




Figure 5.3E: Phosphorylation at Ser-346 masks the NLS of p65 demonstrated by the (i) 
expression of recombinant IκB analogs (HA-p65 was overexpressed and purified from HEK293 
by eluting with peptide; purified HA-p65 was incubated for 30 minutes on ice with equal 
amounts of each of the three GST-tagged IκBβ analogs, diluted 10X times with  co-IP buffer, 
immunoprecipitated with p65 (NLS) or  with p65(C-terminal antibody) and blotted with 
respective antibodies (ii) expression of IκBβ analogs in IκBβ-/- MEFs (HA-tagged IκB analogs 
were also purified like HA-p65 from HEK293 cells, and the previous analysis was repeated 




Figure 5.4A: Immunoprecipitated GSK-3α  and GSK-3β  phosphorylates IκBβ in vitro in kinase 
assay with γ32-ATP (Inhibitor 1 is 6-bromoindirubin-30-acetoxime and  Inhibitor 2 is 
membrane-permeable GSK-3 peptide inhibitor (Calbiochem); both are used at a concentration of 
20nM and 100nM): to confirm equal amounts of substrate and kinase in the kinase-assay, the 
substrate GST- IκBβ was analyzed by coomassie staining; and the amount of 




Figure 5.4B: Recombinant GSK-3β phosphorylates IκBβ in vitro in kinase assay with γ32-ATP 
(Inhibitor 1 is 6-bromoindirubin-30-acetoxime and Inhibitor 2 is membrane-permeable GSK-3 
peptide inhibitor (Calbiochem); both are used at a concentration of 20nM and 100nM) in a 




Figure 5.4C: IκBβ is an unprimed substrate of GSK-3β as wt-GSK-3β and R96A-GSK-3β but 
not kinase-mutant (KM) of GSK-3β phosphorylates IκBβ in vitro in kinase assay with γ32-ATP: 
(HA-tagged GSK-3β constructs were overexpressed in GSK-3β-/- MEFs, and immunoprecipitated 
with GSK-3β antibody;  to confirm equal amounts of substrate and kinase in the kinase-assay, 
the substrate GST- IκBβ was analyzed by coomassie staining; and the amount of 






Figure 5.4D: Immunoprecipitated GSK-3β (left panel) and GSK-3α (right panel) phosphorylates 
Ser-346 of IκBβ (wt- IκBβ but not S346A- IκBβ is phosphorylated in vitro in a kinase assay with 
γ32-ATP: to confirm equal amounts of substrate and kinase in the kinase-assay, the substrate 
GST- IκBβ was analyzed by coomassie staining; and the amount of immunoprecipitated-kinase 
was run out on a separate gel and analyzed by western-blotting) 
 
 
Figure 5.4E: Recombinant GSK-3β  phosphorylates Ser-346 of IκBβ in vitro in a kinase assay 
with γ32-ATP: (wt- IκBβ but not S346A- IκBβ is phosphorylated;  the input substrate GST- 





Figure 5.4F: Phospho-Ser 346-antibody recognizes IκBβ phosphorylated at Ser-346 by GSK-3β 
in presence of cold ATP; band corresponding to phospho-IκBβ disappears upon phosphatase 
treatment of GST-IκBβ previously incubated with GSK-3β (and ATP)  (the input substrate GST- 




Figure 5.4G: GSK-3β phosphorylates IκBβ at Ser-346 in vivo in BMDM (Inhibitor 1 is 6-
bromoindirubin-30-acetoxime and  Inhibitor 2 is membrane-permeable GSK-3 peptide inhibitor 
(Calbiochem); both are used at a concentration of 20nM and 100nM); lysates were run on a 8% 
gel and analyzed by western-blot with respective antibodies; for the western-blot with phospho-





Figure 5.4H: Phosphorylation of IκBβ at Ser-346 decreases upon treatment with GSK-3α/β 
shRNA (lysates were run on a 8% gel and analyzed by western-blot with respective antibodies; 
for the western-blot with phospho-S346 antibody, 200 µgs of lysate was used, while for the blot 
with sc-antibody, 20 µgs of lysate was used) 
 
 
Figure 5.4I: Phosphorylation of IκBβ at Ser-346 increases upon co-transfection of GSK-3β 
(IκBβ-/- MEFs were transfected with wt-IκBβ and S346A-IκBβ; co-transfection of GSK-3β 






Figure 5.4J: LPS-degradation kinetics of IκBβ in WT, GSK-3β -/- and GSK-3α -/- MEFs 
(stimulated with 1ug/ml of LPS); lysates were run on a 8% gel and analyzed by western-blot 
with respective antibodies. 
 
 
Figure 5.4K: LPS-degradation kinetics of IκBβ in MEFs where both isoforms of GSK3 have 
been depleted (inhibitor used is 6-bromoindirubin-30-acetoxime at a concentration of 50nM); 






Figure 5.5A: IκBβ co-immunoprecipitates with GSK-3α  and GSK-3β (BMDMs were left 
unstimulated or stimulated with 100ng/ml of LPS, lysed in IP-lysis buffer and incubated with 
IGG1 isotype (unstimulated lysate), GSK-3β antibody or GSK-3α antibody overnight; followed 
by the addition of Protein-G sepharose, resolved on a 8% gel and analyzed by western blotting) 
 
 
Figure 5.5B: GSK-3β is associated in a complex with hypophosphorylated-IκBβ:p65:cRel in 
stimulated cells (BMDMs were left unstimulated or stimulated with 100ng/ml of LPS, lysed in 
IP-lysis buffer and incubated with IGG1 isotype (unstimulated lysate) or IκBβ antibody 
overnight; followed by the addition of Protein-G sepharose, eluted with the IκBβ-peptide in a 
total volume of 50µl, diluted 20X times with co-IP buffer, incubated with IGG1 isotype 
(unstimulated lysate) or p65 antibody overnight, followed by the addition of Protein-G 
sepharose, resolved on a SDS-PAGE gel and analyzed by western blotting. The second 




Figure 5.5C: The PEST domain of IκBβ is necessary for interaction with GSK3 (HA-tagged 
IκBβ constructs were overexpressed in IκBβ-/- MEFs, and immunoprecipitated with HA antibody 
overnight; followed by the addition of Protein-G sepharose, resolved on a SDS-PAGE gel and 
analyzed by western blotting)   
 
  
Figure 5.5D: BIP inhibits phosphorylation by immunoprecipitated GSK-3β  in vitro in a kinase 
assay with γ32-ATP (peptides are used in increasing concentrations of 50µM, 200 µM and 500 
µM): to confirm equal amounts of substrate and kinase in the kinase-assay, the substrate GST- 
IκBβ was analyzed by coomassie staining; and the amount of immunoprecipitated-kinase was 






Figure 5.5E: BIP does not inhibit phosphorylation by immunoprecipitated GSK-3α in vitro in a 
kinase assay with γ32-ATP (peptides are used in increasing concentrations of 50µM, 200 µM 
and 500 µM): to confirm equal amounts of substrate and kinase in the kinase-assay, the substrate 
GST-IκBβ was analyzed by coomassie staining; and the amount of immunoprecipitated-kinase 
was run out on a separate gel and analyzed by western-blotting) 
 
 
Figure 5.5F: BIP inhibits phosphorylation by recombinant GSK-3β in vitro in a kinase assay with 
γ32-ATP (peptides are used in increasing concentrations of 50µM and 500 µM): to confirm 







Figure 5.5G: BIP inhibits the phosphorylation of GST-IκBβ but not of GST-β-catenin in a kinase 
assay with γ32-ATP (concentration of peptides are 500 µM) : to confirm equal amounts of 
substrate and kinase in the kinase-assay, the substrate GST-IκBβ was analyzed by coomassie 
staining; and the amount of immunoprecipitated-kinase was run out on a separate gel and 





Figure 5.5H: BIP abrogates the association of GSK-3β  with IκBβ in vitro (peptides are used in 
increasing concentrations of 10 µM, 50µM, 200 µM and 500 µM): Equal amounts of 
recombinant GSK-3β (NEB) and GST-IκBβ were incubated in the presence of peptide or mutant-
peptide for 1 hour on ice in a total volume of 50µl; diluted 20X with co-IP buffer, and pulled-
down overnight with glutathione beads or immunoprecipitated with GSK-3β antibody, and 
analyzed by western blot. 
 
 
Figure 5.5I: BIP abrogates the association of GSK-3β  with IκBβ in vivo in wt-BMDM treated 
with peptides as shown (peptides are used in increasing concentrations of 100µM and 200 µM): 
Cells were lysed in IP-lysis buffer, and immunoprecipitated with  GSK-3β (upper-panel) or IκBβ 
antibody (lower-panel); resolved on a 8% gel and blotted with the respective antibodies (the 





Figure 5.6A: S346A-IκBβ fails to inhibit NF-κB in luciferase assay (pcDNA or the three IκBβ 
analogs were transfected into IκBβ-/- MEFs along with κB-luciferase and Renilla construct, left 
unstimulated or stimulated with 10ng/ml of LPS, and relative activation of luciferase was 
analyzed; equal expression of the three IκBβ analogs was analyzed by western blot) 
 
 
Figure 5.6B: Luciferase assay with pTNF-luciferase and pIL6-luciferase (pcDNA or the three 
IκBβ analogs were transfected into IκBβ-/- MEFs along with pTNF-luciferase construct (left) or 
pIL6-luciferase construct (right) and Renilla construct, left unstimulated or stimulated with 
100ng/ml or 1µg/ml of LPS, and relative activation of luciferase was analyzed; equal expression 





Figure 5.6C: Production of TNFα in IκBβ-/- BMDMs reconstituted with wt, S346A and S346D 
IκBβ analogs (IκBβ-/- BMDMs were reconstituted with GFP and the respective IκBβ analogs, 
cells were GFP-sorted; presence of the IκBβ analogs in GFP+ cells were confirmed by western-
blot; reconstituted cells were then left unstimulated or stimulated with LPS for 20 hours, and 







Figure 5.6D: Luciferase assay showing downregulation of NF-κB in GSK-3β -/- MEFs (wild type 
and GSK-3β-/- MEFs  were co-transfected with κB-luciferase and Renilla construct, left 
unstimulated or stimulated with 10ng/ml of LPS, and relative activation of luciferase was 
analyzed) 
 
Figure 5.6E: Differential downregulation of luciferase gene downstream of IL-6 and TNF 
promoter in GSK-3β -/- MEFs (experiment was carried out as above but with pIL-6-luciferase and 
pTNF-luciferase instead of the generic κB-luciferase; HA-S346D-IκBβ or HA-S346A-IκBβ were 





Figure 5.6F: ELISA analysis of TNFα and IL-6 of GFP-sorted wt and GSK-3β -/- MEFs in 
response to 10ng/ml of LPS (MEFs of indicated genotype were reconstituted with GFP and the 
respective IκBβ analogs, cells were GFP-sorted and then left unstimulated or stimulated with 









Figure 5.6G: IκBβ is entirely unphosphorylated upon stimulation with LPS in presence of 
peptide in BMDM (peptides used at a concentration of 200µM); for the western-blot with 
phospho-S346 antibody, 200 µgs of lysate was used, while for the blot with sc-antibody, 20 µgs 
of lysate was used 
 
 
Figure 5.6H: TNFα and IL-6 production on treatment of BMDM with 10ng/ml of LPS in the 




Figure 5.6I: EMSA analysis showing upregulation of p65:cRel complexes at the κB2 site in 
BMDMs upon stimulation with LPS in the presence of  200µM of peptide (but not mutant-
peptide): gel-shift assay was carried out using nuclear fractions and κB2 probe; equal loading 
was confirmed by carrying out the reaction with Oct1 probe and running it on a 5% TBE gel) 
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Figure 5.6J: LPS shock in wild type mice in the presence and absence of peptide (n=7); 
intraperitoneal injection of a sublethal dose of 18 µg/g body weight LPS was administered and 
monitoring for survival every six hours (mice succumb to sublethal dose of LPS only in the 





Figure 5.6K: Tunnel staining of liver and spleen in mice treated with PBS, LPS, LPS+peptide 
and LPS+mu-peptide (significantly increased signs of cell-death in organs of mice treated with 







Figure 5.6L: Serum levels of TNFα, IL-6 and IL-1β in mice treated PBS, peptide (only), mutant-
peptide (only), LPS, LPS+peptide and LPS+mu-peptide (significantly increased production of 






Figure 5.6M: Immunostaining of TNFα, IL-6 and IL-1β (significant upregulation of TNFα but 























Figure 5.6N: LPS shock of wt and IκBβ-/- mice in the presence and absence of peptide (n=7); 
intraperitoneal injection of a sublethal dose of 18 µg/g body weight LPS was administered and 
monitoring for survival every six hours (wild type mice but not IκBβ-/- mice succumb to a 







Figure 5.6O: Serum levels of TNFα, IL-6 and IL-1β in wt and IκBβ-/- mice (significantly 
increased production of TNFα but not IL-6 or IL-1β only in wild-type but not  IκBβ-/- mice after 





Figure 5.6P: Immunostaining of TNFα in wt and IκBβ-/- mice (significantly elevated expression 






Figure 5.6Q: Tunnel staining of liver and spleen in wt and IκBβ-/- mice (significantly increased 






Figure 5.7: Kinase assay with immunoprecipitated nuclear and cytoplasmic GSK-3β (BMDMs 
were fractionated and the cytosolic and nuclear fractions are shown in the left-panel; GSK-3β 
was immunoprecipitated from whole-cell lysates, cytosolic or nuclear fraction; kinase-assay was 
performed by incubating immunoprecipitated GSK-3β with recombinant GST- IκBβ in presence 
of γ32-ATP (right-panel); to confirm equal amounts of substrate and kinase in the kinase-assay, 
the substrate GST- IκBβ was analyzed by coomassie staining; and the amount of 







Figure 5.8: Biological model of GSK-3β regulating IκBβ  
 
(In unstimulated cells, IκBβ is phosphorylated active GSK-3β (both nuclear and cytosolic) at 
Ser-346 (top-left). Phosphorylated-IκBβ masks the NLS of p65, hence the phosphorylated-
IκBβ:p65:cRel complex is cytoplasmic in the resting state (top-left). During early LPS 
stimulation, GSK-3β is inactivated and phospho-IκBβ is proteasomally degraded following 
inducible phosphorylation by IKK at Ser 19 and Ser 23. New IκBβ is resynthesized in the 
unphosphorylated state and cannot mask the NLS of p65. As a result, the trimeric 
unphosphorylated-IκBβ:p65:cRel trimeric complex is found in the nucleus, where it drives the 
expression of proinflammatory genes like TNFα (top-right). Nuclear GSK-3β associates with this 
complex and phosphorylates IκBβ (bottom-left). The phosphorylation masks the NLS of p65, 
translocating the phosphorylated-IκBβ:p65:cRel complex back to the cytoplasm (bottom-right).  
 
GSK3 does not associate with the phosphorylated-IκBβ:p65:cRel trimeric complex in the 
quiescent state (top-left; data in Figure 5.5B), hence it seems that GSK3 does not phosphorylate 
IκBβ in the complex under resting conditions. However nuclear GSK-3β associates with this 
complex after stimulation (bottom-left; data in Figure 5.5B), suggesting that GSK-3β 




























This thesis describes the mechanism of action of two well-known inhibitors of NF-κB, 
A20 and IκBβ. 
6.1: Regulatory ubiquitination and A20 
It is well-appreciated that almost all NF-κB signaling pathways proceed  via the 
activation of the IKK complex as NF-κB activity is absent in mice deficient in both IKKα and 
IKKβ [107]. Phosphorylation of Ser-177 and Ser-181 in the ‘active loop’’ of IKKβ is required 
for the activation of IKK [71]. However, how this phosphorylation happens is unknown [108]. 
There are two obvious possibilities: IKK could either autophosphorylate itself or be 
phosphorylated by some other kinase (like TAK1). The biggest issue is that the receptors leading 
to IKK activation lack kinase activity or other known enzymatic activity. Hence, either kinase 
activity needs to be recruited to the pathway or conformational changes upon receptor ligation 
must somehow lead to IKK phosphorylation.  
It is conceivable that these conformational changes might be caused by the 
oligomerization of adaptor proteins upon receptor ligation. Another hypothesis is that the adaptor 
proteins may be ubiquitinated with K63-linked, non-degradative, ubiquitin chains; and it is these 
ubiquitin chains that activate TAK1/IKK. The first part of the theses broadly tests the second 
hypothesis to determine if regulatory ubiquitination might lead to NF-κB activation. 
Initially, it was thought that these ubiquitin chains provide the oligomeric structure for 
stabilizing the signaling complexes or recruits the kinase complexes, like the IKK complex (via 
NBD of NEMO) or TAK1 complex (via the NBD of the TAB adaptor proteins), bringing these 
kinases closer together for trans-phosphorylation. Another non-exclusive model holds that 
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ubiquitination of upstream adapters may directly activate the downstream kinase complexes. 
Recently though, it was shown that even ubiquitin chains that are not anchored to any substrate 
can directly activate IKK or TAK1 [168]. If direct activation of kinase complexes by substrate-
linked ubiquitin or free-ubiquitin were to occur, it would be expected that short ubiquitin chains 
would be as effective as long ubiquitin chain in activating the kinase complex. However, this 
was not found to be the case. Moreover, it is unclear as to how the IKK complex or the 
TAK/TAB complex would differentiate between regulatory polyubiquitin chains linked to one 
substrate from those linked to a different substrate (or differentiate the substrate-linked chains 
from unanchored ubiquitin chains).  
Crucially, if ubiquitin chains were to directly activate the IKK complex, it would mean 
that IKKβ or NEMO would have to be ubiquitinated. In tissue-culture based experiments and 
knock-down models, regulatory ubiquitination of NEMO at K-399 has been shown to be 
essential for NF-κB activation [165]. However, subsequently knock-in mice generated with a 
single mutation at this residue was found to have normal NF-κB activation. Hence, the genetic 
murine model has conclusive demonstrated that ubiquitination of NEMO at K-399 is not 
essential for NF-κB activation. 
There is however a plethora of biochemical evidence to suggest that upstream adaptor 
molecules like RIP1 indeed get ubiquitinated in response to TNFα stimulation. Western-blot 
analysis shows the slower-migrating forms of RIP1, or ubiquitinated-RIP1 [286]. The slower-
migrating forms of RIP1 are augmented if only RIP1 that is recruited to TNF-receptor complex 
is analyzed [164], [244]. The ubiquitin linkage on RIP1 may be K63-linked [163, 164, 230, 514] 
or linear [244]. Moreover, RIP1 is essential for activation of NF-κB as concluded from mice 
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deficient in RIP1 [241]. In spite of this, for reasons outlined below (in addition to my findings), it 
is doubtful if the ubiquitination of RIP1 is actually essential for RIP1 mediated activation of NF-
κB. 
RIP1 has been shown to be ubiquitinated on Lys-377 and reconstitution studies using the 
K377R mutant in cells deficient in RIP1 showed the importance of this residue in ubiquitination 
of RIP1. However, the K377R mutant is also not recruited to the activated TNF receptor [163, 
230]. Hence, the implications of ubiquitination at this residue remain unclear. Ubc5 (E2) is 
important for RIP1 ubiquitination, and Ubc5 knock-down virtually abrogates RIP1 ubiquitination 
[231] in cells. The cells lacking UbC5 though have only modest impairment in IKK activation. 
Similarly TRAF2/5 (E3-ligase) is important for RIP1 ubiquitination. But reconstitution of cells 
deficient in both TRAF2 and TRAF5 with TRAF2 RING mutants abolishes RIP1 ubiquitination 
without affecting IKK activation [515]. Perhaps the cleanest in vitro experiment, replacing 
endogenous ubiquitin with K63R-ubiquitin (genome knock-in at the ubiquitin locus), has showed 
that K63-linked ubiquitin is not required for TNFR-mediated IKK activation [231].   
The greatest support for regulatory ubiquitination actually comes from the well-
established roles of deubiquitinases as negative regulators of IKK activation [211]. A20 plays an 
essential role in downregulation NF-κB activation and consequent inflammation, as mice lacking 
A20 die from persistent inflammation in multiple organs and cachexia [134]. In humans, 
dysregulation of A20 has been associated with multiple autoimmune disorders. However, what 
was not known till now was if the deubiquitinase function of A20 (directed mainly towards 
RIP1) was actually essential for downregulation of NF-κB.  
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The first part of my theses shows that “the deubiquitinase activity of A20 is dispensable 
for its role in NF-κB signaling”. The knock-in mouse that we have generated selectively 
abrogates the deubiquitinase function of A20 in vivo. These mice display normal NF-κB 
activation without showing any inflammatory phenotype. Our results clearly demonstrate that the 
well-characterized role of A20 in limiting inflammatory responses is due to effects other than 
deubiquitination of K63-ubiquitin chains. Given that the presumed role of A20 as a 
deubiquitinase has been used to support the importance of regulatory K63 ubiquitination in NF-
κB signaling, we believe that our studies will help focus future research efforts into alternative 
target pathways that do not depend on K63 ubiquitination. As A20 clearly has an important role 
in many diseases, understanding the true molecular function of A20 remains an important and 
worthwhile goal for the future. 
It is tempting to speculate that K63-linked ubiquitin chains may play an alternative role in 
stabilizing upstream signal complexes by preventing untimely and inadvertent K48-linked 
degradative ubiquitination of these signaling complexes. In this regard, both A20 and CYLD 
have been shown to work by not only disassembling K63-linked ubiquitin chains (deubiquitinase 
role) but also facilitating the assembly of  K48-linked ubiquitin chains to their substrates [196], 
[516]. It might well be that the timely ligation of the well characterized, K48-linked degradative 
ubiquitin chains is the function of regulatory ubiquitination. 
In the bigger context, the crucial issue is determining the mechanism for activation of 
kinases downstream of receptors that lack inherent kinase activity. Given the absence of 
receptor-enzymatic activity, ubiquitination of adaptor proteins provides an appealing mechanism 
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for the activation of IKK. However, extensive genetic experiments using knock-in models are 
required to show the importance of regulatory ubiquitination in the activation of NF-κB 
 
6.2: GSK-3β and cross-regulation of NF-κB pathway 
The first substrate of GSK-3β discovered in 1984 was glycogen synthase [454]. 
However, subsequently around 50 different substrates of GSK-3β have been discovered and 
GSK-3β has been determined to be the converging point of diverse pathways [455]. A reason for 
this might be that while most kinases are inducibly activated, GSK-3β has been found to be 
constitutively active in the quiescent state but inactivated in response to stimuli. In these theses, 
we report another substrate of GSK-3β, IκBβ, which is constitutively phosphorylated by GSK-3β 
at Ser-346 in unstimulated cells.  
On a global scale, GSK-3β is clearly required for the upregulation of NF-κB, as mice 
deficient in GSK-3β are embryonic lethal, and die from liver degeneration [467]. It does seem 
however that the increased death observed in GSK-3β knockout mice is disproportionate to the 
observed decrease in NF-κB signaling. While luciferase-based reporter assays show that NF-κB 
cannot be activated in GSK-3β-/- MEFs [467], [506], results obtained from EMSA analysis are 
less convincing [506].  It is not clear if GSK-3β directly activates NF-κB and the phenotype of 
GSK-3β-/- mice might result from cross-regulation of other pathways. In any case, this is more 
due to the decreased expression of pro-survival genes during development. 
The evidence that GSK-3β may play a profound role in regulating the inflammatory 
response in adult mice comes from studying the effects of pharmacological inhibitors. In this 
regard, lithium, a well-characterized pharmacological inhibitor of GSK-3β is used an anti-
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depressant and has anti-inflammatory properties ameliorating experimental autoimmune 
encephalomyelitis [517]. However, there are conflicting reports where other pharmacological 
inhibitors of GSK-3β have also been shown to induce the production of pro-inflammatory 
cytokines. For example, certain pharmacological inhibitors have been show to increase IL-17 
mediated IL-6 production [502], TNF-mediated IL-6 production in endothelial cells [500] and 
LPS-induced expression of TNFα in cardiomyocytes [501]. 
Hence, it seems that inhibition of GSK-3β would have different effects in different cell 
types and also depend on the stimuli and signaling context. This is not unique for GSK-3β and is 
indeed common for other kinases that regulate multiple pathways. For example, Protein Kinase 
A (PKA) is thought to have a global anti-inflammatory role [518] and downregulates NF-κB. 
However, multiple studies have  also showed that PKA can also activate NF-κB by 
phosphorylating p65 at Ser-276 [519], [520], [521]  It is now appreciated that PKA selectively 
modulates NF-κB activation in different conditions [518]. 
Our study shows that GSK-3β downregulates basal inflammation by constitutively 
phosphorylating IκBβ at Ser-346. This is profoundly important as mice succumb to endotoxin 
shock because of increased expression of TNFα, when the phosphorylation is abrogated by a 
peptide which selectively inhibits phosphorylation of IκBβ by GSK-3β at Ser-346. The work also 
highlights that a small-molecule mimic of S346D-IκBβ might be a useful therapeutic to reduce 
the side-effects of GSK-3β inhibitors. 
We also show how the same protein can perform two opposite functions. Thus, IκBβ is 
anti-inflammatory when phosphorylated at Ser-346 but selectively increases the expression of 
TNFα in the unphosphorylated state upon stimulation with LPS. Hence, IκBβ acts as a chaperone 
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and stabilizes the p65:cRel dimer. Stabilization by phosphophorylated IκBβ results in 
sequestration of the dimer in the cytoplasm and mediates an anti-inflammatory role. In contrast, 
complexation with the unphosphorylated IκBβ stabilizes the p65:cRel dimer in the nucleus and 
mediates prolonged expression of TNFα. 
It is tempting to speculate about the cross-talk of the IκBβ mediated pathway with the β-
catenin mediated pathway. The absence of GSK-3β leads to the stabilization of β-catenin and the 
formation of unphosphorylated IκBβ. It is unknown but possible that these two molecules 
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